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Staphylococcus aureus is a facultative intracellular pathogen that invades and 
replicates within many types of human cells. S. aureus has shown to rapidly overcome 
traditional antibiotherapy by developing multidrug antibiotic resistance. Furthermore, 
intracellular S. aureus is protected from the last resort antibiotics – vancomycin, 
daptomycin and linezolid – since they are unable to achieve intracellular killing. 
Therefore, there is an urgent need to develop novel anti-infective therapies against S. 
aureus. Here, I proposed the exploitation of host-directed approaches as a promising 
strategy. Specifically, I employed three different approaches to unravel those host 
molecular factors and/or pathways hijacked by MRSA during intracellular infection. 
By characterizing the host cell metabolism after MRSA infection, I observed several 
metabolic changes suggesting a starvation-induced autophagic flux and AMPK 
phosphorylation levels were also increased in MRSA-infected cells. It was 
hypothesized that intracellular S. aureus induces autophagy for energy generation and 
nutrient scavenging. Accordingly, host AMPK-inhibition halted S. aureus intracellular 
proliferation.  
I further screened 140 host-directed drugs and found three host-directed tyrosine 
kinase inhibitors – Ibrutinib, Dasatinib and Crizotinib – that substantially impaired 
intracellular bacterial survival. Particularly, Ibrutinib increased host cell viability after 
S. aureus infection via inhibition of intracellular bacterial invasion or proliferation and 
we confirmed the importance of the host receptor EPHA2 for staphylococcal infection. 
Lastly, I performed a genome-wide shRNA screen to test the importance of 16,000 
host genes and identified several host genes important for intracellular MRSA 
infection. Specifically, I found that silencing the human gene TRAM2 resulted in a 
significant reduction of intracellular MRSA. TRAM2 is associated with the 
endoplasmic reticulum SERCA pumps and accordingly, treatment with the SERCA-
inhibitor Thapsigargin halted intracellular MRSA proliferation. 
In summary, I identified three different host-directed drugs – Dorsomorphin, Ibrutinib 
and Thapsigargin – that impaired intracellular MRSA infection. These findings serve 
as an important example of feasibility for identifying host-directed therapeutics to 
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1.1. BIOLOGY OF STAPHYLOCOCCUS AUREUS 
Staphylococci are Gram-positive cocci, with low G+C content of DNA, 1 µm in 
diameter, which tend to form clumps by growing in clusters, pairs and, occasionally, 
in short chains. S. aureus is characterized by its gold-pigmentation and for being 
catalase and coagulase positive, salt-tolerant and often haemolytic (Foster, T. 1996; 
Lowy 1998).  
The genome of S. aureus consists of a single circular chromosome of approximately 
2.8 Mbp, and extrachromosomal elements, such as conjugative and non-conjugative 
plasmids. Virulence and antibiotic resistance genes can be found in both the 
chromosome and extrachromosomal elements (Młynarczyk, Młynarczyk and 
Jeljaszewicz, 1998).  
The cell wall of staphylococci species is composed of peptidoglycan, teichoic acids 
(WTA) and cell wall-associated proteins. Peptidoglycan is a sugar-based polymer, 
responsible for cell shape and bacterial integrity (Dmitriev et al., 2004). Interestingly, 
the peptidoglycan of S. aureus possesses a unique pentaglycine side chain, which plays 
an important role in both pathogenicity and antibiotic resistance (Rohrer et al., 1999). 




(PAMP), promoting the cytokine release by macrophages, complement activation as 
well as platelets aggregation (Kessler, Nussbaum and Tuazon, 1991). On the other 
hand, WTAs are covalently bound to the peptidoglycan layer (Lowy, 1998) and they 
are involved in nasal colonization (Weidenmaier et al., 2004). Moreover, WTAs have 
also shown to increase staphylococcal virulence and to promote abscess formation by 
activating CD4+ cells through the Major Histocompatibility Complex II (MHC-II) 
(Wanner et al., 2017). 
In addition, most staphylococci strains produce microcapsules, which are formed by 
extracellular polysaccharides and enhance staphylococcal virulence by subverting 
phagocytosis from macrophages (Nilsson et al., 1997; Kuipers et al., 2016). Among 
the 11 different serotypes that have been identified, serotypes 5 and 8 are the most 
common in human infections caused by S. aureus. In particular, microcapsule type 5 
is the most commonly identified in methicillin-resistant S. aureus strains (O´Riordan 
and Lee, 2004). 
S. aureus is an opportunistic pathogen to humans, which are its natural reservoir. S. 
aureus is carried by approximately 30% of the global population (Sollid et al., 2014; 
Sakr et al., 2018). Humans can be colonized by both Methicillin-Sensitive and 
Methicillin-Resistant S. aureus strains (MSSA and MRSA, respectively) (Sollid et al., 
2014; Sakr et al., 2018). Although the anterior nares of the nasal cavity is the most 
common carriage site of S. aureus (Foster, T. 1996; Wertheim et al. 2005), commensal 
S. aureus can also reside in axillae, vagina, pharynx and damaged skin surfaces (Lowy, 
1998; Sollid et al., 2014). Upon penetration of endothelial, epithelial or dermal 
barriers, due to a wound or tissue damage, the bacterium turns pathogenic. Several 




10-fold (Davis et al., 2004; Ellis et al., 2004). Indeed, it has been traditionally believed 
that colonization precedes infection (Archer, 1998). 
 
 
1.2. S. AUREUS INFECTIONS AND EPIDEMIOLOGY 
S. aureus can cause a wide range of diseases, ranging from skin and soft tissue 
infections (SSTIs), deep tissue abscesses, endocarditis, osteomyelitis, toxic shock 
syndrome (TSS), pneumonia, bacteremia and sepsis (Lowy, 1998).  
 
1.2.1. Skin and Soft Tissues Infections (SSTI) 
Pathogenic S. aureus is able to cause a wide variety of SSTIs, from non-serious 
impetigo and uncomplicated cellulites to life-threatening infections, such as 
necrotizing fasciitis or pyomyositis (Tong et al. 2015). The importance of S. aureus in 
relation to SSTIs has increased in the past two decades due to the emergence of 
community-associated MRSA SSTIs (Otto, 2013). Specifically, the S. aureus USA300 
strain has been identified as the most common isolate within SSTIs caused by 
Community-Associated MRSA (CA-MRSA) (King et al., 2006). 
 
1.2.2. Infective Endocarditis 
Infective endocarditis starts with the damage of the cardiac endothelium, either by 
direct trauma, e.g. caused by an inflammatory response due to another disease. 
Afterwards, the exposure of subendothelial cells promote the production of proteins 




formation of vegetations. Infective endocarditis is the result of S. aureus colonization 
into these vegetations (Que and Moreillon, 2011). In industrialized countries, S. 
aureus is the most common causative agent of infective endocarditis (Witchitz et al., 
2005) and intravascular devices are commonly the source of the infection (A. Wang 
et al., 2007). Moreover, other risk factors of S. aureus infective endocarditis are 
persistent bacteraemia, other healthcare-associated infections, as well as injection drug 
use (A. Wang et al., 2007).  
 
1.2.3. Osteomyelitis 
Osteomyelitis is a bone infection that promotes inflammatory destruction, bone 
necrosis and new bone formation. It is quite common among children; however, the 
incidence of vertebral osteomyelitis in adults is increasing and the associated risk 
factors are advanced age, injection drug use, diabetes and immunosuppression 
(Mylona et al., 2009; Akiyama et al., 2013). Healthy bones are normally very resistant 
to infection. However, S. aureus has evolved several mechanisms to overcome this 
resistance and successfully colonize bone tissue. To achieve this, S. aureus expresses 
several surface proteins to gain adherence to the bone matrix and collagen 
(Cunningham, Cockayne and Humphreys, 1996). Besides, S. aureus is also able to 
invade osteoblasts and establish intracellular long-term infections (Shi and Xianlong, 
2012; Kalinka et al., 2014).  
 
1.2.4. Toxic shock syndrome (TSS) 
TSS caused by S. aureus is a superantigen-mediated illness, where the toxic shock 




al., 1990). TSST-1 cross-link T-cell receptor and Major Histocompatibility Class II 
Complexes (MHC-II) on antigen-presenting cells, leading to a large T-cell activation 
and cytokine release.  Consequently, this causes an overactivation of the inflammatory 
response, followed by septic-shock and organ failure (Fraser et al., 2000; Kalyan and 
Chow, 2008).   
While TSS was thought to be associated with the use of tampons in menstruating 
women in the 1980s (Shands et al., 1980), the incidence of menstrual and non-
menstrual cases is very similar and SSTIs usually precedes non-menstrual TSS cases 
(DeVries et al., 2011). In fact, non-menstrual toxic shock syndrome has been 
associated with higher mortality rates than menstrual toxic shock syndrome cases 
(Descloux et al., 2008). 
 
1.2.5. Pulmonary infections 
S. aureus has also been identified as a common cause of pneumonia in both 
Community-Associated and Hospital-Acquired infections and both MSSA and MRSA 
strains are isolated from these patients (De la Calle et al., 2016). It is also a common 
pathogen among cystic fibrosis patients (Schwerdt et al., 2018). In the case of 
pneumonia caused by MSSA, the risk factors are the same as for general pneumonia: 
low body mass index, smoking, chronic lung and liver disease, history of pneumonia 
and diabetes. In the case of MRSA pneumonia, hospitalization, previous surgeries and 
long-term-care residence are included as risk factors (Klevens et al., 2007). 
Among the virulence factors of S. aureus to establish respiratory infections, the pore-
forming α-toxin has been identified essential to develop clinical pneumonia (Bubeck 




the NLRP3 inflammasome, which leads to necrotic lung injury (Kebaier et al., 2012). 
Moreover, the increase of platelet-neutrophil aggregates – also activated by the α- 
toxin – contributes to tissue damage (Parimon et al., 2013). 
 
1.2.6. S. aureus bacteraemia 
S. aureus bloodstream infections are linked to higher rates of mortality and morbidity 
than bacteraemia caused by other Gram-positive pathogens, such as Streptococcus or 
Enterococcus (Naber, 2009). The incidence of S. aureus bacteraemia is very high in 
the first year of life, low through the young adulthood and it gradually rises again with 
increasing age (van Hal et al. 2012; Tong et al. 2015). Males are also associated with 
a higher incidence than females, although the reasons behind this observation are still 
unclear (Humphreys, Fitzpatrick and Harvey, 2015).  
Furthermore, there are several host-factors that increase the risk of developing S. 
aureus bacteraemia, including previous S. aureus infections or colonization, skin 
ulcers during hospitalization, the presence of venous catheters and surgical site 
infections, injection drug use, and an immunosuppressive condition (Naber, 2009). 
Additionally, haemodialysis patients also represent a risk group of invasive S. aureus 
infections, due to the presence of an intravascular device and the use of a tunnelled 






1.3. EMERGENCE OF METHICILLIN-RESISTANT S. AUREUS 
(MRSA) 
Another important feature of S. aureus infection is the pathogen´s ability to acquire 
antibiotic resistance. Many infections are caused by strains that are resistant to 
multiple antibiotics. Similarly to other multidrug-resistant pathogens, MRSA 
infections are associated with higher costs and extended hospitalization periods, as 
well as higher morbidity and mortality rates (Ippolito et al., 2010).  
In 1959, methicillin was introduced to treat S. aureus infections caused by penicillin-
resistant isolates. Two years later, in 1961, the first Methicillin-Resistant S. aureus 
isolate was reported in the UK (Jevons, 1961). Since then, several MRSA clones have 
evolved during the past decades by acquiring resistance to multiple antibiotics, that 
were introduced to treat MRSA infections (Hiramatsu et al., 2001). 
MRSA strains emerged by the acquisition of a large genetic element, known as the 
Staphylococcal Cassette Chromosome mec (SCCmec) (Katayama, Ito and Hiramatsu, 
2000). SSCmec is a 21-67 kb fragment of DNA, which is integrated in the 
chromosome of MRSA near the origin of replication of S. aureus. This specific 
location may play a significant role since genes that are positioned close to the origin 
possess higher chances of being present at multiple copies after DNA replication and 
cell division. Moreover, this integration site is located in an Open Reading Frame 
(ORF) that, although its function is unknown, is well-conserved among clinical S. 
aureus isolates (Hiramatsu et al., 2001).   
Although the large size of SSCmec is comparable to a pathogenicity island, this 
chromosomal cassette does not contain any virulence genes (Ito, Katayama and 




antibiotics resistance (Katayama, Ito and Hiramatsu, 2000), together with the genes 
mecl and mecR1. mecA encodes the resistance to β-lactam antibiotics and mecl and 
mecR1 act as regulators of the transcription of mecA (Zhang et al., 2001). The β-lactam 
resistance in MRSA occurs via a specialised Penicillin-Binding Protein (PBP), which 
is a transpeptidase involved in the formation of cross-bridges in bacterial 
peptidoglycan. mecA encodes Penicillin-Binding Protein 2 (PBP2) with low binding 
affinity to β-lactam antibiotics (Hiramatsu et al., 2001), which makes MRSA resistant 
to methicillin and all β-lactam antibiotics, including isoxazoyl penicillins (e.g., 
oxacillin) and broad spectrum β-lactam antibiotics, such as third-generation 
cephalosporins, cefamycins, and carbapenems (Chambers, 1997). Furthermore, the 
SSCmec cassette may also contain transposons and plasmids that carry resistance 
genes of non-β-lactam antibiotics (Hiramatsu et al., 2001).  
There are different types of SSC described and to date, 13 different types of SSCmec 
(I-XIII) have been identified for S. aureus (Baig et al., 2018). Extensive dissemination 
of SSCmec has occurred among Staphylococci species; however, its origin remains 
unconfirmed (Hiramatsu et al., 2001). 
 
1.3.1. Healthcare-associated vs community-associated MRSA 
Although MRSA infections were initially identified as nosocomial infections in the 
1960s (Archer, 1998), the number of detected MRSA infection cases within healthy-
community settings has risen in the past two decades, especially in the United States 
(Drews, Temte and Fox, 2006; David and Daum, 2010; Otto, 2013). The causative 
agents were classified as Community-Associated MRSA (CA-MRSA) and the first 




in the United States (CDC, 1999). Although the origin of CA-MRSA is still unclear, 
some evidences point towards the acquisition of SSCmec type IV by the multiple 
community-based MSSA strains. The small size of SSCmec type IV makes feasible 
the easy horizontal transfer among different genetic backgrounds (Hiramatsu et al., 
2001).  
Hospital-Acquired MRSA (HA-MRSA) infections are usually linked to advanced age, 
extended hospitalizations, intensive care unit stays, use of catheters and similar 
invasive procedures, haemodialysis patients, other clinical comorbidities and previous 
antibiotic exposure (Lowy, 1998). In contrast, community-associated MRSA (CA-
MRSA) infections have been reported among young and healthy individuals without 
exposure to healthcare facilities or without carrying any of the associated risks to HA-
MRSA (Drews, Temte and Fox, 2006). In paediatric cases, the dermatological 
condition is the underlying common factor associated with CA-MRSA infections; 
whereas in adults, the health of the skin, tobacco smoking and diabetes are the risk 
factors associated with this type of infections (Naimi et al., 2003). 
Regarding clinical manifestations, CA-MRSA infections are usually linked to SSTIs 
whereas HA-MRSA isolates are related to respiratory, urinary infections and 
bloodstream infections (Naimi et al., 2003). However, when invading CA-MRSA 
infections  such as necrotizing pneumonia occur, the patient´s prognosis is usually 
more negative (Drews, Temte and Fox, 2006). 
CA-MRSA and HA-MRSA strains also differ in their genotypic and phenotypic 
characteristics. The resistance to β-lactam antibiotics and methicillin in HA-MRSA 
isolates is mainly acquired through SSCmec type II and III, which are relatively large 
cassettes and carry many other resistance determinants. By contrast, CA-MRSA 




as the only resistance gene (Ma et al., 2002). Accordingly, CA-MRSA isolates are 
susceptible to most antimicrobials apart from β-lactam antibiotics and erythromycin, 
while HA-MRSA isolates are resistant to most available antibiotics (Naimi et al., 
2003). In addition, there are also differences in the expression of virulence factors 
among both strains. For example, Panton-Valentine Leucocidin (PVL) encoding genes 
are highly expressed in CA-MRSA strains (Watkins, David and Salata, 2012). PVL 
genes encode a pore-forming cytotoxin, which targets erythrocytes and leukocytes to 
induce an excessive inflammatory response, followed by tissue necrosis (Drews, 
Temte and Fox, 2006). This cytotoxin has been identified in 85% of CA-MRSA 
isolates causing necrotizing pneumonia, which may explain the higher mortality 
associated with this condition (Lina et al., 1999). 
 
 
1.4. PATHOGENESIS OF S. AUREUS INFECTIONS  
S. aureus is a versatile pathogen, capable of invading and infecting a wide range of 
tissues, and such versatility is related to its diverse repertoire of virulence factors. 
These virulence determinants can mainly be divided into two categories: cell-surface-
associated or secreted proteins (Fig. 1.1; (Gordon and Lowy, 2008)).  
Expression of surface-associated proteins usually occurs during the exponential 
growth phase (replication), whereas secreted proteins are expressed during stationary 
phase. Hence, early expression of surface-associated proteins promotes initial tissue 
invasion and colonization, whereas the expression of secreted proteins, such as toxins, 
facilitates bacterial replication and S. aureus dissemination during infection (Gordon 





Figure 1.1. Surface and secreted proteins that act as virulence factors during S. aureus 
infections. (A) Surface-associated proteins are expressed during exponential growth phase 
and contribute to the initial host invasion and colonization. (B) Secreted proteins are expressed 
during stationary phase and are involved in S. aureus replication and dissemination. TSST-1, 
toxic shock syndrome toxin 1. PVL, Panton-Valentin Leukodicin. PSMs, Phenol-soluble 
modulins. Figure is adapted from Lowy, 1998. 
 
1.4.1. Surface-associated proteins 
S. aureus surface-associated virulence factors include capsular polysaccharides, 
staphyloxanthin and a group of proteins known as Microbial Surface Components 
Recognizing Adhesive Matrix Molecules (MSCRAMMs) (Foster and Höök, 1998). 
Firstly, the role of capsules in S. aureus pathogenesis is mainly related to the 
prevention of phagocytosis by neutrophils, but it has also been associated with the 
enhancement of bacterial colonization and persistence on mucosal surfaces 
(O´Riordan and Lee, 2004). 
Staphyloxanthin, the carotenoid pigment that confers the golden colour to S. aureus 




generated during oxidative burst of neutrophils. Accordingly, inhibition of 
staphyloxanthin synthesis makes S. aureus more vulnerable to the host-immune 
system, contributing to bacterial clearance in mice kidneys after intraperitoneal 
infection challenge (Song et al., 2009). 
Lastly, MSCRAMMs function as adhesin molecules to facilitate adherence to host-
tissues (Foster and Höök, 1998; Gordon and Lowy, 2008). S. aureus is able to invade 
and colonize a wide range of tissues, including cartilage, bones, wounds or soft tissues 
and therefore, it takes advantage of different receptors to attach to specific tissues. For 
instance, bone colonization requires collagen-binding, whereas wound infection 
requires the expression of fibrinogen and fibronectin receptors. Among these 
structural proteins, the best well characterized are Staphylococcal protein A (SpA), 
fibronectin-binding proteins (FnBPs), collagen-binding protein (Cna), fibrinogen-
binding protein (clumping factor) and elastin binding proteins (EbpS) (Fig. 1.1). 
1.4.1.1. Staphylococcal protein A (SpA)  
SpA is a 42 kDa protein, covalently anchored in the staphylococcal cell wall. It 
possesses five immunoglobulins-binding domains and each unit is capable of binding 
to the Fc region of different mammalian IgG subclasses (Sjödahl, 1977; Moks et al., 
1986), which has been directly associated with the protection of S. aureus from 
opsonophagocytosis (Peterson et al., 1977). In addition, it can also interact with the 
Fab domain of B-cell receptors (Sasso, Silverman and Mannik, 1989; Jansson, Uhlén 
and Nygren, 1998) and such interaction promotes B-cells activation (Goodyear and 
Silverman, 2003). Overall, protein A has shown the potential to alter the host-immune 
response against S. aureus during infection and therefore, it has been recently 




levels of protein A have been associated to S. aureus nasal carriage (Muthukrishnan 
et al., 2011). 
1.4.1.2. Fibronectin-binding proteins (FnBPs) 
S. aureus has two main fibronectin-binding proteins, FnBPA and FnBPB, whose 
molecular weight is approximately 200 kDa and they are only expressed during early 
exponential growth phase (Shinji et al., 2011). The structure of both FnBPA and 
FnBPB is quite similar, resulting in high sequence homology (68%) (Meenan et al., 
2007), which suggests similar functions in S. aureus virulence. 
Both FnBPA and FnBPB are major determinants during S. aureus invasion and 
internalization into non-professional phagocytes, such as endothelial and epithelial 
cells, keratinocytes and fibroblasts. Internalization into non-phagocytic cells occurs 
by a “zipper-type mechanism”, which involves the binding of FnBPA and FnBPB to 
the host membrane α5β-integrin via a fibronectin bridge (Sinha et al., 1999; Edwards 
et al., 2011; Shinji et al., 2011). Accordingly, deletion of FnBPA reduced S. aureus 
invasion in human embryonic cells (HEK293T) by 80-85%, while a double knockout 
of FnBPA and FnBPB resulted in a decrease of 95%. These results suggest that 
although both FnBPs proteins are important during S. aureus internalization, FnBPA 
may play a more critical role (Sinha et al., 1999).  
Due to its important role during S. aureus internalization, FnBPs are described as a 
major virulence factor of S. aureus pathogenesis. This importance is further reflected 
by the high expression of FnBPs found among most clinical isolates (around 70%) 




1.4.1.3. Collagen-binding protein (Cna) 
The collagen-binding protein Cna is a cell-anchored protein, expressed by S. aureus 
to attach to collagen-rich tissues, such as cartilage, which is particularly rich in 
collagen II (Switalski et al., 1993). Collagen, the most abundant protein in humans, is 
responsible for the structural support of tissues and therefore, it represents an 
important ligand for the initiation and persistence of numerous bacterial infections 
(Madani, Garakani and Mofrad, 2017).  
Moreover, attachment of S. aureus to cartilage and bone tissue is directly correlated 
with the expression of Cna, showing its involvement in the development of septic 
arthritis (Switalski et al., 1993; Patti et al., 1994). It has also been described as a major 
virulence factor in the pathogenesis of osteomyelitis, keratitis and endocarditis (Hienz 
et al., 1996; Rhem et al., 2000; Elasri et al., 2002).  
1.4.1.4. Clumping factors (Clfs) 
Fibrin is the major constituent of blood clots and fibrinogen/fibrin is one of the 
predominant proteins found in implanted materials. The ability of S. aureus to adhere 
to surfaces coated with these two proteins is crucial to stablish implanted-associated 
infections (Mcdevitt et al., 1997).  
Clumping factor A has the ability to adhere to both fibrinogen and fibrin and it is also 
responsible for bacterial cells clumping (McDevitt et al., 1994). Specifically, ClfA has 
two binding sites of within the γ-chain of the fibrinogen (Mcdevitt et al., 1997; 
Geoghegan et al., 2010). Moreover, ClfA is also associated with platelet aggregation, 
which are thought to promote endovascular infection and dissemination of S. aureus 




 Clumping factor B is a protein able to adhere to fibrinogen. Although its general 
organisation is quite similar to ClfA, the binding mechanism of these two proteins is 
different: ClfB binds the α and β-chains of fibrinogen, whereas ClfA exclusively 
recognize γ-chains (Eidhin et al., 1998). More recent studies revealed that ClfB is also 
able to bind cytokeratin 10, promoting the adhesion to squamous epithelial cells, 
which may be important for nasal colonization (O’Brien et al., 2002; Walsh et al., 
2004). 
1.4.1.5. Elastin binding protein (EbpS) 
EbpS is a surface-associated protein with the ability to bind soluble elastin as well as 
the tropoelastin precursor (Park et al., 1991; Nakakido, Tanaka and Tsumoto, 2007). 
Elastin is one of the major constituents of the elastic fibres within the extracellular 
matrix, which plays an important role in maintaining the structural integrity in those 
tissues where reversible extensibility is required (Park et al., 1991).  S. aureus is 
capable to infect human tissues that are rich in elastin, such as lungs and skin and 
therefore, elastin-binding proteins (EbpS) may facilitate the invasion and colonization 
of these tissues (Downer et al., 2002). 
 
1.4.2. Secreted proteins 
Although research has been traditionally focused on the study of cell surface-
associated proteins in S. aureus pathogenesis, the relevance of secreted-proteins in the 
initiation and progression of staphylococcal infections is now becoming clear. Many 
are identified as toxins, and their distinction from other virulence determinants is due 
to their potential to interfere directly with the host (Otto, 2014). These toxins play key 




well as interfering with the host-immune responses to release nutrients that facilitate 
bacterial replication (Lin and Peterson, 2010). Current antibiotics to treat S. aureus 
infections, kill the bacterium by lysing the staphylococcal cell wall or by inhibiting its 
biosynthesis. However, these drugs are unable to inhibit S. aureus toxins production 
or to neutralize their effects on host cells (Stevens et al., 2007).  
Among the plethora of staphylococcal secreted virulence factors, the best well-
characterized proteins can be classified into two different categories: superantigens 
and pore-forming toxins.  
1.4.2.1. Superantigens  
Enterotoxins and the Toxic Shock Syndrome toxin 1 (TSST-1) are included in this 
category. More than 20 superantigens have been identified among different S. aureus 
strains and approximately 60% of clinical isolates contain at least one superantigen 
(Becker et al., 2003), showing its relevance in S. aureus infections.  
The main function of superantigens is to disturb the host immune response in order to 
ensure bacterial survival and persistence in the host. These toxins are able to activate 
T-cells and antigen-presenting cells – such as macrophages and dendritic cells – 
leading to a massive release of cytokines and chemokines (Bernal et al., 1999; Fraser 
et al., 2000). This cytokine storm causes the symptoms that are observed in the TSS: 
fever, rash, desquamation of the palms of hands and feet, hypotension and multiorgan 
failure (DeVries et al., 2011). To promote S. aureus pathogenesis, superantigens might 
also have direct effects on specific cells. For example, TSST-1 has pro-inflammatory 
and cytotoxic effects on endothelial cells, which leads to capillary leakage and TSS 




in epithelial cells, stimulating neutrophil recruitment, which leads to subsequent tissue 
destruction (Peterson et al., 2005). 
On the other hand, bacteria expressing enterotoxins (SEs) are capable to induce emesis 
and diarrhoea when ingested, caused by an SE-induced inflammation in the abdominal 
area (Dinges et al., 2000). S. aureus produce at least 5 enterotoxins: SEA, SEB, SEC, 
SED and SEE. In particular, Staphylococcal enterotoxin B (SEB) has been described 
as a potential biological weapon (Zapor and Fishbain, 2004), whereas Staphylococcal 
enterotoxin C (SEC) is associated with CA-MRSA in invasive endocarditis and sepsis 
(Salgado-Pabón et al., 2013). 
1.4.2.2. Pore-forming toxins  
S. aureus secretes a great number of pore-forming toxins, including: cytolysins (α-
toxin), toxins from the leucocidin family (PVL), and phenol-soluble modulins (PSMs) 
(Fig.1.1). They differ from each other in the structure and target specificity, despite 
their function on host cells is very similar. They create pores in host cell membranes, 
causing leakage and inflammation at low doses and cell lysis at higher doses (Lin and 
Peterson, 2010). 
The most well-characterized cytolysin is the α-toxin (Berube and Wardenburg, 2013). 
It is encoded by the gene hla, which is expressed in all clinical isolates (Dinges et al., 
2000). The α-toxin is cytolytic to a wide range of mammalian cells, such as 
erythrocytes, leukocytes (monocytes and macrophages), platelets, fibroblasts and 
epithelial cells (Berube and Wardenburg, 2013). The role of the α-toxin in 
staphylococcal pneumonia has also been demonstrated in mice, where the mortality 
rate was associated with the concentration of secreted α-toxin by S. aureus (Kebaier 




metalloproteinase ADAM10, leading to the disruption of focal adhesions (Wilke and 
Wardenburg, 2010; Inoshima et al., 2011).  
Another member of pore-forming toxins is the Panton-Valentin Leukodicin (PVL), a 
virulence determinant associated with CA-MRSA strains. PVL is a bicomponent 
toxin, encoded by lukS and lukF genes (Otto 2010; Watkins et al. 2012; Otto 2013). 
PVL forms pores in the membrane of neutrophils – a major component in the host-
immune response against bacterial infections – causing their lysis. PVL was firstly 
described by Panton and Valentine in 1932 and associated with SSTIs; however, its 
virulence in S. aureus infections remains controversial. For example, Voyich and co-
workers showed that CA-MRSA strains lacking PVL were as virulent as those strains 
expressing the toxin in mice sepsis and abscess formation (Voyich et al., 2006). 
Another study compared two CA-MRSA strains (S. aureus USA300 and S. aureus 
USA400) in a mouse pneumonia model and reported that it was α-toxin, and not PVL, 
the responsible for mice mortality (Bubeck Wardenburg et al., 2007). However, 
Löffler et al. (2010) investigated the cytotoxic effect of PVL in neutrophils from 
human, mice, rabbit and monkeys and they showed that murine neutrophils are not 
sensitive to PVL, suggesting that mice models do not fully replicate staphylococcal 
human infections. In contrast, rabbit neutrophils were much more susceptible to PVL 
than murine cells, indicating a closer model to human disease (Löffler et al., 2010). 
Collectively, PVL is certainly a virulence factor in CA-MRSA infections but its 
contribution to the severity of the disease seems to occur in a strain and host-specific 
manner. 
Lastly, S. aureus is also capable of producing high amounts of small and amphipathic 
peptides with detergent-like properties, which are known as Phenol-Soluble Modulins 




(R. Wang et al., 2007). The main role of PSMs on S. aureus pathogenesis is the 
leukocytes’ destruction and thus, these toxins play a crucial role in the host-immune 
evasion of S. aureus (R. Wang et al., 2007; Otto, 2014).  
In addition to superantigens and pore-forming toxins, S. aureus also secretes several 
extracellular enzymes and other proteins, which are involved in host-tissue disruption, 
modulation of host immune responses and/or inactivation of host antimicrobial 
mechanisms (Lin and Peterson, 2010). Some of these secreted factors are briefly 
summarized in table 1.1.   
Name Putative function Reference 
Exoenzymes   
Serine proteases  Inactivate neutrophils activity 
(Lin and Peterson, 
2010) 
Cysteine proteases (Staphopain) Block of neutrophil activation (Laarman et al., 2012) 




Activate plasminogen; Inactivate 
antimicrobial peptides 
(Bokarewa, Jin and 
Tarkowski, 2006) 
Miscellaneous proteins   
Staphylococcal Complement 
Inhibitor (SCIN) 
Inhibit complement activation 
(Rooijakkers et al., 
2005) 
Chemotaxis Inhibitory Protein 
of S. aureus (CHIPS) 
Inhibit chemotaxis (Foster, 2005) 
Extracellular Adherence Protein 
(Eap) 
Inhibit neutrophil migration (Harraghy et al., 2003) 







1.5. REGULATION OF S. AUREUS VIRULENCE FACTORS 
DURING INFECTION 
As aforesaid, the process of S. aureus infection can be divided in two separate stages: 
(i) an adhesion/invasion phase, and (ii) a proliferation phase, which are characterized 
by the expression of different virulence factors (surface-associated vs secreted, 
respectively). The transition of these two phases and the subsequent expression of 
different virulence factors are commanded by a complex regulatory network, 
including the quorum-sensing Accessory gene regulator (Agr) system, the 
transcriptional regulators of the Sar family, the two-component regulatory systems 
ArlRS and SaeRS, and the sigma factor B (σB) (Hauck and Ohlsen, 2006; Wang and 
Muir, 2016).  
The Agr quorum-sensing system is a 3.5 kb locus that comprises two transcriptional 
units (RNAII and RNA III), whose transcription is controlled by two promoters 
(Promoter 2 and Promoter 3). The RNAII gene cluster encodes a DNA-binding 
response regulator (AgrA) and a sensor kinase (AgrC). Additionally, the precursor of 
Auto-Inducing Peptide (AIP) – AgrD – is firstly processed by membrane-bound 
peptidase – AgrB – to generate an intermediate (Wang and Muir, 2016). AgrC senses 
the concentration of the AIP and at high concentrations of AIP, AgrC phosphorylates 
AgrA. Consequently, phosphorylated AgrA enhances agr transcription by binding to 
the promoter 2 region of RNA II and the promoter 3 region of RNA III (Le and Otto, 
2015; Horn et al., 2017). Besides AIP, the Agr system can also be activated by other 
regulators, such as SarA and SrrAB (Heinrichs, Bayer and Cheung, 1996; Yarwood, 
McCormick and Schlievert, 2001), or by environmental conditions, such as pH or 




RNA III is considered the main intracellular effector of the Agr system. RNA III 
inhibits the expression of surface-associated proteins, allowing the upregulation of 
secreted toxins (Fechter et al., 2014). This regulatory mechanism reflects the temporal 
requirements for different virulence factors during S. aureus infection, which is 
directly related to bacterial cell density and agr-regulation. At the beginning of the 
infection, low bacterial density – and low expression of agr – promote the expression 
of surface proteins required for initial adhesion. Once infection is established, higher 
bacterial density leads to the upregulation of the Agr system and the subsequent 
production of toxins (Le and Otto, 2015). Moreover, activation of the Agr system can 
be triggered within host cells. 
Nevertheless, the quorum-sensing Agr system upregulates 174 genes, and 90 of those 
genes are regulated in a RNAIII-independent manner. Among the virulence factors 
directly-controlled by the Agr system,  the staphylococcal protein A (SpA), α-toxin 
(Hla), bicomponent toxins (PVL, lukSF, lukDE) and proteases (e.g. staphopain) are 
included (Queck et al., 2008).  
In summary, the quorum-sensing Agr system plays an essential role in S. aureus 
pathogenesis. The importance of the upregulation of virulence factors controlled by 
the Agr system in acute infection has been shown in different animal models, including 
SSTIs, infective endocarditis, pneumonia, septic arthritis and osteomyelitis (Le and 
Otto, 2015). Accordingly, agr deletion mutants showed a reduced virulence in a wide 
range of infections (Horn et al., 2017), which makes the Agr system a potential drug 
target for anti-staphylococcal therapies. However, silencing the Agr system activates 
S. aureus biofilm formation, which may support the persistence of chronic infections 




In addition to the well-characterized Agr quorum-sensing system, S. aureus further 
possess other regulatory components, important for S. aureus pathogenesis. The two-
component ArlRS regulates S. aureus exotoxin production and induces the expression 
of the DNA-binding protein SarA (Fournier, Klier and Rapoport, 2001). Also, ArlRS 
enhance intracellular S. aureus growth in the presence of calprotectin, which is an 
immune protein mainly expressed by neutrophils.  
Lastly, the sigma factor B (σB) also contributes to S. aureus pathogenicity. σB is 
required for tolerance to low pH and hydrogen peroxide, which is associated with S. 
aureus survival after being ingested by phagocytes (Chan et al., 1998). In addition, 
the σB-activating protein RsbU is needed for the internalization and intracellular 
growth of S. aureus within HUVEC and THP-1 cells (Olivier et al., 2009). 
Furthermore, σB has shown to promote intracellular persistence through the formation 
of SCVs, being crucial in chronic infections (Tuchscherr et al., 2015).  
 
 
1.6. BIOFILM FORMATION 
S. aureus is also characterized by its ability to produce biofilms, enhancing bacterial 
survival and persistence in host-tissues. A biofilm is a microbial community whose 
cells are attached to a surface or to other cells. Bacterial growth within biofilms might 
be important during infection since it provides a niche, where the pathogen is protected 
from several clearance mechanisms. Biofilms can prevent the access of certain 
immune cells, such as macrophages (Scherr et al., 2014) and they also exhibit 




The process of biofilm formation can be subdivided in three stages: (i) initial 
attachment, (ii) biofilm maturation and (iii) dispersal (Lister and Horswill, 2014).  
(i) S. aureus mediates initial attachment by expressing surface-associated proteins 
(MSCRAMMs). Particularly, protein A, fibronectin-binding proteins (FnBPs), S. 
aureus surface protein (SasG), biofilm-associated protein (Bap) and clumping factor 
B (ClfB) are important for both initial bacterial attachment and biofilm accumulation 
(Foster et al., 2014; Lister and Horswill, 2014).  
(ii) Afterwards, biofilm maturation is characterized by bacterial cell division and the 
formation of an extracellular polymeric matrix. The composition of this extracellular 
matrix is highly strain-dependent (Artini et al., 2012); however, host-factors, 
polysaccharides, extracellular DNA (eDNA), and secreted and lysis-derived proteins 
are commonly found within its composition (Montanaro et al., 2011; Foster et al., 
2014). Another major biofilm component is the Polysaccharide Intracellular Adhesin 
(PIA), which is equally important in both S. aureus and S. epidermis biofilms, and 
confers structural integrity to biofilms in vitro and in vivo (Lister and Horswill, 2014).  
(iii) Eventually, individual bacterial cells are able to disperse from the original biofilm 
site, establishing new loci of infection (Boles and Horswill, 2011). Among the 
staphylococcal factors that support biofilm dispersal, PSMs have shown to play an 
important role. They are able to disrupt non-covalent forces that maintain the 
extracellular matrix together, creating channels that are essential for the dissemination 
of bacterial cells to new sites (Peschel and Otto, 2013; Le et al., 2014). In addition, 
the induction of Agr complex mediates biofilm dispersal by triggering proteases 




Taking altogether, persistence of S. aureus in chronic infections is highly associated 
with biofilm formation and bacterial growth within it. In particular, S. aureus cause 
osteomyelitis and endocarditis by persisting on host tissues like bones or heart valves, 
respectively (Parsek and Singh, 2003). It can also adhere to implanted materials – such 
as catheters, prosthetic joints and pacemakers – that become coated with host-protein, 
facilitating bacterial attachment through matrix-binding proteins (François et al., 
1996; Barrett and Atkins, 2014).  
 
 
1.7. INTRACELLULAR FATE OF STAPHYLOCOCCUS AUREUS  
While traditionally S. aureus was exclusively classified as an extracellular pathogen 
(Finlay and Cossart, 1997), it has been shown that this pathogen is also able to subvert 
phagocytosis by macrophages and neutrophils and to be internalized by non-
phagocytic cells, such as epithelial and endothelial cells, osteoblasts, fibroblasts and 
keratinocytes (Garzoni and Kelley, 2009; Fraunholz and Sinha, 2012; Horn et al., 
2017). It has even been shown to survive within neutrophils and human monocyte-
derived macrophages (Gresham et al., 2000; Kubica et al., 2008). Therefore, and 
taking all these evidences together, S. aureus is currently considered a facultative 
intracellular pathogen.  
Intracellular survival strategies of S. aureus are very diverse, depending on the 
bacterial strain as well as the type of infected host cell (Strobel et al., 2016). 
Particularly, most of the host-pathogen interactions occurring during S. aureus 
infection could be classified into four categories: internalization into host cells, 




1.7.1. S. aureus internalization into non-phagocytic cells 
Mechanistically, invasion of non-professional phagocytes by S. aureus is achieved via 
a zipper-type mechanism, which is mainly mediated by the interaction between S. 
aureus FnBPA and FnBPB, fibronectin and the α5β1-Integrins of the host cell (Fig. 
1.2A) (Sinha and Fraunholz, 2010; Fraunholz and Sinha, 2012; Foster, 2016). The 
efficiency of this type of adhesion (FnBPs / Fibronectin / α5β1-integrins pathway) 
differs between different cell lines. For example, invasion of endothelial cells requires 
only one high-affinity Fibronectin Binding Receptor (FnBR) (Edwards et al., 2010), 
whereas three FnBRs are required to get internalized in keratinocytes (Edwards et al., 
2011).  
Moreover, epithelial or endothelial cells usually do not expose α5β1-integrins in their 
surfaces to be accessible by the pathogen. Only sub-confluent cell monolayers or 
damaged tissues express these fibronectin receptors, which may illustrate why 
intracellular S. aureus is commonly found in disrupted tissues (Horn et al., 2017). 
Nevertheless, S. aureus can also lead to tissue destruction by α-toxin production, 
which ability to disrupt the barrier function of epithelial cells is mediated by interfering 
with tight junction integrity (Kwak et al., 2012). Interestingly, α-toxin has further 
shown to increase β1-Integrins in mast cells, promoting S. aureus internalization 
(Goldmann et al., 2015). In line with this latter observation, cells lacking β1-integrins 
do not internalize S. aureus at the same rate as cells expressing these integrins (Hauck 
and Ohlsen, 2006). Furthermore, it has been recently demonstrated that β1-integrins 
are ectopically expressed on the surface of epithelial cells in cystic fibrosis (CF) 
patients, which explains the persistent S. aureus colonization in the lungs of CF 




In summary, interaction between bacterial FnBPs and host integrins plays an important 
role during S. aureus internalization in non-phagocytic cells. This interaction further 
leads to signal transductions in the host cell to promote cytoskeleton rearrangements, 
which are also necessary for the successful internalization of S. aureus into the host 
cell (Dziewanowska et al., 1999). The relevance of host-actin cytoskeleton is in 
concordance with previous studies where treatment of cells with cytochalasin D – an 
inhibitor of actin polymerization – resulted in a significant reduction of S. aureus 
internalization (Sinha et al., 1999). Specifically, the signalling pathway involves focal 
adhesion kinases (FAKs) and the activation of Src, which consequently recruit 
cortactin to facilitate host-actin polymerization (Fig. 1.2) (Agerer et al., 2005). Some 
specificity among cell lines is also observed regarding the intracellular signalling 
cascades activated during pathogen internalization. For instance, the activation of 
phosphoinositide-3-kinase (PI3K)-Akt pathway is important during S. aureus 
internalization by endothelial cells (Oviedo-Boyso et al., 2011). On the other hand, 
the Extracellular Signal-Related Kinases (ERK) and c-JUN kinases (JNK) are 
involved in the internalization of S. aureus inside osteoblasts, whereas the Mitogen-
Activated Protein Kinase p38 (MAPK) is also upregulated along with ERK in Hep-2 





Figure 1.2. S. aureus mechanisms of internalization into host-cells. FnBPs, Fibronectin-
binding proteins. Atl, autolysin. SdrD, Serine Aspartate Repeat-containing protein D. SraP, 
Serine-Rich Adhesin for platelets. ClfA, Clumping factor A. FAK, Focal Adhesion Kinase. 
PI3-k, phosphoinositide-3-kinase. Hsp60, Heat Shock Protein 60. Hsc70, heat shock cognate 
protein 70. Figure adapted from Josse et al. 2017. 
 
Besides the main internalization pathway (FnBPs / Fibronectin / α5β1-integrins), 
FnBPs are also able to directly bind to the Human Heat Shock Protein 60 (Hsp60), 
which is exposed in the surface of epithelial cells, in order to promote internalization 
(Dziewanowska et al., 2000). Additionally, there are other bacterial factors that also 
interact with specific host factors to facilitate host cell invasion and internalization of 
S. aureus. Among these secondary fibronectin-independent mechanisms, the most 
common bacterial factors are Autolysin (Atl), Clumping Factor A, Serine Aspartate 
Repeat-containing protein D (SdrD) and Serine-Rich Adhesin for platelets (SraP), 
which bind different host-receptors (Fig 1.2). For example, the staphylococcal Atl 
protein acts as an adhesin by directly binding to the heat shock cognate protein 70 
(Hsc70) (Hirschhausen et al., 2010); SdrD mediates adherence to keratinocytes 
through Desmoglein 1 binding (Askarian et al., 2016); and SraP binds the scavenger 




other hand, the mechanism of ClfA differs depending on the cell line. In epithelial 
cells, ClfA directly binds to Annexin 2 (Ashraf, Cheng and Zhao, 2017), whereas in 
endothelial cells ClfA binds to αVβ3-integrin using fibrinogen as a bridge (McDonnell 
et al., 2016). Moreover, it has been shown that S. aureus Newman strain mediates 
internalization to fibroblasts and epithelial cells via Eap (Hussain et al., 2002), 
although the molecular mechanism behind this internalization pathway is still not fully 
elucidated (Fig. 1.2).  
 
1.7.2. Intracellular persistence, the role of Small Colony Variants 
(SCVs) 
The efficiency of intracellular S. aureus survival depends on several factors: (i) the 
bacterial strain, (ii) the host-cell and its gene expression, (iii) the multiplicity of 
infection (MOI), and (iv) the bacterial growth phase employed for the infection 
(Fraunholz and Sinha, 2012). However, the intracellular survival of S. aureus for 
extended periods of time has been reported into different mammalian cell lines 
(Garzoni and Kelley, 2009; Fraunholz and Sinha, 2012; Horn et al., 2017). In 
particular, S. aureus can survive and replicate inside phagocytic cells, such as 
neutrophils and macrophages (Gresham et al., 2000) and interestingly, internalized S. 
aureus in macrophages express anti-apoptotic factors in order to prolong bacterial 
survival (Koziel et al., 2009). S. aureus can also survive inside migratory phagocytes, 
facilitating its own dissemination to new points of infection (Horn et al., 2017).  
In general, intracellular persistence has been commonly associated with small colony 
variants (SCVs) forms, which have further been correlated with chronic and recurrent 




activity, slow growth rates and increased antibiotic resistance (Proctor et al., 2006; 
Sendi and Proctor, 2009).  The visual features of SCV that distinguish them from the 
wild-type phenotype include small colony size, reduced golden pigmentation, and 
decreased haemolysis on blood agar plates (Sendi and Proctor, 2009; Kahl, 2014). At 
molecular level, there are also some differences between both phenotypes. For 
instance, the gene sigB is up-regulated in SCV forms (Horsburgh et al., 2002) and this 
up-regulation promotes the expression of Clf and FnBPs, making SCVs well prepared 
for the attachment to host-cells (Vaudaux et al., 2002).  
Once S. aureus has been internalized into eukaryotic cells, bacteria require several 
features to survive inside host-cells, including: (i) avoid killing the host-cell and (ii) 
subvert intracellular host defences (Sendi and Proctor, 2009). Accordingly, SCVs can 
persist intracellularly through several adaptations. 
(i) SCVs are well-adapted to intracellular survival by limiting their cytotoxicity. For 
this purpose, levels of functional RNAIII and agr expression in SCVs are very low 
compared to wild-type colonies, which results in a reduced expression of 
staphylococcal toxins such as α-toxin and TSST-1 (Proctor et al., 2006). As a 
consequence, SCV-infected cells may remain viable (von Eiff et al., 2001).  
(ii) SCVs possess a thick cell wall and a reduced membrane potential, which confers 
some resistance against cationic antimicrobial peptides, an essential component of the 
host immune defence (Peschel, 2002). Moreover, due to the reduction activity of the 
TCA cycle and acetate catabolism in SCVs, carboxylate is shunted into the production 
of the polysaccharide intercellular adhesin (PIA), which confers resistance against the 
non-oxidative killing machinery of neutrophils (Al Laham et al., 2007). In addition, 




the thrombin-induced platelet microbicidal protein (Koo et al., 1996) and lactoferrin 
B (Samuelsen et al., 2005).  
 
1.7.3. S. aureus phagosomal escape  
Among its several mechanisms to subvert phagocytosis, phagosomal escape of S. 
aureus is an important strategy for intracellular survival (Lâm et al. 2010; Grosz et al. 
2014) and such escape was detected after 2.5 hours of invasion in HEK293 cells 
(Grosz et al. 2014). The dependency of phagosomal escape on the Agr system has 
been demonstrated since agr knockout mutants are confined in the phagosome and not 
detected in the host cell cytosol (Blättner et al., 2016; Münzenmayer et al., 2016). 
PVL has also been described to play an important role for S. aureus phagosomal 
escape in keratinocytes (Chi et al., 2014). In addition, the role of many other S. aureus 
toxins on phagosomal escape has been assessed with deletion mutants. Individual 
deletions of α-toxin, δ-toxin, β-toxin or PSMβ did not affect bacterial escape rates; 
however, PSMα was identified as a key factor in the phagosomal escape of S. aureus 
in both phagocytic and non-phagocytic cells (Grosz, Kolter, Paprotka, A. C. Winkler, 
et al., 2014; Münzenmayer et al., 2016). Nevertheless, PSMα expression alone is not 
sufficient to induce escape to the cytosol, and other phagosomal escape factors have 
been recently suggested (Blättner et al., 2016), but further investigation is needed to 
fully understand their mechanism of action.  
The specific subcellular location of S. aureus intracellular replication seems to be host 
cell-dependent. In non-phagocytic cells, S. aureus is able to proliferate in the host cell 
cytosol after phagosomal escape. However, autophagosomes have also been observed 




observation, the pharmacological control of autophagy can have a very significant 
impact on the intracellular survival of S. aureus in HeLa cells and fibroblasts (Schnaith 
et al., 2007).  
 
1.7.4. Host-cell death induced by S. aureus 
Apoptosis is a programmed cell death mechanism, which is essential for cellular 
homeostasis in eukaryotic cells, and facilitates the eradication of damaged cells 
without promoting an inflammatory response. Other host cellular death mechanisms 
are necrosis and pyroptosis (Fraunholz and Sinha, 2012).  
Some obligate intracellular pathogens, such as Chlamydia or Ricketsia, possess 
mechanisms to prevent host cell death in order to ensure their replication niche. By 
contrast, other intracellular pathogens, such as Salmonella or Listeria, induce host cell 
death mechanisms for different purposes, e.g. to overcome epithelial barriers or to kill 
immune cells. This pathogen-host cell death interplay may be quite complex, since 
most intracellular pathogens can initially promote host cell survival to guarantee 
intracellular replication, and then induce host cellular death at later points of the 
infection to facilitate bacterial cell dissemination (Horn et al., 2017).  
Specifically, S. aureus has shown to promote host cell death in a wide range of 
mammalian cells, including epithelial and endothelial cells, osteoblasts and 
professional phagocytes, such as macrophages and neutrophils. When S. aureus-
induced cell death occurs, this has been mainly identified via apoptosis (Fraunholz and 
Sinha, 2012; Horn et al., 2017), although necrosis induced by the α-toxin has also been 




Regarding bacterial virulence factors involved in S. aureus-induced cell death, there 
is large variability depending on the host cell line as well as the bacterial strain tested. 
In fact, not all S. aureus strains have the ability to induce host cell death after cell 
infection (Krut et al., 2003). Nevertheless, many bacterial factors have been 
commonly identified to be involved in the induction of host cell death. For example, 
the α-toxin and PVL are sufficient to directly induce leukocyte destruction (Otto, 
2010; Berube and Wardenburg, 2013). Furthermore, PVL can also induce cell death 
in human and rabbit polymorphonuclear neutrophils (PMNs) by activation of caspase 
9/3 signalling pathway (Genestier et al., 2005; Chi et al., 2014). Caspase 9 activates 
other effector caspases, which results in membrane blebbing and DNA fragmentation 
(Rudel, Kepp and Kozjak-Pavlovic, 2010). Additionally, caspase 2, which is induced 
by staphylococcal toxins such as α-toxin and aerolysin, is also involved in the initiation 
of caspase signalling that leads to cell death of non-professional phagocytes (Imre et 
al., 2012).  
Caspase-independent mechanisms have also been reported in S. aureus-induced host 
cell death. For example, c-JUN kinases (JNK) can be activated by inflammatory 
cytokines or cytotoxic agents to promote apoptosis by upregulation of pro-apoptotic 
proteins, and may also play an important role in S. aureus-induced cell death 
(Dhanasekaran and Reddy, 2008). Another cytotoxic factor involved in host cell death 
observed in S. aureus infected cells is PSMα (Haslinger-Löffler et al., 2005; Rasigade 
et al., 2013; Surewaard et al., 2013). 
On the other hand, the expression of S. aureus toxins may release cathepsin, which in 
turn activates the inflammasome resulting in host cell death via pyronecrosis (Muñoz-




to induce pyronecrosis, by activating the inflammasome components Caspase 1, NOD-
like receptor protein 3 (NLRP3) and the adaptor protein ASC (Melehani et al., 2015). 
 
 
1.8. CLINICAL MANAGEMENT OF S. AUREUS INFECTIONS 
Treatment of S. aureus infections is becoming a real challenge, especially considering 
the emergence of MRSA strains resistant to last resort of antibiotics, such as 
vancomycin (Howden et al., 2010). Clinical management of MRSA infections varies 
depending on the type of infection as well as the bacterial strain. Overall, most MRSA 
infections usually require prolonged period of antibiotic therapy, hospitalization, and 
the removal of infected tissue or biomaterial in case of localized-infection or prosthetic 
joint infections, respectively (Tong et al. 2015). 
The list of antibiotics currently available and approved to treat MRSA infections are 
vancomycin, daptomycin, linezolid and some other antimicrobials recently developed, 
including tedizolid, telavancin, oritavancin, dalbavancin, ceftaroline and ceftobiprole 
(Boswihi and Udo, 2018). Since these latter antibiotics are mostly employed to treat 
only SSTIs, the most commonly antibiotics used to treat MRSA infections are 
vancomycin, daptomycin and linezolid. However, these three last-resort antibiotics 
also present some limitations. For example, daptomycin cannot be used to treat 
pneumonia infections (Raja et al., 2003), whereas linezolid is not suitable for 
bacteremia or infective endocarditis treatment (Watkins, Lemonovich and File  Jr, 
2012). In addition, strains with reduced susceptibility to daptomycin and linezolid, and 
Vancomycin-Intermediate or even Vancomycin-Resistant S. aureus (VISA & VRSA) 




study showed that intracellular S. aureus is protected from antibiotics exposure, since 
intracellular killing is not achieved at clinically relevant concentrations of 
vancomycin, daptomycin or linezolid (Lehar et al., 2015). This observation is also in 
line with previous studies, which reported that most antibiotics are not capable of 
intracellular S. aureus clearance in vitro (Barcia-Macay et al., 2006) or in vivo 
(Sandberg et al., 2009). 
Additionally, it is becoming clear that the complex interaction between the pathogen 
and the immune system of the host is preventing the development of an efficient 
vaccine. For example, different staphylococcal virulence factors such as protein A 
possess immunosuppressive effects, which compromise the immunological memory 
of the host (Kobayashi and Deleo, 2013). Indeed, it has been recently demonstrated 
that vaccination against staphylococcal antigens located in the cell-surface may even 
aggravate the infection (Spaulding et al., 2014). Another important issue regarding the 
development of a S. aureus vaccine is the use of experimental animals that are not 
natural hosts of this pathogen (Brown et al., 2014). For instance, despite of some 
protection against S. aureus can be obtained in mice, the translation of this protective 
effect into humans has failed repeatedly (Kobayashi and Deleo, 2013). 
Therefore, due to the alarming emergence of antibiotic resistance and the lack of a 
suitable vaccine against S. aureus infections, novel therapeutics capable of targeting 
intracellular bacteria, which have been shown to be protected from conventional 
antibiotics, are needed.  
A recently explored strategy to tackle this problem is the design of antibodies 
conjugated with bactericidal antibiotics that are specifically released within the host 
cell (Lehar et al., 2015). However, in this approach the antibiotics are only active due 




may not be effective against cytosolic S. aureus or bacteria replicating in 
autophagosomes. In addition, the use of antibiotics targeting cell growth or division 




1.9. HOST-DIRECTED APPROACHES, A NEW PERSPECTIVE  
A new strategy to develop novel therapies against intracellular pathogens is emerging 
in the form of host-directed therapies (Zumla et al., 2016; Kaufmann et al., 2018). 
Intracellular pathogens require the exploitation of host molecular factors and 
metabolic pathways to ensure their internalization, survival and proliferation within 
host cells. Therefore, host-directed approaches are focused on controlling the host 
determinants that intracellular bacteria exploit to support their intracellular life 
(Schwegmann and Brombacher, 2008). Future anti-infective therapies may consist in 
the combination of conventional antibiotics targeting bacterial survival outside of the 
host cell with host-directed therapies to efficiently eliminate intracellular pathogens. 
Host-directed approaches require a deep understanding of the host-pathogen 
interactions underlying different intracellular processes. S. aureus has only been 
recently reconsidered as a facultative intracellular pathogen and therefore, our 
knowledge is still limited in this area. In contrast, the intracellular mechanisms as well 
as host metabolic alterations of other important pathogens, such as Legionella 
pneumophila, Listeria monocytogenes, Mycobacterium tuberculosis, Salmonella 
enterica or Shigella flexnerii have received much more attention. While some 




understanding of the host-pathogen interplay in S. aureus infections by comparing it 
with other intracellular pathogens 
In order to gain novel insights about host-pathogen interactions, individual or 
combined strategies that include -omics approaches (genomics, transcriptomics, 
proteomics and metabolomics) and computational biology could be particularly 
useful. Certainly, genome-wide screens employing RNA interference (RNAi), 
microarray analyses and combinatorial chemical libraries have already been employed 
to identify host genes required for bacterial entry and intracellular growth 
(Schwegmann and Brombacher, 2008).  
RNAi approaches allow the development of loss-of-function phenotypic analyses to 
discover novel host-directed targets. Genome-wide RNA interference assays have 
been performed in Drosophila cells to identify host factors exploited and subverted by 
two intracellular pathogens: Chlamydia caviae and L. monocytogenes. In C. caviae 
infections, the depletion of human genes Tomm40 or Tomm22, which are involved in 
protein transport to the mitochondria, resulted in a reduction of intracellular bacteria 
within mammalian cells (Derré et al., 2007). Moreover, 116 host genes were identified 
to be important during L. monocytogenes infection and implicated in entry, bacterial 
escape and intracellular replication (Cheng et al., 2005). Another example is the host-
SKIP protein and its role in Salmonella infection discovered by an RNAi approach. S. 
Typhimurium replicates in a membrane-bound compartment, known as Salmonella-
containing vacuole (SCV), and targets the host protein SKIP, which in turns down-
regulates kinesin recruitment to control vacuole dynamics (Boucrot et al., 2005). 
Interestingly, a study that employed a genetic approach combining RNAi and 
automated microscopy revealed the importance of serine-threonine protein kinases 




as a key regulator of several guanosine triphosphatases (GTPases), which are involved 
in essential host pathways exploited by intracellular pathogens. For instance, S. 
Typhimurium is able to activate host Akt1 to control actin dynamics via p21(Cdkn1a)-
activated kinase 4 (PAK4) and hence, facilitating its intracellular survival. Salmonella 
also controls phagosome-lysosome fusion through Akt1-Rab41 pathway (Kuijl et al., 
2007).  
The use of metabolomics also represents an interesting approach to gain a better 
understanding of the metabolic scenario upon intracellular bacterial infection (Kint et 
al., 2010; Jean Beltran et al., 2017). It has been shown that several intracellular 
pathogens trigger host cell metabolism to support its intracellular survival (Eisenreich 
et al., 2013). For example L. pneumophila interacts with the host mitochondria, 
inducing a Warburg-like effect in the host cell to favour its own replication (Escoll et 
al., 2017). S. flexneri re-routes host central carbon metabolism through the glycolytic 
pathway to obtain an abundant nutrient-flux that allows its intracellular survival 
(Kentner et al., 2014). Moreover, intracellular M. tuberculosis requires host 
cholesterol import to persist inside both macrophages and mice´s lungs (Pandey and 
Sassetti, 2008). Similarly, a recent study investigated the host metabolic response in a 
human airway epithelial cells after S. aureus infection. They observed a reduction in 
nutrient uptake as well as nucleotide biosynthesis in S. aureus-infected cells (Gierok 
et al., 2016), although the underlying mechanisms are still unclear.  
Once specific host factors or metabolic pathways required by the intracellular 
pathogen have been described, blocking those pathways – e.g. by using drug inhibitors 
– may be considered as a novel strategy to control bacterial infections. For example, 




of M. tuberculosis and S. Typhimurium in infected human macrophages (Kuijl et al., 
2007).  
In particular, several studies have already shown that existing and approved drugs, 
which are used for other clinical purposes unrelated to antimicrobial activity, can 
influence the outcome of bacterial infections. The main advantage of finding 
“repurposed drugs” is that they are already clinically approved, shortening the time to 
reach the clinic (Schwegmann and Brombacher, 2008; Czyż et al., 2014). An example 
of repurposed drug is the histone deacetylase inhibitor Sulforaphane, which induces 
the expression of leukocyte protease inhibitor and β-defensin 2 and therefore, 
increases the activity of antibiotics against the multidrug-resistant strain Neisseria 
gonorrhoeae (Yedery and Jerse, 2015). 
Moreover, host-directed therapies can also aim to enhance host cellular responses 
against intracellular pathogens, to activate innate and adaptive host immune responses 
or to modulate disproportionate inflammation. Hence, host-directed therapies also 
include immunomodulatory agents – including monoclonal antibodies or nutritional 
products – as well as cellular therapy (Zumla et al., 2016). For example,  monoclonal 
antibodies anti-TNFα or anti-interleukins, which reduce tissue-destructive 
inflammation by cytokine neutralisation, have shown a bactericidal effect against the 
intracellular pathogens M. tuberculosis and Helicobacter pylori (Wallis, van Vuuren 
and Potgieter, 2009; Wroblewski, Peek and Wilson, 2010; Rossi et al., 2015). Further, 
the nutritional product vitamin D3 is also effective against these two pathogens and its 
mechanism of action has been described as an activation and enhancement of host 
antimicrobial defences (Guo et al., 2013; Rahman et al., 2015).  
 Some of the host-directed drugs that have shown positive effects against intracellular 




about the potential of host-directed approaches to improve the outcome of bacterial 
infections caused by intracellular pathogens. Such therapies have shown the ability to 
achieve intracellular killing and they also possess the benefit of preventing the 
development of antimicrobial resistance. In particular, many host-directed drugs have 
been identified against M. tuberculosis and they are already under clinical trials 





Class Drug Mechanism of action Pathogen Reference 
Monoclonal 
antibody 
Adalimumab anti-TNFα Mycobacterium tuberculosis (Wallis et al. 2009) 
Anti-interleukin 1β Cytokine neutralisation Helicobacter pylori (Wroblewski et al. 2010) 
Antipertussis toxins 
antibody 
Enhancement of immunoglobulins Bordetella pertussis (Scanlon et al. 2015) 
anti-TNFα Cytokine neutralisation Helicobacter pylori (Wroblewski et al. 2010) 
Bevacizumab anti-VEGF Mycobacterium tuberculosis 
(Datta et al. 2015; Oehlers et al. 
2015) 
Nivolumab anti-PD-1 Mycobacterium tuberculosis 
(Singh et al. 2013; Jurado et al. 
2008) 
Siltuximab anti-interleukin 6 Mycobacterium tuberculosis (Ravimohan et al. 2015) 
Recombinant 
protein 
β-defensin 2 Host-antimicrobial peptide Neisseria gonorrhoeae (Leduc et al. 2015) 
Repurposed 
drug 
Aspirin NSAID, TNFα levels reduction Mycobacterium tuberculosis (Tobin et al. 2013) 
Chlorpromazine Calmodulin antagonist 
Staphylococcus aureus (Bleiss et al. 2004) 
Neorickettsia risticii (Rikihisa et al. 1995) 
Salmonella enterica serovar 
Typhimurium 
(Amaral et al. 2000) 




Bordetella pertussis (Skerry et al. 2015) 
Glibendamide Cyclooxygenase inhibition Streptococcus pneumoniae (Koh et al. 2013) 
H-89 PKA inhibitor 
Salmonella typhimurium (Kuijl et al. 2007) 
Coxiella burnetii (Czyż et al. 2014) 




Class Drug Mechanism of action Pathogen Reference 
Repurposed 
drug Ibuprofen NSAID, Cyclooxygenase inhibition 
Streptococcus pneumoniae (Bernard et al. 1997) 
Mycobacterium tuberculosis 
(Vilaplana et al. 2013; Ivanyi et 
al. 2013) 
Imatinib mesylate BCR-ABL tyrosine kinase inhibitor 
Mycobacterium tuberculosis (Napier et al. 2011) 
Anaplasma phagocytophilum (Lin et al. 2007) 
Indometacin Cyclooxygenase inhibition Streptococcus pneumoniae (Hanly et al. 1987) 
Metformin 
Mitochondrial respiratory chain 
blocker 
Mycobacterium tuberculosis (Singhal et al. 2014) 
Niraparib PARP inhibitor Mycobacterium tuberculosis (Pirinen et al. 2014) 
Phenylbutyrate Histone deacetylase inhibitor Mycobacterium tuberculosis (Coussens et al. 2015) 
Pimozide Calcium channel inhibitor 
Listeria monocytogenes (Lieberman & Higgins 2008) 
Bacillus subtilis (Lieberman & Higgins 2008) 
Salmonella enterica serovar 
Typhimurium 
(Lieberman & Higgins 2008) 
Escherichia coli (Lieberman & Higgins 2008) 
Prednisone Glucocorticoid receptor antagonist 
Streptococcus pneumoniae (Blum et al. 2015) 
Mycobacterium tuberculosis (Critchley et al. 2013) 
Raloxifene Oestrogen receptor modulator Pseudomonas aeruginosa (Ho Sui et al. 2012) 
Statins Cyclooxygenase inhibition 
Streptococcus pneumoniae 
(Mortensen et al. 2008, 
Chalmers et al. 2008) 
Mycobacterium tuberculosis (Parihar et al. 2014) 
Sulforaphane Histone deacetylase inhibitor Neisseria gonorrhoeae (Yedery et al. 2015) 
Thapsigargin Calcium ATPase inhibitor Coxiella burnetii (Czyż et al. 2014) 




Class Drug Mechanism of action Pathogen Reference 
Repurposed 
drug Thioridazine unknown 
Listeria monocytogenes (Lieberman & Higgins 2010) 
Staphylococcus aureus (Bleiss et al. 2004) 
Mycobacterium tuberculosis (Amaral et al. 2017) 
Verapamil Calcium channel inhibitor 
Mycobacterium tuberculosis 
(Martins 2008; Gupta et al. 
2015) 
Chlamydia pneumoniae (Salin et al. 2011) 
Vorinostat Histone deacetylase inhibitor Mycobacterium tuberculosis (Shan et al. 2012) 
Zileuton Leukotriene synthesis inhibitor Mycobacterium tuberculosis (Mayer-Barber et al. 2014) 
Vitamin Vitamin D3 Activation of antimicrobial defences Helicobacter pylori (Guo et al. 2014) 




1.10. JUSTIFICATION AND AIMS 
S. aureus is an opportunistic and versatile human pathogen responsible for a wide 
range of diseases worldwide (Lowy, 1998; Nelson et al., 2015). Besides its 
pathogenic capacity, it is also a commensal microorganism and approximately 30% 
of the global population is asymptomatically and permanently colonized by MSSA 
or MRSA strains (Wertheim et al., 2005). Importantly, persistent nasal colonization 
has been associated with recurrent staphylococcal infections, increased mortality 
rates and healthcare costs (Sollid et al., 2014; Sakr et al., 2018). 
The versatility of S. aureus is characterized by its large plethora of virulence factors 
and, consequently, its ability to invade a wide range of host cells and tissues 
(Gordon and Lowy, 2008). For initial invasion and colonization, S. aureus 
possesses various surface-associated proteins that are capable of binding different 
host-surfaces and receptors (Foster and Höök, 1998). It can also secrete a wide 
range of proteins, toxins and enzymes, that support bacterial replication and later 
dissemination (Otto, 2014).  
Furthermore, the ability of S. aureus to acquire antibiotic resistance has been 
extensively reported (Lowy, 2003). The emergence of MRSA strains dates back 
from 1960s and since then, S. aureus has evolved resistance to multiple antibiotics 
and, in particular, HA-MRSA strains are resistant to most available antibiotics 
(Naimi et al., 2003). The last-resort antibiotics commonly used to treat MRSA 
infections are daptomycin, linezolid and vancomycin. However, reduced 
susceptibility to daptomycin and linezolid, as well as the emergence of 
vancomycin-intermediate and vancomycin-resistant S. aureus strains (VISA & 




In addition to its virulence determinants and the increase of multidrug-resistant 
strains, S. aureus is also able to survive and proliferate within mammalian cells, to 
subvert phagocytosis and to induce host-cell death (Fraunholz and Sinha, 2012; 
Horn et al., 2017). Moreover, S. aureus has been shown to produce biofilms, which 
enhance its intracellular persistence, thereby contributing to chronicity of infections 
and later dissemination from initial site of infection to secondary loci (Kong, Vuong 
and Otto, 2006). The intracellular state of S. aureus may protect this pathogen from 
decolonization procedures as well as antibiotic pressure (Horn et al., 2017). 
Accordingly, it has recently been shown that the last resort antibiotics daptomycin, 
vancomycin and linezolid  are unable to achieve intracellular killing (Lehar et al., 
2015). 
Considering the increase of multidrug-resistant S. aureus strains as well as its 
intracellular protection against the currently available antibiotics, there is an urgent 
need to investigate novel therapeutic approaches. Traditional therapies have been 
focused on targeting bacterial cell growth and cell division. The main advantage of 
pathogen-directed therapies is their limited cytotoxicity, but the use of these 
treatments quickly leads to the emergence of multidrug-resistant strains 
(Schwegmann and Brombacher, 2008). Host-directed approaches offer the 
opportunity to overcome the problem of antibiotic resistance and to achieve 
intracellular killing. They target host-molecular pathways that intracellular bacteria 
exploit to support survival and replication within mammalian cells (Zumla et al., 
2016; Kaufmann et al., 2018).  
Thus, this study aimed to characterize the host molecular factors and metabolic 
pathways hijacked by S. aureus during intracellular infection in order to discover 




provides novel insights into S. aureus-host interactions, contributing to a better 
understanding of intracellular staphylococcal infections. 
Specifically, I employed three different approaches to identify the host cellular 
pathways exploited by intracellular S. aureus and these approaches resulted in 
different result chapter as follows:  
(i) First, I characterized the host-metabolic changes upon intracellular 
staphylococcal infection by using a metabolomic approach.  
(ii) Second, I screened a panel of host-directed drugs in order to find “repurposed 
drugs” that may have a potential effect against intracellular S. aureus.  
(iii) Lastly, I pursued the identification of novel host-genes that are involved in 
intracellular invasion and/or proliferation. By using a genome-wide shRNA 
screening, we assessed the effect of silencing human genes on S. aureus infection. 
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2.1.1. Bacterial strains and culture conditions 
All bacterial strains used in this study are listed in table 2.1. S. aureus strains were 
cultured in Nutrient Broth (NB) medium (Sigma-Aldrich) and E. coli strains were 
grown in Luria Broth (LB) medium (Sigma-Aldrich). For growth in liquid culture, 
bacterial strains were incubated at 37°C, with vigorous shaking (300 rpm) in an 
Incu-shake MIDI 4020 incubator (SciQuip). For growth on solid medium, Nutrient 
agar (Sigma-Aldrich) and LB agar (Sigma-Aldrich) plates were prepared following 
manufacturer’s instructions and employed for S. aureus and E. coli strains’ growth, 
respectively. Agar plates were incubated in a 37°C incubator (LMS). When 
necessary, medium was supplemented with ampicillin (100 µg/ml) for E. coli 
growth and chloramphenicol (7.5 µg/ml) for S. aureus growth, as indicated in table 
2.1. 
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2.1.2. Preparation of bacterial stock 
A single colony from a fresh agar plate was used to inoculate 10 ml of NB or LB 
medium and liquid culture was incubated overnight with shaking (37°C; 300 rpm). 
Next day, the overnight culture was aliquoted in 1 ml cryovials (Thermo Fisher 
Scientific) containing 20% glycerol and aliquots were stored at -80°C. 
 
2.1.3. Bacterial pre-inoculum preparation for intracellular assays 
S. aureus USA300 and NCTC 13626 strains were grown in 10 ml of NB at 37°C 
with shaking (300 rpm) overnight and 0.5 ml of this overnight culture was used to 
inoculate a flask containing 50 ml of NB (dilution 1:100). Bacterial culture was 
grown until an optical density (OD600nm) of 1 was reached, upon which the culture 
was centrifuged (4,000 rpm, 15 min, 4ºC). Pellets were then washed twice with 
PBS, resuspended in 1.5 ml of PBS supplemented with 20% glycerol and aliquots 
of 100µl were stored at -80ºC until further use. The concentration of each 
preinocula was calculated the next day by serial dilution plating and Colony 
Forming Units (CFU) counting. 
 
2.1.4. In-vitro growth assays 
Bacterial strains were grown overnight in NB liquid medium at 37°C, with shaking 
(300 rpm). The overnight culture was diluted (1:100) in fresh NB medium and 
aliquots of 90 µl were dispensed per well in a 96-wells plate (Sarstedt). When 
different conditions were assessed, 10 µl of either drug or antibiotic was added to 
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each well. To evaluate bacterial growth, optical density (OD600nm) was measured at 
time points 0, 2, 4, 6, 8 and 24 hours by using EL800 Microplate reader (Bio-Tek).
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Table 2.1. List of bacterial strains used in this study 
Strains Description Source 
S. aureus   
MRSA USA300 LAC LAC strain of the CA-MRSA USA300 lineage 
Dr. Andrew Edwards 
(Edwards, 2012) 
MRSA NCTC 13626 HA-MRSA strain originally isolated at St Thomas’ Hospital London NCTC 
Lac*pcL55-ptet-gfpmut2 
S. aureus USA300 strain expressing constitutively the green fluorescent 
protein (GFP). Chloramphenicol resistant (7.5 µg/ml) in LB agar plates. 
Dr. Angelika Grundling 
(Reichmann et al., 2014) 
E. coli   
DH5-α-Select Gold Host strain for molecular cloning. Resistant to ampicillin (100 µg/ml). Bioline 
DH5-α _pCR2.1-TOPO-mChe-TRAM2 
DH5-α strain carrying the plasmid pCR2.1-TOPO-mChe-TRAM2. Resistant 
to ampicillin (100 µg/ml). 
This study 
DH5-α _pCR2.1-TOPO- mChe-SaCWT 
DH5-α strain carrying the plasmid pCR2.1-TOPO-mChe-SaCWT-IRES. 




DH5-α strain carrying the plasmid P12-MMP-mChe-TRAM2-IRES-Hyg. 




DH5-α strain carrying the plasmid P12-MMP-mChe-LC3A-IRES-Hyg. 
Resistant to ampicillin (100 µg/ml). 
This study 
DH5-α _P12-MMP- mChe-SaCWT- 
IRES-Hyg 
DH5-α strain carrying the plasmid P12-MMP-mChe-SaCWT-IRES-Hyg. 
Resistant to ampicillin (100 µg/ml). 
This study 
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2.2. CELL CULTURE 
2.2.1. Cell lines and culture conditions 
All cell lines employed in this study are listed in table 2.2 and every cell line was 
incubated at 37°C and 5% of CO2 in a Heraeus® BB15 incubator (Thermo 
Scientific). 
HeLa cells (ECACC) and HEK293T cells were grown in Dulbecco´s Modified 
Eagle´s medium (DMEM, Gibco) containing pyruvate, glucose and glutamine and 
supplemented with 10% heat-inactivated foetal bovine serum (FBS, Gibco) and 5% 
of penicillin and streptomycin solution (Gibco), unless otherwise specified. When 
stated, HeLa cells carrying the P12-MMP vector were cultured in DMEM medium 
supplemented with hygromycin (200 µg/ml). 
BALB/c Mouse Bone Marrow Macrophages (Calltag Medsystems) were cultured 
on Complete Macrophage Medium supplemented with granulocyte-macrophage 
colony-stimulating factor, penicillin, streptomycin and FBS (Calltag Medsystems). 
Human Umbilical Vein Endothelial Cells (HUVEC, Sigma-Aldrich) were grown in 
Endothelial Cell Growth Medium (Sigma-Aldrich), supplemented with 5% of 
penicillin and streptomycin solution (Gibco), unless otherwise stated. 
For the 13C isotope labelling experiment for Gas-Chromatography Mass-
Spectrometry (GC-MS), Minimum Essential Media (MEM; Gibco) – containing 
10% of heat-inactivated FBS (Gibco) – was supplemented with either labelled or 
unlabelled glucose (5.6 mM) or glutamine (2 mM) as described below: 
I. MEM supplemented with both unlabelled glucose (Gibco) and glutamine 
(Gibco). 
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II. MEM supplemented with 13C6-labelled glucose (Cortecnet) and unlabelled 
glutamine. 
III. MEM supplemented with 13C5&15N2-labelled glutamine (Cortecnet) and 
unlabelled glucose.  
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Table 2.2. List of cell lines used in this study 
Cell lines Description Source 
HeLa  Human cervix epithelial carcinoma cells ECACC 
BALB/c Mouse Bone Marrow 
Macrophages 
Primary mouse bone marrow cells Caltag Medsystems 
HEK-293T 
Human embryonic kidney SV40 transformed cells. Used for the production of retrovirus 
to transduce HeLa cells 
Dr. Yolanda Calle 
HUVEC Human Umbilical Vein Endothelial cells.  Sigma 
HEK-293T EPHA2 KO EPHA2 knockout cell lines derived from HEK-293T cells 
Prof. Richard 




HeLa cells carrying the plasmid P12-MMP-mChe-TRAM2- IRES-Hyg on their 




HeLa cells carrying the plasmid P12-MMP-mChe-LC3A- IRES-Hyg on their 
chromosome. Resistant to hygromycin (200 µg/ml) 
This study 
HeLa_ P12-MMP- mChe-SaCWT- 
IRES-Hyg 
HeLa cells carrying the plasmid P12-MMP-mChe-SaCWT- IRES-Hyg on their 
chromosome. Resistant to hygromycin (200 µg/ml) 
This study 
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2.2.2. Transduction of mammalian cells  
For the shRNA screening, HeLa cells were transduced with the Mission® LentiPlex 
Human shRNA Library (Sigma-Aldrich). This library is comprised by 10 sub-pools 
of lentiviral particles carrying around 75,000 shRNA constructs that target 
approximately 16,000 human genes. HeLa cells were seeded in ten different 10 cm 
plates (Sarstedt) in complete DMEM medium at a cell density of 2x106 cells per 
dish and placed them into the incubator overnight (37ºC, 5% CO2). The following 
day, the ten lentiviral sub-pools were thawed on ice and added to HeLa cells at a 
Multiplicity of Infection (MOI) of 1, in the presence of hexadimethrine bromide (8 
µg/ml; Sigma-Aldrich). After an overnight incubation, the virus-containing media 
were replaced with fresh DMEM, without hexadimethrine bromide. The next day, 
HeLa cells were exposed to puromycin selection (1 µg/ml; Sigma-Aldrich) and 
medium was replaced with fresh puromycin-containing media every two days until 
only positive transduced-cells remained.  
To produce individual knockdowns, HeLa cells were transduced with 29 individual 
shRNA lentiviral constructs (Table 2.3, Sigma-Aldrich). HeLa cells were seeded in 
24 wells-plate at a cell density of 8x104 cells per well and incubated overnight 
(37ºC, 5% CO2). Transduction of mammalian cells was performed as described 
above, employing a MOI of 1.  
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Table 2.3.List of lentiviral particles employed to produce individual knockdowns in 
HeLa cells 
Clone ID Symbol Gene description 
TRCN0000127872 ATG10 ATG10 autophagy-related 10 homolog 
TRCN0000122869 AVEN Apoptosis; caspase activation inhibitor 
TRCN0000199388 BCKDK Branched chain ketoacid dehydrogenase kinase 
TRCN0000130856 CCDC82 Coiled-coil domain containing 82 
TRCN0000057589 CD5L CD5 molecule-like 
TRCN0000056919 CD83 CD83 molecule 
TRCN0000056647 CDKAL1 CDK5 regulatory subunit associated protein 1 
TRCN0000055994 CLTB Clathrin; light polypeptide (Lcb) 
TRCN0000058248 CSF2RA 
Colony stimulating factor 2 receptor alpha; low 
affinity 
TRCN0000142964 FAM63B Family with sequence similarity 63, member B 
TRCN0000129900 IFIT1B 
Interferon-induced protein with tetratricopeptides 
repeats 1-like 
TRCN0000044726 KCNK1 Potassium channel; subfamily K; member 1 
TRCN0000055585 MEGF9 Multiple epidermal growth factor-like; domain 9 
TRCN0000053959 MYL2 
Myosin; Light polypeptide 2; regulatory; cardiac; 
slow 
TRCN0000053505 MYL9 Myosin; light polyeptide 9; regulatory 
TRCN0000054308 NELL2 NEL-like 2 
TRCN0000138344 NSUN7 NOL1/NOP2/Sun domain family; member 7 
TRCN0000144974 ORC1L Origin recognition complex; subunit 1-like 
TRCN0000053075 POLA2 Polymerase (DNA directed); alpha 2 
TRCN0000056506 RAB11FIP4 RAB11 family interacting protein 4 (Class II) 
TRCN0000047220 RAB3GAP2 
RAB3 GTPase activating protein subunit 2 (non-
catalytic) 
TRCN0000141304 RAB41 RAB41; member RAS; oncogene family 
TRCN0000044061 SLC36A3 
Solute carrier family 36 (proton/amino acid 
symporter), member 3 
TRCN0000044314 SLC43A1 Solute carrier family 43; member 1 
TRCN0000057018 TLR2 Toll-like receptor 2 
TRCN0000059251 TNFRSF10C 
Tumor necrosis factor receptor superfamily; 
member 10C 
TRCN0000141247 TRAM2 Translocation associated membrane protein 2 
TRCN0000011171 UBXN10 UBX domain containing 3 
TRCN0000137602 ZNF618 Zinc finger protein 618 
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2.2.3. Intracellular infection assays 
Different intracellular infections were performed for different purposes in this study 
and therefore, the type of plate or pre-inoculum’s strain that was employed as well 
as the number of cells that were seeded varies among experiments (such variables 
are summarised in table 2.4). 
For mammalian DNA extraction and further sequencing, HeLa cells stably 
expressing the shRNA library, were seeded in 10 cm cell culture dish (Sarstedt) in 
DMEM without antibiotics, at a cell density of 2x106 cells per dish. For 
metabolomics approaches, HeLa cells were seeded in 6-well plates (Sarstedt) in 
DMEM without antibiotics and at a cell density of 5x105 cells per well. For host-
cell viability and immunofluorescence assays, HeLa cells and individual 
knockdowns produced in HeLa cells were seeded in 24-well plates (Sarstedt) in 
DMEM without antibiotics and at cell density of 7.5x104 cells per well. For the 
drug-screening and host cell viability experiments, HeLa cells and HUVEC were 
seeded in 96-wells plate at cell density of 1.8x104 cells per well. In all cases, cells 
were allowed to settle in the incubator (37°C, 5% CO2) for an overnight.  
The next day, an aliquot of bacterial pre-inoculum was thawed, diluted in 900 µl of 
Dulbecco’s Phosphate-buffered saline (PBS; Sigma-Aldrich) and centrifuged at 
4,000 rpm for 5 minutes. Pellet was washed twice with PBS prior to addition of 
DMEM without antibiotics at a bacterial density that corresponds to a MOI of 100. 
Then, bacterial suspension was added to each well, plates were immediately 
centrifuged at 1,500 rpm for 5 minutes and incubated at 37ºC in 5% CO2 for 45 
minutes to allow bacterial internalization. When heat-killed condition was included, 
bacterial pre-inoculum was incubated for 10 min at 95ºC prior to centrifugation. 
Material & methods 
56 
 
The medium was then replaced by DMEM supplemented with either 100 µg/ml 
gentamycin or 5 µg/ml vancomycin depending on the strain employed (Fig. 2.1) 
and cells were incubated for 1 hour to kill extracellular bacteria. After one hour of 
incubation, the medium was replaced again by DMEM supplemented with 10 µg/ml 
gentamycin or 5 µg/ml vancomycin and cells were placed back in the incubator 
(37ºC, 5% CO2) for four additional hours, until time point 6 was reached. 
 
Figure 2.1. Analysis of host cell viability and intracellular bacterial survival during S. 
aureus USA300 and NCTC 13626 infection assays, and their resistance to gentamycin, 
vancomycin and lysostaphin. (A) Quantification of host cell viability at different time 
points of infection, measured by flow cytometry using double annexin V-FITC and PI 
staining. (B) Intracellular survival of USA300 and NCTC13626 at different time points; 
HeLa cells were infected with S. aureus and lysed in 0.1% Triton X-100 for CFU 
evaluation. (C) Bacterial growth levels at 6 hours in NB medium supplemented with 
gentamycin (100 µg/ml), vancomycin (5 µg/ml) and lysostaphin (5 µg/ml). Graphs display 
means ± standard error of three independent experiments. Statistical significance was 
analysed by one-way ANOVA and post hoc Tukey’s multiple comparison tests. p-value 
≤0.05 (*); ≤0.01 (**); ≤0.001 (***). 
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2.2.4. Host cell viability assay 
Cell infection was performed as described above and samples for host cell viability 
quantification were collected after six hours of MRSA infection. In order to recover 
both necrotic and apoptotic cells, the medium of each well was aspirated and 
transferred into clean Eppendorf’s tubes (Fisher Scientific). Cells were trypsinized 
for 5 minutes, diluted in DMEM without antibiotics and centrifuged at 1,500 rpm 
for 10 minutes. Afterwards, cells were double stained with 2.5 µl of annexin V-
FITC and 5µl of propidium iodide (PI) (Becton Dickinson, BD) diluted in 50 µl of 
DMEM per sample and incubated for 15 minutes at room temperature. Stained cells 
were centrifuged at 1,500 rpm for 10 minutes, supernatant aspirated and cell pellets 
were fixed using 150 µl of BD Cytofix buffer (Becton Dickinson, BD) for 15 
minutes at 4°C. Finally, samples were diluted with 350 µl of DMEM without 
antibiotics and host cell viability was measured by flow cytometry (BD AccuriTM 
C6 Plus). 
For the high-throughput drug-screening, a modified protocol was applied. After 
infection was performed in 96-wells plate and time 6 was reached, plate was 
centrifuged at 1,200 rpm for 10 minutes and supernatant was discarded, retaining 
only alive cells that are attached to the surface of the well. Afterwards, cells were 
fixed using 20 µl of BD Cytofix buffer (Becton Dickinson, BD) for 15 minutes at 
4°C and samples were diluted with 100 µl of DMEM without antibiotics. Host cell 
viability was estimated in the flow cytometer by counting the number of events 
within an alive-gating in 1 min per sample. 
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2.2.5. Intracellular bacterial estimation  
When USA300 wild type strain was employed for intracellular infection assays, 
cells were lysed using 0.1% Triton X-100 diluted in PBS (5 min, RT) and serial 
dilutions were plated in NB agar plates for CFU counting. For the high-throughput 
drug-screening, where USA300-GFP bacterial strain was employed, intracellular 
bacterial survival was calculated by measuring the percentage of GFP in the flow 
cytometer. 
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Table 2.4. Experimental specifications for the different intracellular infection assays of this study 
Experiment Plate  Numbers of cells seeded Bacterial strain Bacterial pre-inocula Antibiotic 
shRNA screening 10 cm TC dish 2x106 cells/well MRSA NCTC 13626 2.1x109 CFU/ml Vancomycin 
Metabolomics assays 
6-wells plate 5x105 cells/well MRSA NCTC 13626 2.1x109 CFU/ml Vancomycin 
6-wells plate 5x105 cells/well MRSA USA300 1.8x109 CFU/ml Gentamicin 
Host cell viability assays 
24-wells plate 7.5x104 cells/well MRSA NCTC 13626 2.1x109 CFU/ml Vancomycin 
24-wells plate 7.5x104 cells/well MRSA USA300 1.8x109 CFU/ml Gentamicin 
Immunofluorescence assays 24-wells plate 7x104 cells/well MRSA USA300-GFP 8.7x108 CFU/ml Gentamicin 
Drugs screening 96-wells plate 1.8x104cells/well MRSA USA300-GFP 8.7x108 CFU/ml Gentamicin 
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2.3. MOLECULAR BIOLOGY 
2.3.1. Polymerase chain reaction (PCR) 
Polymerase chain reactions (PCRs) were carried out in T100TM Thermal Cycler 
(Bio-Rad). The oligonucleotides used in this study (table 2.5) were purchased from 
Thermo Fisher Scientific. Oligonucleotides were reconstituted in molecular grade 
pure water (Sigma-Aldrich) to a final concentration of 100 mM. Before establishing 
PCR cycling conditions, oligonucleotide’s annealing temperatures were calculated 
using the OligoCalc webpage 
(http://biotools.nubic.northwestern.edu/OligoCalc.html). 
For molecular cloning purposes, PhusionTM High Fidelity DNA polymerase 
(Thermo Fisher Scientific) was employed. A 50 µl master mix volume was prepared 
containing: 10 µl of 5X Phusion HF Buffer, 1 µl of dNTPs (10 mM), 2.5 µl of each 
oligonucleotides (10 mM), 2.5 µl of DMSO unless otherwise stated, 2 µl of template 
DNA and 0.5 µl of Phusion DNA Polymerase. Master Mix reaction was mixed well 
by pipetting and spinned briefly before placing in the Thermal Cycler (BioRad). 
PCR cycling conditions were as follows: 30 seconds of initial denaturation at 98°C, 
25 cycles of amplification which involves 10 seconds of denaturation at 98°C, 30 
seconds of oligonucleotide annealing at the corresponding melting temperature and 
30 seconds of elongation per kilo base (kb) at 72°C and another 10 extra minutes of 
final elongation at 72°C at the end of the cycle.  
For routine PCR checking, 5Prime HotMaster mix polymerase (QuantaBio) was 
used. A 10 µl master mix volume was prepared containing: 0.5 µl of each 
oligonucleotides (10 mM), 3 µl of template DNA and 4 µl of 5Prime HotMaster 
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mix polymerase. PCR cycling conditions were the same as stated above but 1 
minute of elongation per kb was applied. 
 
2.3.2. Agarose gel electrophoresis 
PCR reactions were verified by visualization of DNA bands in 1% agarose 
electrophoresis gels. In order to make 1% agarose gels, one Topvision agarose 
tablet (Thermo Scientific) was diluted per 50 ml of Tris-Acetate-EDTA(TAE) 
buffer (40 mM Tris base, pH 7.6; 20mM acetic acid; 1mM EDTA) in a 250 ml 
Erlenmeyer flask. Agarose was melted in a microwave oven for 1-2 minutes at 
maximum power, until agarose was completely dissolved. Agarose solution was 
allowed to cool down for a few minutes at room temperature, SYBR safe DNA gel 
stain (Thermo Fisher Scientific) was diluted 1: 10,000 and agarose solution was 
poured in the gel tray. After 20-25 minutes of incubation at room temperature, the 
comb and tape from the edges of the solidified gel tray were carefully removed and 
gel tray was placed on the Sub-Cell tank (Bio-Rad), filled with TAE buffer. 
To load the samples, each 5 µl of DNA was mixed with 1 µl of Orange Loading dye 
(Thermo Fisher Scientific) and carefully loaded to each well. 5-10 µl of a 1 kb DNA 
molecular weight ladder (Thermo Fisher Scientific) was added to the first wells. 
Electrophoresis gels were run at a constant voltage of 90V for 30 minutes – 1 hour 
using a PowerPac Basic Power Supply (Bio-Rad).
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Table 2.5. List of oligonucleotides used in this study for molecular cloning. Restriction enzymes are underlined in the sequence 




TRAM2-HindIII FW tagcta aagctt gccacc ATGGCTTTCCGCAGGAGG 
To amplify TRAM2 gene (forward), including a 
restriction enzyme site (HindIII) 
TRAM2-mChe RV GCCCTTGCTCACCAT GGGAGACTTGAGTTT To amplify TRAM2 gene (reverse) 
TRAM2-mChe FW AAACTCAAGTCTCCC ATGGTGAGCAAGGGC To amplify mCherry (forward) 
mChe-NotI RV tagcta gcggccgc ttta CTTGTACAGCTCGTCCAT 
To amplify mCherry (reverse), including a 




mChe-HindIII FW tagcta aagctt gccacc ATGGTGAGCAAGGGCGAG 
To amplify mCherry (forward), including a 
restriction enzyme site (HindIII) 
mChe-SaCWT RV TGATGGGCTCGAGCCCTTGTACAGCTCGTC To amplify mCherry (reverse) 
mChe-SaCWT FW GACGAGCTGTACAAGGGCTCGAGCCCATCA To amplify SaCWT (forward) 
SaCWT-NotI RV tagcta gcggccgc ttta CTTTATAGTTCCCCAAAG 
To amplify SaCWT (reverse), including a 
restriction enzyme site (NotI) 
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2.3.3. DNA extraction 
2.3.3.1. Plasmid extraction  
All plasmids used in this study are stated in table 2.6. For plasmid extraction, one 
colony of the E. coli strain was taken to inoculate 10 ml of LB liquid medium, 
supplemented with the appropriate antibiotic, depending on the plasmid, and 
incubated overnight with shaking (37°C, 300 rpm). Next morning, plasmid 
extractions were performed using Monarch® Plasmid Miniprep kit (New England 
Biolabs, NEB) and manufacturer’s guidelines were followed. 
2.3.3.2. Bacterial DNA extraction  
When PCR reaction produced only one clear band, the GeneJET DNA clean-up kit 
(Thermo Fisher Scientific) was used to extract DNA, following manufacturer’s 
instructions. When several bands were visualized in the electrophoresis gel, the 
band of interest was cut out from the agarose gel and DNA was extracted from the 
agarose by using GeneJET DNA extraction kit (Thermo Fisher Scientific), 
following manufacturer’s indications. 
For routine PCR checking, DNA from E. coli was extracted by picking one colony 
from a LB agar plate, resuspending the colony into 50 µl of molecular grade water 
(Sigma-Aldrich) and boiling the suspension at 100°C for 5 minutes in a QBD4 heat-
block (Grant). The boiled mix was centrifuged on a bench top centrifuge 
(Eppendorf) to remove bacterial debris at 13,000 rpm for 2 minutes and supernatant 
was used for PCR (3 µl per reaction) as a template DNA. 
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2.3.3.3. Mammalian DNA extraction  
Attached HeLa cells to the tissue culture dish (Sarstedt) were washed once with 
Dulbecco’s PBS and collected by using a cells scraper (Fisher Scientific). Total 
DNA was then extracted from HeLa cells by using GenElute Mammalian Genomic 
DNA Miniprep Kit (Sigma-Aldrich), following manufacturer’s instructions.  
 
2.3.4. Molecular cloning and DNA manipulation 
As described in figure 2.2, our cloning strategy includes the amplification of the 
gene of interest by PCR – to generate a transcriptional fusion with a fluorescent 
protein –,  cloning the PCR product into pCRII- TOPO plasmid (4 kb; Thermo 
Fisher Scientific) in the first place and eventually, cloning the PCR product into 
P12-MMP (8 kb), a plasmid that was kindly supplied by Dr Felipe X. Pimentel 
Muiños (Centro de Investigación del Cancer de Salamanca, Spain). The expression 
of any gene in P12-MMP is driven by the LTR region of the retrovirus. In addition, 
our P12-MMP vector carries the resistance genes to puromycin and ampicillin, 
which are selective markers in mammalian cells and bacteria, respectively. 




Figure 2.2. The cloning strategy followed to produce constructs that were fused with 
fluorescent markers. The gene of interest was fused with the fluorescent marker by PCR 
and cloned into pCRII_TOPO vector (1). Our construct was then double digested from 
pCRII-TOPO vector using HindIII and NotI as restriction enzymes (2). In parallel, IRES 
fragment was digested from P12-MMP vector using the restriction enzymes NotI and 
BspHI and P12-MMP was double digested with HindIII and BspHI enzymes and 
dephosphorylated (3). Triple ligation was performed and transformed into DH5-α E. coli 
competent cells (4). 
 
2.3.4.1. pCRII-TOPO cloning 
The pCRII-TOPO vector and all the reagents necessary for TOPO cloning were 
purchased from Thermo Fisher Scientific. Direct cloning of DNA products 
amplified by proofreading polymerases such as Phusion polymerase is normally 
difficult since proofreading polymerases remove the 3’ A-overhangs that are 
necessary for pCRII-TOPO cloning. Therefore, an additional step to clone these 
blunt-ended fragments was required. Eppendorf tubes containing the PCR products 
amplified by a proofreading polymerase were placed on ice and 1 unit of 5Prime 
Hot Master mix polymerase (QuantaBio) was added per tube, without changing the 
buffer. PCR mixture was incubated at 72°C in the QBD4 heat-block (Grant) for 10 
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minutes, placed them back on ice and immediately used for pCRII-TOPO cloning 
reaction.  
The pCRII-TOPO cloning reaction was prepared as follows: 4 µl of PCR product, 
1 µl of salt solution and 1 µl of TOPO vector. The cloning reaction was mixed, 
incubated for 30 minutes at room temperature and placed it on ice to proceed to 
bacterial transformation. 
2.3.4.2. Bacterial transformation  
E. coli DH5-α-Select Gold (Bioline) were used as chemical competent cells and 
transformation was performed by heat-shock. 5 µl of DNA were added to a vial 
with 50 µl of competent cells and the tube was placed on ice for 30 minutes, 
followed by 30 seconds at 42°C in the QBD4 heat-block (Grant) and returned back 
to the ice box for 5 last minutes. After the heat-shock was done, 4 volumes of SOC 
medium (Thermo Fisher Scientific) were added to the mixture and incubated for at 
least 1 hour at 37°C and with shaking (300 rpm). 50 and 200 µl of the mixture were 
plated in two LB agar plates, containing 100 µg/ml of ampicillin and plates were 
incubated at 37°C overnight. Next day, plates were checked, and individual colonies 
were picked and streaked into new LB agar plates to further validate whether the 
construction was correct by PCR. 
2.3.4.3. DNA digestion 
The incorporation of restriction enzyme´s sites were designed using the Addgene’s 
sequence analyser webpage (https://www.addgene.org/analyze-sequence/) and they 
were purchased from New England Biolabs (NEB). The enzymes employed in this 
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study were high fidelity (HF) and all of them were sharing the reaction buffer 
(CutSmart buffer; NEB) to facilitate double digestions. 
10 µl of digestion mix was performed as follows: 1 µg of DNA, 1 unit of each 
restriction enzyme, 1 µl of CutSmart buffer and molecular-grade water up to 10 µl. 
Digestions were incubated for 30 minutes at 37°C and results of the digestion were 
visualized by electrophoresis gel (Material and Methods, section 2.3.2). 
2.3.4.4. Dephosphorylation of P12-MMP vector 
Once the P12-MMP vector has been double digested with the appropriate restriction 
enzymes, 1 µl of Fast Thermosensitive Alkaline Phosphatase (AP; Thermo Fisher 
Scientific) was added per 20 µl of final volume. Reaction was mixed by pipetting 
and incubated for 10 minutes at 37°C. Enzymatic and alkaline phosphatase 
reactions were stopped by incubating the mixture at 80°C, for 20 minutes. 5 µl of 
digested and dephosphorylated vector was run in an electrophoresis gel to verify 
that the digestion was efficient. 
2.3.4.5. DNA ligation 
The DNA ligation mixture was prepared as follows: 50 ng of dephosphorylated 
P12-MMP vector, 150 ng of each digested inserts, 1 µl of 10x T4 DNA ligase buffer 
(New England Biolabs) and 1U of T4 DNA ligase (New England Biolabs) and 
water up to 10 µl. Reaction was mixed by pipetting and incubated at 16°C in the 
Thermal Cycler overnight. 5 µl of ligation mixture was used for bacterial 
transformation of 50 µl of chemically competent cells, as previously described 
(Material and Methods, section 2.3.4.2). 
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2.3.4.6. Retroviral production and HeLa transduction 
HEK-293T cells were seeded in a 24-wells plate at a cell density of 1x105 cells per 
well and incubated overnight (37ºC, 5% CO2). Next day, 1 µg of DNA for 
transfection was prepared as follows: 0.5 µg of P12-MMP vector with the gene of 
interest, 0.36 µg of OGP helper plasmid and 0.14 µg of VSV-G helper plasmid. 2 
µl of JetPEI (Polyplus) were used to enhance the transfection per µg of DNA and 
both DNA and JetPEI were diluted in 150mM NaCl to a final volume of 50 µl. 
JetPEI solution was added to the DNA solution and the mix was immediately 
vortexed and incubated for 30 minutes at room temperature. Then, 100 µl of 
jetPEI/DNA mix was added per well to the cells and plates were placed them back 
into the incubator until the next day. The following day, medium of transfected 
HEK-293T cells was replaced with fresh complete DMEM and cells were returned 
to the incubator for another day. After this overnight incubation, supernatant of 
293T containing the retroviral particles was collected and filtered with a sterile PES 
Syringe Filter of 0.45 µm (GE Healthcare Life Sciences) to eliminate HEK-293T 
cells. Transduction of mammalian cells was carried out as described before 
(Material and Methods, section 2.2.2), using puromycin (1 µg/ml; Sigma-Aldrich) 
as selective pressure. 
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Table 2.6. List of plasmids used in this study 
Plasmids Description Antibiotic  Source 
pCR 2.1-TOPO Plasmid used for routinely cloning.  Amp (100 µg/ml) Invitrogen 
pCMV-Sport 6 Plasmid carrying the human gene TRAM2.  Amp (50 µg/ml) Source Bioscience 
pLVTHM-Pm_YFPCWT 
Plasmid expressing the YFP-CWT phagosomal escape 
marker.  
Amp (50 µg/ml) Dr. Martin Fraunholz (Giese et al., 2011) 
P12-MMP-mCherry-LC3A-
IRES-Hygro 
P12-MMP vector expressing mChe-LC3A driven by 
LTR region of the retrovirus.  
Amp (100 µg/ml)* 
Hyg (200 µg/ml)** 
Dr. Felipe X. Pimentel Muiños (Boada-
Romero et al., 2013) 
*Antibiotic resistance in bacterial cells 
**Antibiotic resistance in eukaryotic cells 
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2.3.5. ShRNA screening  
For shRNA screening, PCRs were performed over genomic DNA samples 
employing oligonucleotides complementary to constant sequences in all shRNA 
vectors (Lentiplex Amplification Primers) and following the protocol described 
before (Material and Methods, section 2.3.1). The individual shRNA occurrence in 
the different samples was provided by the company Sigma-Aldrich. Briefly, 
genomic DNA samples were submitted to the Sigma Deconvolution platform, and 
the abundance of each shRNA clone in samples was tested by amplifying and next-
generation sequencing (at ×1,000) shRNA regions and barcoding samples; short 
reads were aligned to the reference. Data were obtained as the number of shRNA 




2.4.1. Cell extractions and protein lysates 
Cells were harvested by adding ice-cold Dulbecco’s PBS to each well and detached 
by using a cell scrapper (Fisher Scientific). Cell suspensions were transferred to a 
15 ml Falcon tube and centrifuged (2,000 rpm, 10 min, 4°C). Cells pellet was 
washed with ice-cold Dulbecco’s PBS and immediately placed on ice for cell lysis. 
Lysis buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 5 mM EDTA; 1% NP40) was 
reconstituted with protease inhibitor cocktail (Sigma-Aldrich), phosphatase 
inhibitor cocktail (Sigma-Aldrich) and phenylmethylsulfonyl fluoride 
(PMSF;Sigma-Aldrich), following manufacturer’s instructions. Cell pellets were 
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resuspended in 50 µl of lysis buffer per well, transferred to Eppendorf’s tubes and 
incubated on ice for 30 minutes, applying heavy vortexing every 10 minutes. Then, 
samples were centrifuged at maximum speed for 5 minutes at 4°C and supernatants 
were transferred to new Eppendorf´s tubes and immediately stored at -80ºC until 
needed. 
Protein concentration was quantified by using DC Protein Assay Kit (Biorad) and 
every cell lysate was adjusted to same concentration by diluting each sample in lysis 
buffer containing protease and phosphatase inhibitors. 
 
2.4.2. SDS-PAGE electrophoresis  
Cell extractions were mixed with 2X Reducing Sample Buffer (100 mM Tris, pH 
6.8; 10% β-mercaptoethanol; 4% SDS; 0.3% bromophenol blue; 20% glycerol) and 
boiled in a QBD4 heat block (Grant) at 100ºC for 5 minutes. Samples were loaded 
on polyacrylamide gels using 1X of Running Buffer (25 mM Tris; 20 mM Glycine; 
0.05% SDS) and run on a Mini-PROTEAN Tetra electrophoresis system (Bio-Rad) 
with a constant voltage of 100 V for 90 minutes using a PowerPac Basic Power 
Supply (Bio-Rad). 
 
2.4.3. Western-blotting and antibody detection 
Proteins were transferred onto nitrocellulose membranes (GE Healthcare Life 
Sciences) by using a Mini Trans-Blot cell (Bio-Rad) with 1X Transfer buffer (25 
mM Tris; 192 mM Glycine; 20% methanol) and Whatman filter paper (GE 
Healthcare Life Sciences), following manufacturer’s guidelines. The Western-blot 
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was run on the Tetra electrophoresis system (Bio-Rad) at a constant voltage of 90 
V for two hours. 
Nitrocellulose membranes were blocked using 5% skimmed milk diluted in Tris 
buffer saline (TBS) solution (50 mM Tris, pH 7.6; 150 mM NaCl) for 1 hour at 
room temperature. Once the blocking solution was removed, membrane was 
washed twice with TBS containing 0.05% of Tween20 (TBS-T) and subsequently 
incubated overnight at 4°C with the primary antibody, diluted in TBS-T containing 
2% BSA and 0.1% sodium azide. After three washes of TBS -T, membrane was 
incubated with the corresponding secondary antibody diluted in 5% skimmed 
milk/TBS-T for 1 hour at room temperature. Membrane was again washed three 
times with TBS-T and was developed employing Odyssey® Fc Imaging System 
(Licor). Images were taken, processed and quantified by using Image Studio 
Software (Licor). 
Primary and secondary antibodies used in this study are listed in table 2.7 and 
dilution recommended by the suppliers and used for the experiments is also 
specified in table 2.7. 
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Table 2.7. List of antibodies used in this study 
 Species Type Dilution Source Purpose 
Primary antibodies      
β-actin Mouse Monoclonal 1:1000 Sigma-Aldrich Western-blot 
GAPDH Mouse Monoclonal 1:500 Santa Cruz Biotechnology Western-blot 
TRAM2 Rabbit Polyclonal 1:1000 Novus biologicals Western-blot 
LC3B Rabbit Polyclonal 1:2000 Thermo Scientific Western-blot 
AMPK Rabbit Polyclonal 1:1000 Cell signalling Western-blot 
p-AMPK Rabbit Polyclonal 1:1000 Cell signalling Western-blot 
ERK 1/2 Rabbit Polyclonal 1:1000 Cell signalling Western-blot 
pThr202/Tyr204-ERK 1/2 Mouse Polyclonal 1:1000 Cell signalling Western-blot 
N-WASP Mouse Polyclonal 1:1000 Novus biologicals Western-blot 
pTyr256-N-WASP Rabbit Polyclonal 1:1000 Novus biologicals Western-blot 
EPHA2 Mouse Monoclonal 1:100 Santa Cruz Biotechnology Western-blot 
pSer901-EPHA2 Rabbit Polyclonal 1:1000 Signalway Antibodies Western-blot 
c-Jun Rabbit Polyclonal 1:1000 St John's Laboratory Western-blot 
pTyr231-c-Jun Rabbit Polyclonal 1:1000 St John's Laboratory Western-blot 
p-Tyr239-c-Jun Rabbit Polyclonal 1:1000 St John's Laboratory Western-blot 
S. aureus Methicillin Resistant Mouse Polyclonal 1:2000 Thermo Scientific Immunofluorescence 
      
Secondary antibodies      
IRDye® 680LT Goat anti-mouse Mouse  1:5000 Licor Western-blot 
IRDye® 800LT Goat anti-rabbit Rabbit  1:5000 Licor Western-blot 
Donkey anti-mouse TRITC conjugate Mouse  1:5000 Thermo Scientific Immunofluorescence 
 




2.5.1. Samples preparation for phosphoproteomics analyses  
After 6 hours of MRSA infection, cell extracts were obtained by lysing the cells 
with 50 µl of lysis buffer (20mM HEPES (pH 8) buffer containing 8M urea, 1mM 
Na3VO4, 1mM NaF, 1mM β-glycerol phosphate and 2.5mM Na2H2P2O7) per well. 
After lysis buffer was added to the cells, samples were thoroughly vortexed for 5 
minutes and immediately stored at -80ºC. Following sonication, cell lysates were 
centrifuged at 20,000 g for 10 min and the protein concentration was determined by 
Bradford analysis. 
Protein digestion was performed at Barts Cancer Institute facilities. A digestion 
protocol was applied as follows: cell extracts were diluted to 2M Urea with 20mM 
HEPES pH 8.0 and incubated with immobilized TLCK-trypsin (20 TAME 
units/mg) for 16 h at 37ºC. Digestion was then stopped by adding 1% of 
trifluoroacetic acid (TFA). The resultant peptide solutions were desalted using Sep-
Pak C18 columns (Waters UK Ltd, Manchester, UK) following manufacture’s 
guidelines (Casado and Cutillas, 2011).  
 
2.5.2. LC-MS/MS 
Mass Spectrometry analyses were also carried out at Barts Cancer Institute 
facilities. LC-MS/MS protocol was applied as follows: phosphopeptide enrichment 
was performed using an Immobilized Metal Ion Affinity Chromatography (IMAC) 
enrichment protocol as previously described (Alcolea, Kleiner and Cutillas, 2009). 
Phosphopeptides were detected in a Liquid Chromatography Tandem Mass 
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Spectrometry (LC-MS/MS) system as previously reported (Casado and Cutillas, 
2011; Alcolea et al., 2012).  
Mascot Daemon (v2.2.2; Matrix Science, London, UK) was employed to analyse 
the LC-MS/MS data. The parameters included trypsin as digestion enzyme, 
carbamidomethyl (C) as fixed modification and pyro-glu (N-terminal), oxidation 
(M) and phosphor (STY) as variable modifications. Datasets were searched with a 
mass tolerance of ±7 ppm and a fragment mass tolerance of ±600 mmu. Hits were 
considered significant when they had an expectation value ˂0.5 (as returned by 
Mascot). False discovery rates were ̴2% as determined by decoy database searches. 
An bespoke script was used to extract Mascot results, which were then placed in 
Excel file database for further analysis (Montoya et al., 2011). PESCAL was used 
to quantify the intensities of peptides present in the database across all samples to 
compare. PESCAL uses the restrictions on the molecular mass, retention time, 
charge and isotopes distribution to confidently identify the studied phosphopeptides 
(Cutillas and Vanhaesebroeck, 2007). The resulting quantitative results were then 
exported to Excel files for further normalization and statistical analysis. Peptides 
intensities were normalized to the total chromatogram intensity and to the mean 
intensities across samples to be compared (Alcolea et al., 2012).  
 
2.5.3. Functional analysis  
Phosphoproteomics data was plotted as heat-map as well as Volcano plot. Statistical 
differences in phosphopeptides quantification were assessed by Student´s t-test and 
adjusted for multiple testing using the Benjamini Hochberg false discovery rate 
method. R software was used for principal component analysis (PCA) and 
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performed by Pedro R. Cutillas. Regarding functional analysis, DAVID 
Bioinformatic software v.6.8 (Huang, Sherman and Lempicki, 2009) was used to 
identify the most important KEGG pathways, and KSEA analysis (performed by 
Pedro R. Cutillas as described in Casado et al. 2013) were carried out to find out 




2.6.1. Samples preparation for extracellular metabolome analysis 
After 6 hours of infection, 1.5 ml of medium was sampled, centrifuged (2,000 rpm, 
5 min, 4ºC) and the supernatant was stored immediately at -80ºC. To prepare 
samples for analysis by Nuclear Magnetic Resonance (NMR) spectroscopy, 0.8 ml 
of cell supernatant were mixed with 0.2 ml of NMR buffer. The NMR buffer 
contained 1 mM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) as internal 
standard and 25 mM NaN3 (to ensure sterility) in 
2H2O that serves as frequency 
lock for the spectrometer, resulting in a final concentration 0.2 and 5 mM, 
respectively.  
 
2.6.2. Nuclear Magnetic Resonance (NMR) 
NMR spectroscopy was performed on a Bruker DRX600 Avance spectrometer 
(Bruker Biospin, Rheinstetten, Germany) with a magnetic field strength of 9.4T and 
400 MHz 1H resonance frequency. Spectra (at 298K) were acquired into 32K data 
points using a one-dimensional solvent-suppression sequence, essentially as 
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described before (Beckonert et al., 2007). Data analysis was performed using in-
house software, following a work-flow described in La Rosa et al. 2015. 
 
2.6.3. Samples preparation for intracellular metabolome analysis 
Cells were washed with 1 ml of ice-cold Ringer´s solution (Oxoid) after 6 hours of 
infection and were quenched by adding 1 ml of cold (-20ºC) LC-MS grade 
methanol (Sigma-Aldrich) (Sellick et al., 2009). Cells were then detached by using 
a cell scraper (Fisher Scientific) and the cold methanol suspension was transferred 
into a clean Eppendorf tube. Extraction was repeated with a further 0.5 ml of cold 
methanol and extracts were pooled and stored at -80ºC. 
To obtain separated organic and aqueous fractions, extracts were dried using an 
Eppendorf Vacufuge Concentrator (Eppendorf). A dual phase extraction was 
performed by adding 300 µl of CHCl3/MeOH (2:1; Sigma-Aldrich) and vortexing 
for 30 seconds. After addition of 300 µl of water and centrifugation (13,000 rpm, 
10 minutes, RT), the top aqueous layer was transferred into an inactivated glass vial 
(Agilent Technologies) and dried before storing at -80ºC. The lower organic layers 
were placed into glass vials and dried overnight before being stored at -80C. The 
process was repeated, and fractions were pooled.  
For Gas Chromatography-Mass Spectrometry (GC−MS) analysis, aqueous 
fractions were derivatized by a two-step methoximation/silylation derivatization 
procedure. For normalisation, a standard of 10 µl of 1.5 mg/ml myristic acid d27 
standard solution (Sigma-Aldrich) was added and samples were dried. The dried 
samples were first methoximated using 20 μl of 20 mg/mL methoxyamine 
hydrochloride (Sigma-Aldrich) in anhydrous pyridine at 37 °C for 90 min. For 
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unlabelled samples, this was followed by silylation with 80 μl of N-methy-N- 
(trimethylsilyl) trifluoroacetamide (MSTFA; Thermo Fisher Scientific) at 37 °C for 
30 min (Kind et al., 2009). Labelled-samples were derivatized by adding 80 µl of 
N-(tert-butyldimethylsilyl)-N-methyltrifluro-acetamide (MBTSFA, Thermo Fisher 
Scientific). After being vortexed, samples were placed in a heat block (Grant) at 
70°C for 1 hour. Eventually, samples were centrifuged at 2,000 rpm for 5 minutes 
prior to transferring them into a clean vial for GC-MS analysis. 
The organic fraction was reconstituted in 300 µl of methanol/toluene solution (1:1 
ratio), treated with 200 µl of 0.5 M sodium methoxide and incubated for 1 hour at 
room temperature. Reaction was stopped by adding 500 µl of 1M NaCl and 25 µl 
of concentrated HCl. Fatty acids were extracted by using 500 µl of hexane and 
organic layers were dried in the fume cupboard under N2. Organic samples were 
then derivatized with 40 µl acetonitrile and 40 µl of MBTSFA (Thermo Fisher 
Scientific) and incubated at 70°C for 1 hour. Samples were finally centrifuged at 
2,000 rpm for 5 minutes prior to transferring them into a clean vial for GC-MS 
analysis. 
 
2.6.4. Gas Chromatography-Mass Spectrometry (GC-MS) 
GC-MS analysis was performed on an Agilent 7890 GC equipped with a 30 m DB-
5MS capillary column with a 10 m Duraguard column connected to an Agilent 5975 
MSD operating under electron impact (EI) ionization (Agilent Technologies). 
Samples were injected with an Agilent 7693 autosampler injector into deactivated 
splitless liners according to the method of Kind et al. (2009), using helium as the 
carrier gas (Tredwell and Keun, 2015).  
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Metabolites in the unlabelled pool were identified and quantified using a workflow 
described in Behrends et al. 2011. Briefly, samples were deconvoluted in AMDIS 
(Stein, 1999; Kind et al., 2009) and quantified using an in-house script. Integration 
of labelled metabolites was carried out based on an in-house fragment/retention 
time database using an updated version of the Matlab script capable of natural 





2.7.1. Immunofluorescence microscopy 
HeLa cell lines expressing the protein/s of interest fused with a fluorescent marker 
were seeded in coverslips at a cell density of 7.5x104 cells per well in 24 well plates 
and S. aureus USA300-GFP (Reichmann et al., 2014) was used to infect the cells 
at a MOI of 100 (Table 2.3). Infection was performed as previously described 
(Material and Methods, section 2.2.3) and after 6 hours of infection, cells were fixed 
with 0.5 ml of fresh 4% of paraformaldehyde (PFA; Fisher Scientific) for 15 
minutes. Coverslips were then washed twice with PBS and mounted on microscope 
slides (Thermo Fisher Scientific) using ProLong Gold Antifade mountant with 
DAPI (Thermo Fisher Scientific) for nuclear staining. 
For routine microscopy assays, the Olympus BX51 immunofluorescence 
microscope was used to observe the preparations and pictures were taken using 
Pixera software.  
 
Material & methods 
80 
 
2.7.2. Confocal microscopy 
Slides were observed on a confocal microscope ZEISS LSM 800 with Airyscan and 
images were acquired and processed by using Zen Blue Software (Zeiss). 
2.7.2.1. Phagosomal escape quantification by confocal microscopy 
HeLa cells expressing the phagosomal escape reporter mCherry-CWT (Grosz, 
Kolter, Paprotka, A. C. Winkler, et al., 2014) were seeded on coverslips in 24-well 
plates (7x104 cells per well) and infected with S. aureus USA300-GFP (Reichmann 
et al., 2014) at a MOI of 100. After 6 hours of infection, medium was aspirated, and 
cells were fixed and analysed as previously described.  
 
 
2.8. STATISTICAL ANALYSIS 
Statistical tests and graphs plotting were conducted using GraphPad Prism software. 
Student’s t-test and post hoc Tukey’s multiple comparison tests were employed to 
examine significant differences across treatments. 
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3. Intracellular Staphylococcus aureus 






Bacterial pathogens requires large amount of energy to support intracellular 
proliferation and hence, the interaction between intracellular pathogens and host 
cell metabolism is an important feature of virulence, since bacteria need to adapt to 
the host microenvironment (Abu Kwaik & Bumann 2015; Dandekar & Eisenreich 
2015). Once bacteria have been internalized, both bacteria and the host cell share - 
and compete for - the same nutrients, such as carbon sources or amino acids (Abu 
Kwaik & Bumann, 2015). In addition, metabolic products of the pathogen, e.g. 
derived from fermentation, are released to the host cell where they can activate 
different responses and alter the host metabolism (Olive and Sassetti, 2016). This 
interplay between host and pathogen represents a complex biological process and 
the site of infection could be considered as a closed system where the metabolism 
of two organisms work in parallel (Olive and Sassetti, 2016). The manipulation of 
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specific bacterial adaptations as well as the host-metabolic pathways targeted by 
the pathogen may be important to develop future treatments against bacterial 
infection. That said, the knowledge in this area is still limited (Dandekar & 
Eisenreich 2015). 
Pathogens exploit the host cell as a rich source of nutrients and in response, host 
immune responses seek to restrict bacterial access. Consequently, bacterial 
pathogens have developed different mechanisms to evade host immune response 
and virulence factors to access nutrients from the host (Abu Kwaik and Bumann, 
2015).  
Host immune responses are commonly activated by microbial surface components 
such as lipopolysaccharides (LPS) and other pathogen associated molecular 
patterns (PAMPs) molecules (Eisenreich et al., 2015) leading to several host 
immune responses. Some of these responses have a direct antimicrobial activity 
such as the production of reactive oxygen species (ROS) and reactive nitrogen 
intermediates (RNI) (Nathan and Shiloh, 2000). Others seek to deprive the pathogen 
from the access to scarce and important nutrients: expression of the transporter 
Nramp1 promoting iron depletion (Cellier, Courville and Campion, 2007) or the 
activation of indoleamine 2,3-dioxygenase by IFN-γ to degrade tryptophan (Taylor 
and Feng, 1991). 
As a result, successful intracellular pathogens must overcome these antimicrobial 
host responses and have developed different mechanisms to acquire nutrients from 
the host (Abu Kwaik and Bumann, 2015). Nutrients acquisition can be achieved by 
different actions: by altering host metabolic pathways (Escoll et al., 2017), by 
raising nutrient import (Lee et al., 2009) or by exploiting/subverting host 
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mechanisms to degrade macromolecules such as autophagy (Steele, Brunton and 
Kawula, 2015).  
Autophagy is a catabolic mechanism that involves the formation of double-
membrane vesicles – autophagosomes – and subsequent lysosomal fusion to 
degrade damaged or undesirable cytosolic material (Mizushima, 2007; Glick, Barth 
and Macleod, 2010). It is a well-conserved pathway in eukaryotic cells and plays 
important physiological roles in response to nutrient starvation, physiological stress 
and recycling of organelles (Mizushima, 2009; Glick, Barth and Macleod, 2010; 
Galluzzi et al., 2014).  
Despite the names, (auto)-phagosomes, these structures are also involved in a 
common host response against intracellular bacteria called xenophagy (Wileman, 
2013). It is known that several intracellular pathogens, including S. aureus, can 
subvert xenophagy to persist within the autophagosomes before escaping to the 
cytosol (Schnaith et al., 2007). However, it is not yet fully understood how S. 
aureus achieves this and which host pathways and/or metabolites it uses to enhance 
its intracellular survival and/or replication. S. aureus may also exploit this host 
pathway to support its energy demands since autophagy degrades macromolecules 
into accessible nutrients (Steele, Brunton and Kawula, 2015). 
Although there is still limited knowledge of how the host metabolism is triggered 
by different pathogens, the research that has been done on this topic was focused 
on more established intracellular pathogens such as S. flexneri, E. coli, L. 
monocytogenes, S. Typhimurium, L. pneumophila and C. trachomatis (Eisenreich 
et al., 2015). By contrast, not a lot is known about how the host cell metabolism is 
modulated and exploited by the pathogen S. aureus.  
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The aim for this chapter was to understand the host metabolic changes induced by 
intracellular MRSA infection with a view of identifying possible novel host-
directed anti-infective strategies against MRSA infections.  
3.2. RESULTS 
3.2.1. The extracellular metabolome of MRSA-infected host cells  
We used nuclear magnetic resonance (NMR) spectroscopy to analyse the media 
composition during gentamycin-protection assays in HeLa cells exposed to both 
alive and heat-killed S. aureus USA300. Results showed an increased concentration 
of organic acids in the medium of infected cells with viable USA300, such as 
formic, pyruvic and succinic acid. In particular, the highest increase was detected 
for acetic acid, with an increase of more than 100-fold compared to uninfected cells 
(Fig. 3.1). Levels of some amino acids (leucine, alanine and methionine) were also 
increased in the medium of infected cells (Fig. 3.1). In contrast, glucose levels were 
significantly reduced when compared to the uninfected control (Fig. 3.1), 
suggesting more rapid glucose uptake. No significant changes were found in the 
medium of cells infected with heat-killed USA300, suggesting that the increased 
secretion of organic acids and the lower levels of glucose were resulting from 
metabolic changes in the host cell triggered by viable intracellular bacteria.  




Figure 3.1. Comparison of metabolites identified in the media after MRSA infection. 
HeLa cells were exposed to alive and heat-killed USA300 (MOI 100; 6 hours) and media 
composition was analysed by NMR spectroscopy. Results are shown as log10 fold change 
relative to the uninfected condition and the figure shows mean ± SE of two independent 
experiments performed in triplicates. Shredded bars and black bars represents cells infected 
with USA300 and heat-killed USA300, respectively. p-value ≤0.05 (*); ≤0.01 (**); ≤0.001 
(***). Leu: leucine; Ile: isoleucine; Val: valine; Lac: lactate; Ala: alanine; Arg: arginine; 
Ace: acetate; Met: methionine; Glu: glutamate; Pyr: pyruvate; Succ: succinate; Gln: 
glutamine; Lys: lysine; Glc: glucose; Tyr: tyrosine; His: histidine; Phe: phenylalanine; For: 
formate. 
 
3.2.2. Changes in the host cell metabolism in response to MRSA 
infection 
3.2.2.1. Central carbon metabolism after S. aureus USA300 infection  
The intracellular metabolome of MRSA-infected cells was analysed by GC-MS 
(Figs. 3.2 & 3.3). We detected a major increase of several glycolytic intermediates 
during MRSA invasion. Levels of both 3-phosphoglycerate (3-PG) and 
phosphoenolpyruvate (PEP) were over 50 times higher in MRSA infected cells 
when compared to uninfected cells or cells exposed to heat-killed bacteria (Fig. 
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3.2). In addition, the glycerate pool size in the MRSA-infected cells significantly 
increased when compared to controls (Fig. 3.2). The labelling distribution of 
glycerate (Fig. 3.3) suggests that it was formed from glycolytic 3-phosphoglycerate. 
In contrast, pyruvate levels only increased slightly in the MRSA-infected cells, 
whereas lactate levels remained mostly unchanged among the three conditions (Fig. 
3.2). 
Several tricarboxylic acid (TCA) cycle intermediates such as α-ketoglutarate, 
citrate and succinate were present at higher levels in HeLa cells infected with 
USA300 (Fig. 3.2). Interestingly, this increase was not universal, as levels of 
fumarate remained unchanged among the three conditions and malate levels were 
reduced in cells infected with MRSA (Fig. 3.2). Further, stable isotope tracing 
suggested that most of the carbon of succinate is derived from glutamine; in 
contrast, the labelling pattern of fumarate and malate showed an enhancement of 
glucose-derived label, suggesting an increased importance of extra-mitochondrial 
pools of these metabolites. Interestingly, an increase in glucose-derived carbon can 
also be seen in aspartate (Fig. 3.3). For both fumarate and aspartate, this increase 
was due to a rise in the M+3 isotope (Fig. 3.4). 




Figure 3.2. Differences in the pool sizes of metabolites of the central carbon 
metabolism after S. aureus USA300 infection in HeLa cells. HeLa cells were lysed after 
gentamycin-protection assays with both alive and heat-killed USA300 and metabolites 
were detected by GC-MS. Graphs show absolute levels of each metabolite in uninfected 
cells (white bars), cells infected with USA300 strain (shaded bars) and cells exposed to 
heat-killed USA300 strain (black bars). Figure shows means ± SE of two independent 
experiments performed in triplicates. Statistical differences were tested using Student´s t-
test against uninfected cells. p-value ≤0.05 (*); ≤0.01 (**); ≤0.001 (***). Y-axis scale units 
are arbitrary units (x1,000). Green lines: metabolites of microbial origin. 




Figure 3.3. Differences in the labelling pattern of metabolites of the central carbon 
metabolism after MRSA infection. HeLa cells were infected with USA300 and exposed 
to heat-killed USA300 strains (MOI 100; 6 hours). Metabolites and labelling distribution 
were obtained by GC-MS. Figure illustrates the labelling pattern of each metabolite in 
uninfected cells (left pie-chart), cells infected with USA300 strain (middle pie-chart) and 
cells exposed to heat-killed USA300 strain (right pie-chart). Pie-charts depict the labelling 
distribution where blue slides represent labelled carbon coming from glucose; red slides 
are labelled carbon coming from glutamine and white slides show carbon from other 









Figure 3.4. Analysis of labelling pattern distribution of metabolites of the central 
carbon metabolism after MRSA infection. HeLa cells were infected with USA300 (MOI 
100) for 6 hours and labelling distribution were obtained by GC-MS. This figure illustrates 
the labelling pattern of each metabolite in cells infected with USA300 strain. The area of 
the filled circle depicts the fraction of label for each isolate, where blue represents carbon 
coming from glucose-labelled, red is carbon coming from glutamine-labelled and the black 
line is 100% of labelling. 
 
 
3.2.2.2. Amino acids metabolism 
We observed an activation of glutaminolysis in HeLa cells infected with USA300, 
with higher uptake of glutamine from the medium and unchanged intracellular 
levels. In contrast, glutamate and alanine levels were significantly higher in MRSA-
infected cells compared to uninfected cells or cells exposed to heat-killed MRSA 
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(Fig. 3.2). In the case of alanine, there is a slight increase of glucose-derived label, 
indicating increased flux from pyruvate (Figs. 3.2 & 3.3).  
Branched-chain amino acids are thought to be important for the virulence of S. 
aureus (Kaiser et al., 2015). However, we have observed no differences in the levels 
of valine, leucine and isoleucine among the three experimental conditions (Fig. 3.5).  
Importantly, the pool sizes of histidine, threonine and serine (three essential amino 
acids for both S. aureus and HeLa cells) were significantly reduced after USA300 
infection (Fig. 3.5). In contrast, phenylalanine levels of infected cells were also 
increased. While phenylalanine cannot be synthesized de novo by mammalian cells, 
MRSA is able to synthesize phenylalanine from phenylpyruvate and histidine via 
HisC (SAUSA300_0708), a histidinol-phosphate aminotransferase, potentially 
explaining both higher levels of phenylalanine and lower levels of histidine in 
MRSA-infected cells.  




Figure 3.5. Changes of absolute levels of amino acids in HeLa cells after S. aureus 
USA300 infection. HeLa cells were infected with USA300 and exposed to heat-killed 
USA300 strains (MOI 100; 6 hours). Levels of amino acids were detected and quantified 
by GC-MS. Graphs show absolute levels of each amino acid in uninfected cells (white 
bars), cells infected with USA300 strain (shaded bars) and cells exposed to heat-killed S. 
aureus USA300 strain (black bars). Figure shows mean ± SE of two independent 
experiments performed in triplicates. Statistical differences were tested using Student´s t-
test against uninfected cells. p-value ≤0.05 (*); ≤0.01 (**); ≤0.001 (***). Y-axis scale units 
are arbitrary units (x1,000). 
 
3.2.2.3. Changes in the central carbon metabolism after vancomycin-
protection assays with S. aureus NCTC 13626  
The significance of certain host-pathogen interactions may vary depending on the 
cell line or bacterial strain tested (Fraunholz and Sinha, 2012; Strobel et al., 2016). 
For example, the metabolism of cancer cell lines is conditioned by the Warburg 
effect (Potter, Newport and Morten, 2016) and therefore, the metabolomics findings 
described in HeLa cells may not be applicable to primary cells. To address this, we 
studied the metabolism of HeLa cells and BALB/c mouse bone marrow 
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macrophages when infected with the MRSA strain NCTC 13626, a reference strain 
for the healthcare-associated MRSA ST239 lineage (Edgeworth et al., 2007; 
Holden et al., 2010). NCTC 13626 is resistant to gentamycin, therefore the infection 
assays were carried out in the presence of vancomycin (Fig. 2.1). Interestingly, most 
of the changes induced in the metabolism of both types of host cells tested with 
NCTC 13626 were in concordance with the results observed in HeLa cells infected 
with USA300 (Figs. 3.6 & 3.7). The levels of glucose were reduced in HeLa cells 
and bone marrow macrophages in response to NCTC 13626 infection (Figs 3.6 & 
3.7), whereas glutamate levels were significantly increased, especially in bone 
marrow macrophages (Fig. 3.7), suggesting an activation of both the glycolysis and 
glutaminolysis pathways. The increased levels of glycolytic intermediates were 
found in HeLa cells irrespective of the infecting strain. 
Similar to the USA300-infected cells, several metabolites from the TCA cycle such 
as citrate and α-ketoglutarate were significantly increased in NCTC 13626-infected 
cells when compared to uninfected controls (Figs 3.6 & 3.7). The levels of succinate 
were also increased in HeLa cells infected with NCTC 13626 (Fig. 3.6), whereas 
succinate levels were stable in bone marrow macrophages (Fig. 3.7). In contrast 
with USA300 infection, both levels of fumarate and malate were higher in HeLa 
cells and bone marrow macrophages when infected with NCTC 13626, suggesting 
a strain-dependent metabolic change (Figs 3.6 & 3.7). 




Figure 3.6. Differences in the pool sizes of metabolites of the central carbon 
metabolism after S. aureus NCTC 13626 infection of HeLa cells. HeLa cells were lysed 
after vancomycin-protection assays with NCTC 13626 (MOI 100; 6 hours) and metabolites 
were detected by GC-MS. Graphs show absolute levels of each metabolite in uninfected 
cells (white bars) and cells infected with NCTC 13626 strain (shaded bars). This figure 
shows means ± SE of two independent experiments performed in triplicates. Statistical 
differences were tested using Student´s t-test against uninfected cells. p-value ≤0.05 (*); 
≤0.01 (**); ≤0.001 (***). Y-axis scale units are arbitrary units (x1,000). 




Figure 3.7. Differences in the pool sizes of metabolites of the central carbon 
metabolism after S. aureus NCTC 13626 infection of BALB/c Mouse Bone Marrow 
macrophages. Bone marrow macrophages were lysed after vancomycin-protection assays 
with NCTC 13626 (MOI 100; 6 hours) and metabolites were detected by GC-MS. Graphs 
show absolute levels of each metabolite in uninfected cells (white bars) and cells infected 
with NCTC 13626 strain (shaded bars). This figure shows means ± SE of two independent 
experiments performed in triplicates. Statistical differences were tested using Student´s t-
test against uninfected cells. p-value ≤0.05 (*); ≤0.01 (**); ≤0.001 (***). Y-axis scale units 
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3.2.3. Staphylococcal infection induces autophagy in HeLa cells 
A number of the metabolic changes we observed in this study have previously been 
linked to autophagy, i.e. an increase in glutaminolysis and low levels of glucose and 
essential amino acids may activate the autophagic flux in mammalian cells (Russell, 
Yuan and Guan, 2014). Further, autophagy/xenophagy is a common host response 
against intracellular infection, where the autophagosomes are employed to engulf 
intracellular bacteria for later degradation. However, different studies have proved 
that S. aureus is able to survive and replicate within these autophagosomes before 
escaping to the cytosol of the cell (Fraunholz and Sinha, 2012).  
Autophagy is commonly monitored by examining the conversion of the 
microtubule-associated protein light chain 3 (from LC3I to LC3II), since LC3II has 
been shown to directly correlate with the number of autophagosomes (Mizushima, 
2009; Mizushima, Yoshimori and Levine, 2010). We therefore investigated 
autophagy status – the conversion of endogenous levels of LC3-I to LC3-II – by 
Western-blotting in our infection model (Fig. 3.8). 
  




Figure 3.8. MRSA infection induces autophagy in HeLa cells. (A) HeLa cells were 
infected with USA300 strain (MOI 100; 6 hours) and protein lysates were analysed by 
Western-blot against LC3. The figure shows that MRSA infection promotes autophagy by 
activating the conversion of LC3-I to LC3-II. Both actin and GAPDH antibodies were 
employed as loading controls. The figure is a representative example of three independent 
experiments. (B) Quantification of the conversion of LC3-I to LC3-II in uninfected and 
infected-HeLa cells. Data are expressed as means ± SE of three different experiments and 
Student´s t-tests were performed to validate statistical significance across conditions. p-
value ≤0.01 (**). U= uninfected cells; M= MRSA-infected cells. 
 
Accordingly, the levels of conversion of LC3-I to LC3-II are markedly increased in 
MRSA-infected HeLa cells when compared to a non-infected control (Fig. 3.8). 
However, after careful analysis by confocal microscopy, we observed that cells with 
vacuoles staining positive for the auto-phagosomal marker mCherry-LC3 did not 
necessarily co-localize with bacteria (Fig. 3.9). Furthermore, 45% of intracellular 
bacteria were cytosolic at six hours post-infection, which may allow direct access 
to host metabolites present in the cytosol such as glucose (Fig. 3.10). 




Figure 3.9. Colocalization assay of MRSA-GFP and mCherry-LC3A by confocal 
microscopy. (A) Uninfected HeLa cells expressing mCherry-LC3A. (B) HeLa cells 
expressing mCherry-LC3A infected with USA300-GFP strain (MOI 100; 6 hours); DAPI 
was employed for nucleus staining. The MRSA-free autophagosomes were detected around 
the whole cell. Bar indicates 5µm. (C) Quantification of percentage of cells containing 
MRSA-free autophagosomes in uninfected and infected-HeLa cells. Data are expressed as 
means ± SE of three different experiments and Student´s t-tests were performed to validate 
statistical significance across conditions. p-value ≤0.001 (***). U= uninfected cells; M= 
MRSA-infected cells. 
 




Figure 3.10. Co-localization assay of USA300-GFP and mCherry-CWT by confocal 
microscopy. (A) HeLa cells expressing the fluorescent escape marker mCherry-CWT were 
infected with USA300-GFP strain (MOI 100; 6h); DAPI was employed for nucleus 
staining. The recruitment of mCherry-CWT (red) to the bacterial cell wall of USA300-GFP 
(green) identifies cytosolic bacterial cells. (B) Quantification of percentage of USA300-
GFP cells labelled with mCherry-CWT. Data are expressed as means ± standard errors of 




3.2.4. AMPK and ERK1/2 pathways are activated in HeLa cells 
after MRSA infection.  
The low levels of glucose, the activation of glutaminolysis and the drop of some 
amino acid levels in HeLa cells infected with USA300 point towards starvation and 
this may explain the induction of autophagy by the pathogen. As one of the main 
roles of autophagy is degradation of organelles for energy generation and nutrient 
scavenging (Rabinowitz and White, 2010), we have studied the phosphorylation 
state of AMPK and ERK during MRSA intracellular infection, which are sensors 
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of energy stress and amino acid deprivation in mammalian cells. Particularly, AMP-
activated protein kinase (AMPK) is a key regulator in cellular energy homeostasis 
in eukaryotes and this pathway is activated when intracellular levels of ATP are 
lower (Carling et al., 2011; Mihaylova and Shaw, 2011). Furthermore, a drop of 
amino acids in eukaryotic cells has been linked to a stimulation of autophagy by 
activating the Ras/Raf1/Erk1/2 pathway (Goldsmith, Levine and Debnath, 2014). 
We investigated the role of AMPK and Erk1/2 in HeLa cells and we found that both 
pathways were activated in response to MRSA infection in HeLa cells. Basal levels 
of Erk1/2 and AMPK were increased in HeLa cells infected with MRSA; however, 
levels of the phosphorylated version of both proteins was even higher (Fig. 3.11A). 
Thus, ratios of phospho-AMPK/AMPK and phospho-Erk2/Erk2 were 4 and 1.7 
times higher, respectively in MRSA-infected cells (Fig. 3.11B).  
 
Figure 3.11. Activation of AMPK and ERK2 pathway was detected in MRSA-infected 
cells. HeLa cells were infected with USA300 (MOI 100; 6 hours). (A) Protein lysates were 
analysed by Western-blot against AMPKα (AMPK), phosphor-AMPKα (p-AMPK), 
p44/42 MAPK (ERK1/2) and phospho-p42/44 MAPK (p-ERK1/2). β-actin antibody was 
employed as loading control. (B) Quantification of the ratio phospho-AMPK/AMPK and 
phospho-Erk2/Erk2. Data were normalized to β-actin levels for each condition. Data are 
expressed as means ± SE of three different experiments and Student´s t-tests were 
performed to validate statistical significance across conditions. p-value ≤0.05 (*), ≤0.01 
(**). U= uninfected cells. M=MRSA-infected cells. 
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To further validate these results, we tested the effect of dorsomorphin – an AMPK 
inhibitor (Zhou et al., 2001) – on MRSA infection. We first confirmed that 
dorsomorphin has no direct effect on USA300 growth (Fig. 3.12).  
 
Figure 3.12. Dorsomorphin does not have a direct effect on S. aureus growth. MRSA 
USA300 was grown in 96-wells plates in the presence of DMSO (Mock), Dorsomorphin 
at different concentrations ranging from 1-10 µM, or gentamicin. Absorbance (OD600nm) 
was measured at 2, 4, 6 and 24 hours to produce the growth curves. Data are expressed as 
means ± SE of three different experiments performed in triplicates. D, Dorsomorphin.  
 
We then tested the effect of dorsomorphin on the cell viability of USA300-infected 
cells. High concentrations of dorsomorphin did not restore host cellular viability 
during infection, indicating this drug can be cytotoxic at high doses to mammalian 
cells (Fig. 3.13A). However, in the presence of 2 µM dorsomorphin, host cell 
viability was increased in comparison to non-treated control, whereas intracellular 
MRSA survival was inhibited after 6 hours of infection in HeLa cells (Fig. 3.13A-
B). Furthermore, the levels of conversion of LC3-I to LC3-II were also significantly 
reduced in dorsomorphin-treated cells compared to non-treated cells after MRSA 
infection (Fig. 3.13C-D).  
Additionally, we investigated the effect of AMPK inhibition on HUVEC, an 
endothelial cell line in which S. aureus has also shown to survive intracellularly 
(Strobel et al., 2016). In this cell line, host cell viability was increased in the 
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presence of dorsomorphin, in a similar manner as in HeLa cells (Fig. 3.13E). On 
the other hand, the effect of AMPK inhibition on MRSA intracellular survival was 
more pronounced in HUVEC than in HeLa cells (Fig. 3.13F).  
 
Figure 3.13. AMPK inhibition increases cell viability while reduces intracellular 
MRSA survival and autophagy levels. HeLa cells and HUVEC were infected with 
USA300 (MOI 100; 6 hours) in the presence or absence of dorsomorphin. (A & E) Host 
cell viability after USA300 infection was quantified by flow cytometry in HeLa cells and 
HUVEC, respectively. (B & F) Intracellular MRSA survival was measured by CFU 
counting in agar plates in HeLa cells and HUVEC, respectively. (C) Protein lysates were 
analysed by Western-blot against LC3I/II, AMPKα (AMPK), phosphor-AMPKα (p-
AMPK). β-actin antibody was employed as loading control. (D) Quantification of the 
conversion of LC3-I to LC3-II. Data are expressed as means ± SE of three different 
experiments and Student´s t-tests were performed to validate statistical significance across 
conditions. p-value ≤0.05 (*), ≤0.01 (**), (***) ≤0.001. 
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3.2.5. Analysis of lipid-bound fatty acids   
Fatty acids could also act as powerful signalling molecules and be involved in 
different metabolic processes during intracellular MRSA infection (Quehenberger, 
Armando and Dennis, 2011). Thus, we determined the levels of esterified fatty acids 
in MRSA-infected cells.  
We quantified ten fatty acids in our samples. Seven of them showed no differences 
among treatments, such as stearic acid. However, the levels of three long-chain 
saturated fatty acids were markedly increased during intracellular MRSA infection: 
palmitic, docosanoic and eicosanoic acid (Fig. 3.14). Absolute levels of eicosanoic 
acid increased in cells exposed to heat-killed USA300 bacteria but were even higher 
in cells infected with alive USA300 (Fig. 3.14).  
On the other hand, the carbon labelling distribution varies across the three 
experimental conditions, especially for docosanoic and eicosanoic acids. In MRSA-
infected cells, both eicosanoic and docosanoic acids showed a similar labelling 
distribution, displaying an increase in glucose-derived label (Fig. 3.12). These two 
free fatty acids are elongation products obtained from intermediates of the 
glycolysis pathway, hence the rise in glucose-label is in accordance what we would 
expect. However, the percentage increase in abundance outstrips the percentage 








Figure 3.14. Differences in lipids metabolism in HeLa cells after USA300 infection. 
HeLa cells were infected with USA300 and exposed to heat-killed USA300 strains (MOI 
100; 6 hours) and fatty acids levels and their labelling distribution were detected by GC-
MS. Bar graphs show absolute levels of each fatty acid in uninfected cells (white bars), 
cells infected with USA300 strain (shredded bars) and cells exposed to heat-killed USA300 
strain (black bars). Pie charts display the labelling pattern of each fatty acid in uninfected 
cells (left pie-chart), cells infected with USA300 strain (middle pie-chart) and cells exposed 
to heat-killed USA300 strain (right pie-chart). Within pie-charts, blue slides represent 
carbon coming from glucose-labelled, whereas red slides are carbon coming from 
glutamine-labelled and white slides show carbon from other sources. Data are expressed as 
means ± SE of two independent experiments performed in triplicates and Student´s t-tests 
were performed to validate statistical significance across conditions. p-value ≤0.05 (*); 
≤0.01 (**); ≤0.001 (***). Y-axis scale units are arbitrary units (x1,000). 
 
We then evaluated the impact of these three fatty acids on MRSA infection by 
measuring the host cell viability during infection assays and the bacterial growth in 
medium supplemented with 30 µM of palmitic, docosanoic or eicosanoic acid (Fig. 
3.15). We used stearic acid as an additional control, since the levels of this fatty 
acid were not increased in MRSA-infected cells (Fig. 3.14).  
When compared to the negative control, the host cell viability was significantly 
increased during infection assays when DMEM was supplemented with either 
palmitic, docosanoic or eicosanoic acid, but not with stearic acid (Fig. 3.15A). In 
addition, bacterial growth at 6 and 8 hours was halted in the presence of both 
docosanoic and palmitic acids, and at 24 hours bacterial growth was attenuated by 
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all the three cytoprotective fatty acids (Fig. 3.15B), but not by the presence of 
stearic acid in the medium. These results suggest that the increase of host cell 
viability after MRSA infection is due to the directly reduction of MRSA growth in 
the presence of these three fatty acids. 
 
Figure 3.15. Three fatty acids increase host cell viability after USA300 infection by 
decreasing growth. HeLa cells were infected with USA300 (MOI 100; 6 hours) in the 
presence of DMSO (C), eicosanoic acid (E), docosanoic acid (D), palmitic acid (P) and 
stearic acid (S), and host cell viability as well as bacterial growth were tested. (A) 
Quantification of host cell viability after USA300 infection, measured by flow cytometry 
using double annexin V-FITC and PI staining. (B) Bacterial growth curves in NB (up) and 
the growth levels at 6, 8 and 24 hours (down). Data are expressed as means ± SE of three 
independent experiments performed in duplicates. Statistical significance was analysed by 
one-way ANOVA and post hoc Tukey’s multiple comparison tests. p-value ≤0.05 (*); ≤0.01 
(**); ≤0.001 (***). 
 
 




3.3.1. MRSA intracellular infection leads to extensive metabolic re-
routing leading to the host exhibiting signs of metabolic starvation 
In this study, we were interested in the metabolic changes brought about by 
intracellular S. aureus infection of mammalian cells. I performed NMR and MS-
based profiling and found that intermediates of lower glycolysis – such as 
phosphoenolpyruvate (PEP) and 3-phosphoglycerate (3-PG) – were highly 
increased in HeLa cells infected with the USA300 strain of S. aureus. Although the 
absolute levels of PEP and 3-PG were raised in HeLa cells after infection with the 
USA300 strain, the levels of lactate were relatively unaffected in both intracellular 
and extracellular compartments. Interestingly, the levels of intracellular pyruvate 
were (slightly, compared to PEP) increased in HeLa cells infected with the USA300 
strain and the secretion of this metabolite to the medium was also elevated in 
infected cells. This is suggestive of a down-stream block explaining the 
accumulation of PEP and 3-PG. While the nature of this block is unknown, potential 
targets include a (partial) inhibition of pyruvate kinase, the mitochondrial pyruvate 
carrier and/or the pyruvate dehydrogenase complex as well as regulatory 
interference of pyruvate dehydrogenase kinases. 
In stark contrast, MRSA-infected cells excreted vastly increased quantities of 
acetate and formate. Acetate excretion is not uncommon in HeLa cells infection 
models as a product of bacterial activity  (Kentner et al., 2014) and our findings 
suggest elevated flux through bacterial pyruvate-formate lyase (Pfl). Pfl generate 
formate and acetyl-CoA, which has been shown to be converted to acetate via 
phosphate acetyltransferase (Pta) and acetate kinase (AckA) for ATP generation 
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(Halsey et al., 2017) in some conditions. Furthermore, the increase of excretion 
(Fig. 3.1) as well as labelling pattern in USA300-infected cells (Fig. 3.3) for both 
formate and acetate is similar to each other and to that of pyruvate, suggesting a 
common source. These results suggest that despite higher glucose uptake in infected 
cells, bacterial metabolism might subvert some of the carbon intake, possibly 
contributing to a starvation response. While Pfl activity has mainly been activated 
under anaerobic conditions and in biofilms (Leibig et al., 2011), intracellular Pfl 
activity might be a hallmark of intracellular MRSA/S. aureus proliferation but 
further investigation is needed to confirm this hypothesis. 
Among all the metabolic changes generally seen in a host cells after an intracellular 
infection, alterations of the TCA cycle are relatively common (Eisenreich et al., 
2013, 2015). The TCA cycle represents an important source of carbons and 
chemical energy for intracellular pathogens (Abu Kwaik and Bumann, 2015), 
therefore it is likely that intracellular pathogens exploit this pathway for their 
intracellular survival and proliferation. In this study, the TCA cycle was greatly 
affected by MRSA infection, regardless the strain or cell line employed. While 
glutamine was the main source of carbon for most of the intermediates, there was a 
clear rise in the glucose-derived label in fumarate and aspartate of infected cells. 
The reason for this difference in label distribution between fumarate/aspartate and 
succinate is not fully clear but could arise via several pathways. As the increase in 
glucose-derived label was mainly due to an increase in the M+3 ion (Fig. 3.4), this 
suggests an anaplerotic flux from either pyruvate or PEP. One possibility is an 
increased flux through pyruvate carboxylase forming oxaloacetate, potentially as a 
consequence of reduced flux through succinate dehydrogenase (Sdh), as previously 
observed in a study looking at the metabolic effects of loss-of-function sdh mutants 
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(Lussey-Lepoutre et al. 2015). Moreover, the same study also found amino acid 
pool size alterations similar to those seen in the current study (Lussey-Lepoutre et 
al. 2015). Given the high levels of PEP, it is also possible that the reaction of PEP 
carboxykinase might be reversed (it usually catalyses the decarboxylation of 
oxaloacetate to PEP during gluconeogenesis) (Yang, Kalhan and Hanson, 2009). 
On its own, however, this would not explain the difference between fumarate and 
malate labelling patterns. In addition, the increase in glutaminolysis that we have 
detected will increase the availability of ammonium, which can be used to convert 
oxaloacetate to aspartate, and this in turn is converted to fumarate in the urea cycle. 
Activation of the urea cycle is imminently plausible due to increased amounts of 
glutamate, an activator of  N-acetylglutamate synthase, the product of which, N-
acetylglutamate, is a key positive regulator of urea cycle activity (Caldovic and 
Tuchman, 2003). 
 
3.3.2. MRSA-induced starvation initiates an autophagy response 
that is exploited by the bacteria 
Several host metabolic changes observed in MRSA-infected cells pointed towards 
starvation and this condition commonly leads to autophagy. Since autophagy has 
already been described to benefit some intracellular pathogens, we explored 
whether host-autophagy was implicated in intracellular MRSA infection. 
Among all its physiological functions, the role of autophagy as a defence against 
intracellular pathogens has been widely described (Levine, 2005; Mizushima, 2009; 
Deretic, Saitoh and Akira, 2013; Wileman, 2013). However, intracellular pathogens 
have developed refined mechanisms to subvert autophagy and successfully survive 
Results and discussion 
108 
 
within mammalian host cells (Colombo, 2005; Kimmey and Stallings, 2016; 
Casanova, 2017). For instance, S. Typhimurium and M. tuberculosis inhibit the 
autophagy initiation signalling (Shin et al., 2010; Tattoli et al., 2012), whereas S. 
flexneri escapes from autophagy recognition by recruiting Toca-1 via IcsB to inhibit 
recognition by autophagy machinery (Ogawa, 2005; Krokowski and Mostowy, 
2016). In contrast, S. aureus is able to replicate in the autophagosomes and to 
eventually escape to the host cytosol (Schnaith et al., 2007; Neumann et al., 2016), 
although the molecular mechanisms behind this are not yet fully understood. 
However, our analysis of LC3 and MRSA co-localization by confocal microscopy 
revealed that a significant number of autophagosomes do not contain bacteria in 
MRSA-infected cells, suggesting that these autophagosomes may have been formed 
for an alternative purpose. 
Autophagy-inhibition with wortmannin impairs the intracellular proliferation of S. 
aureus, whereas the induction of autophagy by rapamycin results in an increased 
number of intracellular bacteria (Schnaith et al., 2007). On the other hand, 
autophagy confers cellular protection to the α-toxin produced by S. aureus (Maurer 
et al., 2015). However, the α-toxin is not sufficient to permeabilize phagosomes in 
HeLa cells, probably reflecting expression differences in the receptor of α-toxin 
monomers: the ADAM10 metalloprotease (Lâm et al., 2010; Fraunholz and Sinha, 
2012; Inoshima et al., 2012). Therefore, we have hypothesized here that MRSA-
free autophagosomes could be produced in response to a different autophagy-
inducing stimulus other than leaky phagosomes containing bacterial cells or the α-
toxin produced by the pathogen.  
The role of autophagy as a host-defence pathway against intracellular pathogens 
has been already questioned, since the replication of some bacteria was impaired in 
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autophagy-deficient cells and the treatment with autophagy-activators recovered 
bacterial replication (Mostowy and Cossart, 2012). Considering that autophagy 
could increase the nutrients access, intracellular pathogens may have evolved some 
mechanisms to manipulate host-autophagosomes and to exploit the products of 
autophagic degradation for bacterial survival and proliferation (Steele, Brunton and 
Kawula, 2015; Escoll, Rolando and Buchrieser, 2016). Intracellular MRSA causes 
multiple changes in cellular metabolism during infection and many of the changes 
we observed point towards a situation of starvation, probably induced by the 
pathogen. This state of induced-starvation might also explain the presence of 
numerous MRSA-free autophagosomes.  
In response to nutrient deprivation, autophagy is induced in mammalian cells 
(Rabinowitz and White, 2010; Goldsmith, Levine and Debnath, 2014). This process 
is mainly regulated by mammalian target of rapamycin (mTOR), which acts as 
sensor of the host metabolic state (Kroemer, Mariño and Levine, 2010). In a wide 
range of mammalian cell lines, low levels of glucose enhance the autophagic 
machinery (Goldsmith, Levine and Debnath, 2014), whose regulation is usually 
dependent on AMPK signalling (Williams et al., 2009). During glucose 
deprivation, the proautophagy Beclin 1/VPS34 complex is activated via AMPK-
dependent Beclin 1 phosphorylation (Kim et al., 2013). Moreover, a drop in the 
amino acids levels also induce autophagy in mammalian cells via Ras/Raf-1/ERK1-
2 signalling pathway (He and Klionsky, 2009; Goldsmith, Levine and Debnath, 
2014). Additionally, in response to low levels of glucose, glutaminolysis is 
activated to sustain the TCA cycle and ATP production (Goldsmith, Levine and 
Debnath, 2014) and as a consequence of the ammonia produced by the 
glutaminolysis pathway, the autophagic flux is increased (Eng et al., 2010; Cheong, 
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Lindsten and Thompson, 2012). In HeLa cells infected with the USA300 strain, all 
these starvation signals were present: reduction in the levels of glucose, drop of 
several amino acids and activation of glutaminolysis pathway. Interestingly, these 
changes were also observed in both HeLa cells and BALB/c mouse bone marrow 
macrophages infected with MRSA NCTC 13626 strain, suggesting that the results 
previously mentioned are not just strain and host dependant. In addition, we also 
observed an activation of both AMPK and ERK signalling pathway in HeLa cells 
after MRSA infection. In accordance with these findings, a recent study has shown 
that the levels of ATP in human alveolar epithelial cells were significantly 
decreased between two and six hours of S. aureus infection (Gierok et al., 2016), 
further pointing to a starvation-induced response. Crucially, once we inhibited the 
host-AMPK pathway using dorsomorphin, intracellular MRSA survival was 
significantly hampered, and autophagy levels were also reduced, supporting our 
hypothesis that the activation of autophagy is caused by the state of starvation 
induced by the intracellular pathogen, which benefits the intracellular survival of 
MRSA. Future studies need to be carried out to identify additional components of 
this regulatory, but our findings suggest a novel host-directed anti-staphylococcal 
strategy based on the inhibition of AMPK-mediated autophagy. 
 
3.3.3. Increase in the levels of three saturated fatty acids in HeLa 
cells in response to MRSA infection 
Lipid droplets (LDs) are cellular organelles where triglycerides (TGs) and steryl 
esters (STEs) are stored and surrounded by a phospholipids and protein monolayer. 
LDs are considered the main lipid reservoir in eukaryotic cells (Martin and Parton, 
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2006). Recent studies have pointed the link between LDs and autophagy since this 
cellular process is able to degrade triglycerides (TGs) and cholesterol from LDs 
(Singh et al., 2009; Cingolani and Czaja, 2016). Also, many LD-associated proteins 
are related to membrane trafficking and particularly in HeLa cells, the requirement 
of LDs and their interactions with early autophagosomes has been shown (Dupont 
et al., 2014). Furthermore, in starved-cells there is an increase in the number of LDs 
over time (Rambold, Cohen and Lippincott-Schwartz, 2015). The observed 
accumulation of LDs in starved cells and its complex link with the autophagosomes 
biogenesis may explain the increase in the absolute levels of some fatty acids in 
cells infected with MRSA. These results are in line with the starvation-induced 
autophagy, probably in response to the intracellular MRSA infection. Additionally, 
some studies have shown that palmitic acid stimulates autophagy, mediated by 
JNK1 and PKC activity and independent from mTOR pathway (Tan et al., 2012; 
Goldsmith, Levine and Debnath, 2014).  
The absolute levels of eicosanoic acid were also significantly increased in HeLa 
cells exposed to heat-killed bacteria, suggesting that part of this increase is due to a 
host-immune response. Considering that eicosanoids have been related to 
inflammation and are considered a main component of the host innate immune 
responses (Dennis and Norris, 2015), the rise of eicosanoic acid in the host cell in 
response to heat-killed bacteria exposure is not surprising. In relation to the 
labelling distribution, the increase in glucose-derived label of both eicosanoic and 
docosanoic acids – whose labelling pattern is very similar to each other – agrees 
with the fact that elongation of fatty acids is driven from Acetyl-CoA (AcCoA) and 
thus, glycolysis (Pietrocola et al., 2015).  
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The cytoprotective role of palmitic, docosanoic and eicosanoic acids that we have 
observed during MRSA infection is directly related to the bacterial killing as there 
is a significant reduction of MRSA when cultured in the presence of these three 
saturated fatty acids. The bactericidal role of fatty acids against Gram positive and 
Gram negative bacteria has been widely studied (Desbois and Smith, 2010). 
Although some studies have shown bactericidal activity of unsaturated acids on S. 
aureus growth (Desbois and Smith, 2010; Cartron et al., 2014) not many have 
investigated the role of saturated fatty acids and their effect on S. aureus survival.  
The specific answer of how fatty acids mediate their antibacterial activity remains 
still unclear. The key membrane-associated process altered by the presence of fatty 
acids is the production of energy through the disruption of the electron transport 
chain and oxidative phosphorylation. However, fatty acids could also inhibit 
bacterial growth by promoting cell lysis, inhibiting enzyme activity or impairing 
nutrient acquisition from the host cell (Desbois and Smith, 2010). Our study shows 
that the presence of palmitic, docosanoic and eicosanoic significantly affect MRSA 
growth in vitro, reducing bacterial growth. Nevertheless, the precise mechanism 
underlying the antibacterial activity of these lipids is unknown and further 
experiments need to be carried out to unravel the mechanistic behind.  
The combination of fatty acids along with existing therapies may increase their 
effect and could contribute to the reduction of antimicrobial resistance. The 
combination of free fatty acids and cholesteryl esters have been recently tested 
against P.aeruginosa and S. epidermis and results have shown a potential as novel 
antimicrobial agents (Cheung Lam et al., 2016). 
 
 




In summary, we observed that autophagy in host cells is activated in response to 
intracellular MRSA-infection. During intracellular MRSA proliferation, the levels 
of glucose and several amino acids become significantly low in the host cell (likely 
due to bacterial metabolic activity), whereas glutaminolysis is highly activated. 
These observations are indicative of a state of starvation induced by the pathogen, 
which would explain the production of MRSA-free autophagosomes observed in 
infected host cells. This hypothesis is also supported by the activation of AMPK 
and ERK pathways, which act respectively as a key sensors of cellular energy 
homeostasis and amino acid deprivation.  
In addition, the presence of this intracellular pathogen also alters the host-lipidome. 
We found that the levels eicosanoic, docosanoic and palmitic acids significantly 
increased in MRSA-infected cells. Interestingly, the presence of these three fatty 
acids seems to have a cytoprotective role in HeLa cells after MRSA infection, due 
to direct reduction of MRSA in vitro. 
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4.  Host-directed kinase inhibitors act 






Current approaches to manage staphylococcal infections are focused on targeting 
specific processes, pathways or enzymes of the pathogen. The main advantage of 
this strategy is the minimal host toxicity. However, the major disadvantage of 
pathogen-directed therapies is the development of multidrug microbial resistance. 
This emerging and serious health issue requires the development of either effective 
vaccines or the identification of novel targets against multidrug resistant pathogens 
(Schwegmann and Brombacher, 2008). 
As part of their host-defense evasion mechanism, intracellular pathogens subvert 
and exploit a wide range of host factors and pathways to support their intracellular 
survival (Finlay and Cossart, 1997). They are able to target multiple pathways to 
assure their intracellular proliferation (Bhavsar, Guttman and Finlay, 2007). In the 
case of S. aureus, it has been shown that host-integrins are required for the 
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internalization of S. aureus into non-phagocytic cells (McDonnell et al., 2016). This 
interaction further leads to a cascade of signal transduction in which several host 
genes and pathways, such as FAK, Src, PI3-Akt, are involved (Agerer, 2005; 
Oviedo-Boyso et al., 2011). Host actin and cytoskeleton rearrangement has also 
been identified to play an important role during staphylococcal infection. 
Intracellular S. aureus induced the formation of actin comet tails, by recruiting 
Neural Wiskott-Aldrich syndrome N-WASP protein, to  facilitate bacterial 
movements during invasion to endothelial cells (Schröder et al., 2006). Similarly, 
there are other host genes that have been described to be important at different 
points of intracellular staphylococcal infection, including bacterial invasion, 
intracellular persistence or host cell death induced by the pathogen (Fraunholz and 
Sinha, 2012; Horn et al., 2017). 
Therefore, the study of host-pathogen interactions may lead to the identification of 
novel pathogen-specific drug targets and/or host-directed therapeutics. Host-
directed approaches could: (i) interfere with the host-pathways exploited by 
intracellular pathogen to survive within the host cell, (ii) enhance the immune 
response by stimulating host-defense responses against intracellular infection, (iii) 
target those pathways that cause hyper-inflammation and (iv) adjust host factors 
that lead to unstable responses at the site of infection (Kaufmann et al., 2018). 
Specifically, host-directed strategies comprise a range of different therapeutic 
agents such as monoclonal antibodies, vitamins, cytokines, cellular therapy, 
recombinant proteins and repurposed drugs (Zumla et al., 2016).  
Repurposing commercially available drugs that target specific host-pathways 
hijacked by intracellular pathogens is a particularly interesting strategy. The main 
advantage of using repurposed drugs is that they show minimal toxicity to the host-
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cell and they have already been approved for other clinical purposes, which would 
importantly reduce the necessary time to have these drugs in the market 
(Schwegmann and Brombacher, 2008; Czyz et al., 2014). 
There are currently several repurposed drugs that are in preclinical development to 
treat bacterial and viral infections. For instance, dasatinib – a tyrosine kinase 
inhibitor – inhibits the replication of Dengue virus via blockade of host proto-
oncogene kinase FYN (de Wispelaere et al. 2013). Imatinib – and inhibitor of BCR-
ABL tyrosine kinase – reduces bacterial load and pathology in murine lungs 
infected with Mycobacterium tuberculosis (Napier et al., 2015). In addition, 
cholesterol inhibitors has shown potential activity against S. aureus infection (Liu 
et al., 2008) since it is needed for internalization of the bacterium and the activation 
of virulence factors (Schwegmann and Brombacher, 2008).  
Moreover, we recently discovered that host-autophagy is induced by MRSA 
through the activation of the AMPK pathway. Our study showed a significant 
reduction of intracellular bacterial load in both primary and established cell lines 
due to host-directed AMPK inhibition of dorsomorphin (Bravo-Santano et al., 
2018). 
Based on these previous observations, here we screened for host-directed drugs that 
have already been approved for other clinical purposes, seeking to identify novel 
host-directed compounds to control the cell infection caused by S. aureus. 
Interestingly, we identified a host-kinase inhibitor – Ibrutinib – that hampered 
intracellular S. aureus survival and we investigated its mechanism of action by 
performing phosphoproteomics analyses. 
 





4.2.1. Host-directed drugs screening against intracellular MRSA 
We initially tested the effect on intracellular MRSA infection of 11 host-targeting 
drugs used to treat non-microbial diseases (Table 4.1). In particular, Amitriptyline-
HCl, Cyproheptadine-HCl, Thioridazine-HCl and Trifluoperazine-2HCl are used to 
treat high blood cholesterol levels or psychosis, and have been previously shown to 
clear other intracellular pathogens (Czyz et al., 2014). Hence, we tested these four 
compounds, along with other host-directed drugs, to investigate whether they have 
a similar effect on MRSA infection.  
We aimed to find host-targeted therapeutics that would impair MRSA cell infection 
without affecting the host cell viability and thus, we first tested whether the selected 
drugs would show any cytotoxicity at a concentration of either 10 or 33 µM as 
previously reported (Czyż et al., 2014) (Fig 4.1). We did not observe any significant 
increase in cell death in the presence of any drug at those concentrations except for 
Thioridazine-HCl and Trifluoperazine-2HCl, for which the minimal cell toxicity 
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Bortezomib Proteasome (26S) inhibitor Multiple Myeloma 
Ibrutinib 




Blebbistatin Myosin inhibitor 
Control of muscle 
contraction 
Amitriptyline-HCl G-protein coupled receptor Depression 
Cyproheptadine-HCl 
G-protein coupled receptor 
and Ca2+ signals 
Allergies 
Niacin Inhibition of TG synthesis High blood cholesterol 
Simvastatin 
Induction of hepatic LDL 
receptors 
High blood cholesterol 
Thioridazine-HCl 




Trifluoperazine-2HCl Adrenergic receptors Psychosis 
Table 4.1.Pilot screen for host-directed drugs tested on S. aureus infection in HeLa 
cells.   
 




Figure 4.1. Effect of several host-directed drugs in HeLa cells viability. (A) HeLa cells 
viability was measured by flow cytometry in the presence of each drug after 6 hours of 
exposure, employing a double staining of Annexin V-FITC and Propidium iodide. (B) The 
highest viability of HeLa cells in the presence of Thioridazine-HCl and Trifluoperazine-
2HCl was only reached at a concentration of 0.25 µM. Data are expressed as means ± SE 
of three independent experiments performed in duplicates. 
 
In order to identify host-directed drugs against intracellular S. aureus, we 
hypothesized that if the drug hampers intracellular MRSA without causing any 
cytotoxic effect, host cell viability should be higher in comparison to untreated and 
MRSA-infected cells. Therefore, we measured the host cell viability after six hours 
of MRSA infection in the presence of DMSO (control) or specific drugs at the 
maximum concentration within the therapeutic window (Fig 4.2). Interestingly, we 
found that in the presence of Ibrutinib, cell viability was significantly increased 
(Fig. 4.2).  
In contrast, we did not observe any significant results for the other 10 compounds 
we tested. In fact, cell viability under Trifluoperazine-2HCl treatment, which had a 
positive effect against L. pneumophila, Brucella abortus, and Rickettsia conorii 
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(Czyz et al., 2014), was negatively affected by this treatment during S. aureus 
infection (Fig 4.2).  
 
Figure 4.2. Host cell viability after S. aureus infection in the presence of different host-
directed drugs. HeLa cells were infected with S. aureus USA300 (MOI 100; 6 hours) in 
the presence of different drugs. Host cell viability was measured by flow cytometry 
employing a double staining of Annexin V-FITC and Propidium iodide. Percentage of cell 
viability was normalized to untreated S. aureus-infected cells. Data are represented as 
means ± SE of two independent experiments performed in duplicates. One-way ANOVA 
and multiple comparison Tukey´s tests were performed to validate statistical significance 
across conditions. p-value ≤0.05 (*). 
 
4.2.2. Developing a high-throughput screening for host-targeted 
therapeutics against intracellular S. aureus 
To systematically screen a large number of drugs for their activity against 
staphylococcal invasion, we developed a fluorescence-based high-throughput assay 
(Fig. 4.3).  Briefly, the assay uses flow cytometry to quantify viable host cells 
expressing the red fluorescent protein mCherry while also counting infected cells 
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with bacteria constitutively expressing the green fluorescent protein (GFP; Fig. 
4.3A). After establishing the scalability of the approach (Fig. 4.3B), we used a 
length of infection of 6 hours with a multiplicity of infection (MOI) of 100 to screen 
the effect of 133 host-targeting FDA-approved drugs (Approved Oncology Drugs 
Set VIII – National Cancer Institute, US) on host and bacterial cell viability.  
 
Figure 4.3. Host-directed drug-screening approach and standardization. (A) 
Experimental design of the drug screening approach. Untreated samples were always 
included as internal controls in each plate: four uninfected (white circles) and four MRSA-
infected (grey circles). Each drug was added in a different well (green circles). After 6 
hours of infection, samples were analyzed in the flow cytometer where cell number and 
percentage of cells containing S. aureus-GFP was quantified for every sample. (B) This 
approach was first standardized by using different MOIs. Data are expressed as mean ± SE 
of three independent experiments. 
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The effect of 10 µM of each drug is summarized in figure 4.4 and table 4.2.  In 
order to identify the most interesting candidates, we established a restricted cut-off 
according to the following criteria: (a) 90% reduction of intracellular MRSA 
compared to the untreated host cells and (b) host cell viability of at least 80% 
compared to uninfected host cells. Following these two premises, we found three 
drugs within this threshold: Ibrutinib, Dasatinib and Crizotinib (Fig. 4.4B).  
Of these three, Ibrutinib induced the clearest inhibitory effect on MRSA survival 
and the lowest variability across experimental replicates. Taken together, our data 
suggested that the host molecular pathway inhibited by Ibrutinib may play an 
important role in intracellular S. aureus infection and thus, we selected this drug for 
further validation and downstream experiments. 




Figure 4.4. Host-directed drugs screening in HeLa cells after S. aureus infection. HeLa 
cells were infected with S. aureus USA300-GFP (MOI 100; 6 hours) in the presence of 
different drugs. (A) Host cell viability and percentage of HeLa cells containing USA300-
GFP was measured by flow cytometry and normalized to uninfected cells and untreated S. 
aureus-infected cells, respectively. Each dot represents a different treatment. The dashed 
line in the right bottom corner depicts the established cut-off. (B) Percentage of cell 
viability and S. aureus-GFP for the three drugs within the cut-off values. Means ± standard 
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Drug Mean SE p-value Mean SE p-value 
Ibrutinib 93.12 17.17 0.0301 3.58 0.87 0.0073 
Dasatinib 99.5 44.5 0.0405 4.84 0.16 0.0078 
Crizotinib 98.94 46.62 0.0497 5.91 2.77 0.0083 
Mitoxantrone 59.57 25.75 0.6609 8.42 0.72 0.0095 
Ceritinib 41.84 3.55 0.2399 10.43 2.51 0.0000 
Mitomycin 138.13 7.25 0.0002 10.94 1.34 0.0109 
Capecitabine 107.42 29.04 0.0177 10.94 1.34 0.0109 
Panobinostat 94.32 37.49 0.0837 12.01 1.59 0.0116 
Afatinib 89.41 39.84 0.1310 13.08 4.51 0.0125 
Gefitinib 70.54 10.14 0.2308 13.27 0.56 0.0124 
Imatinib 98.78 17.61 0.0175 13.46 3.39 0.0127 
Clofarabine 81.07 4.90 0.0695 14.52 0.47 0.0133 
Mitotane 83.97 7.29 0.0528 15.40 6.41 0.0144 
Teniposide 74.61 25.38 0.3498 15.41 6.62 0.0000 
Nelarabine 65.57 12.88 0.3077 16.81 7.05 0.0045 
Raloxifene 101.86 19.81 0.0150 17.92 4.36 0.0163 
Plicamycin 116.02 11.61 0.0023 19.66 5.02 0.0002 
Dexrazoxane 60.17 16.65 0.5481 20.20 8.87 0.0060 
Belinostat 69.25 30.48 0.3873 20.43 2.30 0.0186 
Uracil mustard 60.47 6.94 0.4625 20.83 8.24 0.0062 
Vemurafenib 94.41 25.77 0.0648 21.70 8.76 0.0004 
Tretinoin 64.65 18.97 0.3964 22.00 12.64 0.0078 
Celecoxib 74.46 9.63 0.1548 22.26 10.58 0.0222 
Letrozole 74.09 18.63 0.1597 23.05 12.78 0.0084 
Idelalisib 107.33 53.60 0.0770 23.33 7.66 0.0228 
Sorafenib 109.77 53.11 0.0654 25.27 2.15 0.0245 
Trifluridine 64.28 10.40 0.3301 25.49 14.22 0.0106 
Olaparib 48.91 7.80 0.8805 26.22 17.61 0.0314 
Altretamine 76.06 22.92 0.1644 26.78 14.84 0.0119 
Bleomycin sulfate 65.36 17.57 0.5975 27.10 18.76 0.0005 
Chlorambucil 97.00 12.98 0.0160 27.79 0.10 0.0282 
Fludarabine phosphate 96.06 15.76 0.0206 27.98 3.86 0.0288 
Pomalidomide 51.82 6.63 0.9596 29.34 13.03 0.0132 
Pentostatin 43.41 12.50 0.5703 30.14 15.30 0.0153 
Methotrexate 53.39 12.50 0.8898 30.50 5.91 0.0337 
Uridine triacetate 99.62 32.52 0.0426 30.88 13.82 0.0379 
Lenalidomide 68.22 20.01 0.2987 31.27 16.56 0.0174 
Niraparib hydrochloride 113.25 43.05 0.0302 32.44 3.89 0.0372 
Mercaptopurine 73.09 27.40 0.2590 33.15 14.99 0.0186 
Thioguanine 97.80 28.93 0.0334 34.67 4.58 0.0156 
Temsirolimus 77.37 12.41 0.1698 35.58 10.35 0.0004 
Cisplatin 65.38 15.48 0.3377 36.09 16.35 0.0241 
Dactinomycin 59.55 7.40 0.8521 37.23 9.33 0.0018 
Cytarabine hydrochloride 55.71 16.07 0.7579 37.56 16.97 0.0274 
Ribociclib 88.45 28.22 0.0840 39.99 2.27 0.0572 
Bendamustine 
hydrochloride 
145.72 27.91 0.0008 40.18 6.22 0.0589 
Mechl rethamine 
hydrochloride 
62.84 16.37 0.4362 40.32 19.67 0.0368 
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Drug Mean SE p-value Mean SE p-value 
Carboplatin 109.45 5.44 0.0031 40.56 14.13 0.0655 
Axitinib 103.77 38.65 0.0449 41.06 0.66 0.0607 
Bortezomib 97.36 24.94 0.0321 42.01 19.11 0.0767 
Thiotepa 51.13 18.88 0.9964 43.00 22.76 0.0499 
Palbociclib 81.45 10.52 0.0963 44.99 9.60 0.0010 
Thalidomide 54.46 10.16 0.8029 45.05 25.84 0.0643 
Ponatinib 107.82 10.52 0.0033 45.06 5.14 0.0007 
Erlotinib hydrochloride 63.49 18.80 0.4792 45.14 16.31 0.0871 
Oxaliplatin 103.68 11.83 0.0075 45.40 14.28 0.0859 
Docetaxel 68.48 6.88 0.3887 45.58 3.04 0.0006 
Methoxsalen 54.15 12.03 0.8268 46.23 24.06 0.0646 
Cobimetinib 55.14 27.27 0.9171 47.23 28.19 0.0120 
Aminolevulinic acid 
hydrochloride 
60.95 6.66 0.4387 47.24 21.67 0.0630 
Vismodegib 123.78 30.64 0.0054 47.92 16.34 0.1014 
Topotecan hydrochloride 127.64 41.48 0.0101 48.60 5.51 0.0949 
Pemetrexed, Disodium 
salt, Heptahydrate 
69.55 2.43 0.2337 49.17 17.36 0.1101 
Pipobroman 55.94 15.97 0.7741 49.67 2.58 0.0998 
Cabozantinib 91.36 12.52 0.0242 49.83 11.99 0.0008 
Imiquimod 84.91 18.72 0.1029 51.78 14.43 0.0037 
Gemcitabine 
hydrochloride 
109.45 23.35 0.0059 51.86 27.93 0.1052 
Ifosfamide 66.43 4.50 0.2269 51.99 21.89 0.0864 
Irinotecan hydrochloride 83.32 4.05 0.0585 52.01 6.67 0.0017 
Rucaparib phosphate 103.26 24.46 0.0182 52.38 8.59 0.1196 
Pazopanib hydrochloride 65.83 4.23 0.7443 53.88 8.68 0.0016 
Dacarbazine 163.44 23.53 0.0001 54.42 22.83 0.1039 
Estramustine phosphate 
sodium 
68.12 11.44 0.4327 54.93 18.37 0.0164 
Megestrol acetate 102.06 24.26 0.0201 55.46 22.50 0.1648 
Melphalan hydrochloride 115.20 1.93 0.0016 55.52 11.15 0.1451 
Tamoxifen citrate 74.55 24.73 0.3449 56.36 29.88 0.0319 
Omacetaxine 
mepesuccinate 
92.97 21.80 0.0552 56.46 11.47 0.0047 
Everolimus 56.16 11.45 0.9448 56.66 6.42 0.0110 
Lapatinib 55.84 21.64 0.9396 57.19 15.09 0.0169 
Venetoclax 110.18 5.85 0.0017 58.29 16.43 0.0099 
Lenvatinib 124.12 2.27 0.0007 58.36 32.46 0.2194 
Temozolomide 92.02 9.37 0.0087 60.45 16.46 0.1286 
Lomustine 57.68 12.56 0.6359 60.82 29.82 0.1856 
Cladribine 97.04 12.58 0.0062 61.21 20.60 0.1493 
Decitabine 115.40 21.14 0.0024 61.38 16.22 0.1359 
Erismodegib 92.04 40.25 0.0626 62.16 18.05 0.0040 
Exemestane 96.46 17.26 0.0114 62.43 20.58 0.1610 
Vorinostat 140.89 11.51 0.0000 62.80 24.34 0.1805 
Paclitaxel 68.75 7.90 0.3834 62.85 9.20 0.0086 
Vinorelbine tartrate 60.78 3.56 0.7706 63.88 3.88 0.0071 
Regorafenib 74.30 25.90 0.3632 64.22 12.72 0.0307 
Fluorouracil 83.45 37.59 0.1842 64.51 15.92 0.1656 
Arsenic trioxide 119.92 12.76 0.0004 65.23 26.52 0.2185 
Dabrafenib mesylate 114.96 7.27 0.0010 66.14 27.12 0.0610 
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Drug Mean SE p-value Mean SE p-value 
Ixabepilone 75.36 6.41 0.1764 66.17 32.04 0.0933 
Plerixafor 77.44 16.90 0.2028 66.27 25.02 0.0525 
Azacitidine 136.35 14.25 0.0001 67.08 19.92 0.2108 
Anastrozole 85.42 5.94 0.0172 67.12 23.48 0.2273 
Cyclophosphamide 73.29 11.29 0.1195 67.95 17.12 0.2106 
Hydroxyurea 90.96 27.83 0.0568 69.12 16.04 0.2222 
Floxuridine 62.40 14.30 0.4343 69.52 51.57 0.4179 
Trametinib 65.86 21.06 0.6028 69.61 19.37 0.0467 
Pralatrexate 72.81 31.93 0.3153 70.98 6.60 0.3172 
Osimertinib 78.61 20.66 0.2123 72.02 54.97 0.3076 
Amifostine 106.90 22.39 0.0139 72.88 20.04 0.0697 
Streptozocin 114.96 26.89 0.0055 74.16 21.16 0.3237 
Cabazitaxel 87.69 15.33 0.0605 76.53 12.46 0.0628 
Zoledronic acid 51.39 10.20 0.6732 77.25 5.39 0.0479 
Procarbazine 
hydrochloride 
115.10 34.60 0.0133 77.43 15.01 0.3587 
Triethylenemelamine 54.61 10.97 0.8549 79.17 33.63 0.2470 
Carmustine 83.97 16.63 0.0465 80.53 23.99 0.4652 
Vincristine sulfate 78.41 2.42 0.1103 80.72 21.01 0.1629 
Fulvestrant 80.46 21.57 0.1860 83.22 30.71 0.2963 
Allopurinol 108.69 40.74 0.0378 86.60 21.97 0.6044 
Bosutinib 95.63 26.56 0.0281 86.88 55.49 0.1253 
Etoposide 102.81 8.99 0.0055 87.25 15.77 0.2465 
Enzalutamide 73.87 26.47 0.3802 91.54 4.70 0.3893 
Carfilzomib 43.78 11.96 0.3491 92.38 32.29 0.5477 
Busulfan 53.11 10.92 0.8850 93.11 20.47 0.7855 
Alectinib 51.68 8.86 0.2841 93.37 34.10 0.5642 
Valrubicin 48.42 6.45 0.5039 94.33 17.34 0.4869 
Nilotinib 43.89 4.80 0.7537 95.03 45.99 0.4474 
Ixazomib citrate 93.03 14.03 0.0789 97.69 46.66 0.3669 
Sirolimus 46.20 15.14 0.4658 101.05 15.19 0.7794 
Daunorubicin 
hydrochloride 
70.06 9.43 0.3443 103.79 46.47 0.9578 
Vandetanib 96.11 30.67 0.0788 104.60 97.73 0.9911 
Vinblastine sulfate 79.02 15.06 0.1586 109.81 16.22 0.7601 
Abiraterone 63.92 8.91 0.6105 116.20 23.79 0.5374 
Romidepsin 66.63 6.35 0.1377 134.18 16.87 0.7031 
Sunitinib 62.87 36.85 0.6078 200.50 25.70 0.0097 
Doxorubicin 
hydrochloride 
90.64 6.81 0.0238 222.83 27.38 0.0002 
Epirubicin hydrochloride 92.22 8.06 0.0207 405.48 63.93 0.0000 
Idarubicin hydrochloride 66.27 23.03 0.6012 5341.22 3598.06 0.0182 
Table 4.2. Results of drug-screening on MRSA infection in HeLa cells. The effect of 
133 FDA-approved drugs was tested in HeLa cells after MRSA infection (MOI 100, 6h). 
The percentage of cell number was normalized to percentage of uninfected cells. The 
percentage of HeLa cells containing S. aureus USA300-GFP was normalized to the 
untreated infected cells. Data show mean, standard error and p-value of three biological 
replicates. 
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4.2.3. Ibrutinib halts the cell invasion and intracellular survival of 
S. aureus 
To test whether the observed effect of Ibrutinib on host cell infection by S. aureus 
was due to the host-pathway inhibition or a direct effect on bacterial growth, we 
measured bacterial growth in the presence and absence of Ibrutinib as well as other 
controls. We did not find any significant differences in S. aureus growth in the 
presence of Ibrutinib when compared to the growth on rich media only, indicating 
that the previous observations resulted from a host-directed effect (Fig. 4.5). 
 
Figure 4.5. Ibrutinib does not have a direct effect on S. aureus growth. S. aureus 
USA300 was grown in 96-wells plate in the presence of DMSO (Mock), Ibrutinib, 
vancomycin or gentamicin. Absorbance (OD600nm) was measured at 2, 4, 6 and 24 hours to 
produce the growth curve. Data are expressed as means ± SE of three different experiments 
performed in triplicates. 
 
To validate cell viability readings based on mCherry expression, I measured 
markers that are activated upon cell death (Annexin-FITC and Propidium Iodide) 
and found again a significant increase of cell viability in S. aureus-infected cells 
that were treated with Ibrutinib in comparison to the untreated cells (Fig 4.6A). 
Additionally, we then measured the intracellular survival of S. aureus in the 
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presence of Ibrutinib (10 µM) and found that recovery of intracellular S. aureus was 
significantly lowered after both two and six hours of infection in the presence of 
Ibrutinib (Fig 4.6B). Specifically, the reduction of intracellular MRSA was more 
pronounced at early times of infection (two hours), suggesting that the drug’s effect 
is particularly important for cell invasion and/or internalization.   
 
Figure 4.6. Ibrutinib treatment during S. aureus infection increases host cell viability 
whereas intracellular bacterial survival is hampered. HeLa cells were infected with S. 
aureus USA300 (MOI 100; 6 hours) in the presence of DMSO (Mock) or Ibrutinib. (A) 
Host cell viability was quantified by flow cytometry, using a double annexin V-FITC and 
PI staining. Cell viability was normalized by the percentage of uninfected and untreated 
cells. (B) Intracellular MRSA survival was quantified by CFU counting after 2 and 6 hours 
of infection. Data are expressed as means ± SE of at least three different experiments 
performed in duplicates and Student´s t-tests were performed to validate statistical 
significance across conditions. p-value ≤0.001 (***). 
 
Cytoplasmic replication of S. aureus upon phagosomal escape is considered one of 
the last steps of a successful cell invasion (Grosz, Kolter, Paprotka, A. Winkler, et 
al., 2014). Consequently, the quantification of the number of cytosolic bacteria per 
cell could be considered an alternative way to evaluate the intracellular proliferation 
of S. aureus. Therefore, we quantified the number of cytosolic bacteria per cell 
using a phagosomal escape reporter C-terminal cell wall-targeting domain (CWT) 
of lysostaphin (Bravo-Santano et al., 2018) and found a four-fold reduction in 
bacterial numbers in the cytosol in the presence of Ibrutinib (Fig. 4.7) .  




Figure 4.7. Phagosomal escape of S. aureus USA300-GFP to the host cytosol under 
Ibrutinib treatment. HeLa cells expressing the phagosomal escape reporter mCherry-
SaCWT were infected with S. aureus USA300-GFP (MOI 100; 6 hours) in the presence or 
absence of Ibrutinib. (A) Images were taken using confocal microscopy. DAPI was 
employed for nucleus staining. Bar indicates 10 µm.  (B) Quantification of number bacteria 
positively stained with mCherry-SaCWT per cell. Data are expressed as means ± SE of 
three different experiments and Student´s t-tests were performed to validate statistical 
significance across conditions. p-value ≤0.001 (***). M, Mock; I, Ibrutinib. Microscopy 




4.2.4. Ibrutinib’s effect on S. aureus intracellular infection is likely 
to be BTK-independent  
Ibrutinib is a potent inhibitor of the Bruton’s tyrosine kinase (BTK) pathway in B 
cells. However, BTK is mainly expressed in cells of the immune system (Genevier 
et al. 1994) and a number of alternative protein kinases that are targeted by Ibrutinib 
have been recently identified, e.g. EGFR, ITK or TEC (Berglöf et al., 2015). 
To test the putative role of BTK in our model, we evaluated the effect on 
intracellular S. aureus survival of another two BTK inhibitors, Acalabrutinib and 
ONO-4059 (Wu et al., 2016). We did not detect significant differences on host cell 
viability or bacterial intracellular survival for these compounds (Fig. 4.8), 
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suggesting a BTK-independent mechanism of action due to an off-target effect of 
Ibrutinib in epithelial-like cells.  
 
Figure 4.8. Effect of Btk’s inhibitors – Ibrutinib, Acalabrutinib and ONO-4059 – on 
S. aureus infection in HeLa cells. HeLa cells were infected with S. aureus USA300 (MOI 
100; 6 hours) in the presence of DMSO (Mock), Ibrutinib, Acalabrutinib or ONO-4059. 
(A) Host cell viability was quantified by flow cytometry, using a double annexin V-FITC 
and PI staining. Cell viability was normalized by the percentage of uninfected and untreated 
cells. (B) Intracellular MRSA survival was quantified by CFU counting after 6 hours of 
infection. Data are expressed as means ± SE of three different experiments performed in 
duplicates and Student´s t-tests were performed to validate statistical significance across 
conditions. p-value ≤0.001 (***), (n.s) no statistical significance. 
 
4.2.5. Phosphoproteomics of S. aureus-infected cells in response to 
Ibrutinib identifies candidate pathways 
To elucidate the putative mechanism of action of Ibrutinib in our model, I 
performed a phosphoproteomics analyses in S. aureus-infected cells in presence 
and absence of Ibrutinib.  
Overall, I detected approximately 10,000 hits with four different types of 
modification: phosphorylation in the tyrosine kinases (P(Y)), phosphorylation in 
serine/threonine kinases (P(ST)), phosphorylation in both sites at the same time 
(P(Y)+P(ST)) or oxidation (O). Phosphorylation in the serine/threonine kinase sites 
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was the most common modification detected in our study, representing the 88% of 
the total modified peptides (Fig. 4.9).  
 
Figure 4.9. Overview of the phosphoproteome analysis and peptide modifications 
detected. (A) HeLa cells were infected with S. aureus USA300 in the presence of DMSO 
(Mock) or Ibrutinib. Cells were lysed after 6 hours of infection and samples were analysed 
by LC-MS/MS to identify phosphoproteomics changes. (B) Total number of peptides 
detected by LC-MS/MS classified by the different modifications that were detected: P(Y), 
phosphotyrosines; P(ST) phosphorserines/threonines; P(Y)+P(ST), phosphotyrosine 
phosphorserines/threonines; Oxidated, peptides with residues subjected to oxidation. 
 
For the phosphoproteomics analysis, we included two biological replicates for each 
condition – Mock (DMSO) and Ibrutinib – and samples were also run twice through 
the LC-MS to have two additional technical replicates. Overall, we found that the 
phosphoproteome of MRSA-infected cells was clearly affected by the treatment 
with Ibrutinib (Fig. 4.10A). Moreover, although some variability was observed 
across samples, biological and technical replicates were highly reproducible (Fig. 
4.10B). 




Figure 4.10. Differences of phosphopeptides levels in S. aureus-infected cells under 
Ibrutinib treatment. (A) Relative values of every phosphopeptide detected through LC-
MS/MS was plotted as a Heat-map. Each treatment is comprised by four replicates (two 
technicals and two biologicals) of each treatment: mock (DMSO) and Ibrutinib. (B) 
Principal Component Analyses (PCA) of the phosphoproteomics data in MRSA-infected 
cells. Untreated samples are represented in black whereas Ibrutinib-treated samples are 
displayed in red. Both plots were provided by Dr. Pedro Cutillas from Barts Cancer Institute 
facilities. 
 
Ibrutinib is an inhibitor of tyrosine (Y) kinases; however, as an off-target effect of 
this drug may play a role during S. aureus infection, we also included peptides with 
phosphoserine/threonine (S/T) sites in our analyses. We focused our analyses on 
the most significant hits, and 34 proteins were identified when applying a strict cut-
off (log2 fold change ≤ -2 and log10 p-value ≥ 2; Fig. 4.11).  




Figure 4.11. Phosphoproteome of S. aureus-infected HeLa cells under Ibrutinib 
treatment. Log2 Fold change is plotted against the Log10 p-value of each phosphopeptide 
under Ibrutinib treatment in relation to the untreated control. Orange dots comprise 
phosphopeptides whose Log2 fold was lower than -2 and Log10 p-value was higher than 
2.   
 
Of these, several proteins could control host pathways that could be crucial during 
cell infection. Our hits included several phosphopeptides of the JUN and JUND 
transcriptional factors of the AP-1 complex, which are at the crossroad of different 
signalling pathways required for proliferation, survival or apoptosis (Hernandez et 
al., 2008; Meng and Xia, 2011). In addition, we also identified ANXA2, a 
multifaceted protein that is involved in intracellular membrane repair, among many 
other processes (Hajjar, 2015); RAB3GAP1 modulates autophagosomal biogenesis 
Results and discussion 
134 
 
(Spang et al., 2014) and FLNA have different roles on cytoskeleton remodelling 
(Ohta, Hartwig and Stossel, 2006). Finally, EPHA2 stimulates the MAP/ERK 
kinase signalling cascade through SHC1 (Pratt and Kinch, 2002), which controls 
the expression of several genes involved in cell cycle. 
To further explore the phosphoproteome of S. aureus-infected cells under Ibrutinib 
treatment, I performed a functional pathway analysis by using DAVID 
Bioinformatics Resources 6.8 (Huang, Sherman and Lempicki, 2009). For this, 
phosphopeptides with p-values <0.05 and log2 fold change ≤ -1.1 were selected. As 
a result, 158 phosphopeptides were analysed to investigate the KEGG pathways 
affected by the treatment, which revealed that Ibrutinib mainly influences five 
cellular pathways in the infected host cells: focal adhesion, ERBB and MAPK 
signalling pathway, adherens junction and the regulation of actin cytoskeleton 
(Table 4.1).  
Cellular pathway Number of genes p-value Benjamini 
Focal adhesion 13 5.10E-08 3.80E-06 
ErbB signaling pathway 10 2.10E-08 3.10E-06 
Adherens junction 7 1.90E-05 9.30E-04 
MAPK signaling pathway 11 2.60E-05 1.00E-03 
Regulation of actin cytoeskeleton 10 3.70E-05 1.10E-03 
Table 4.3. Cellular pathways affected by Ibrutinib treatment during MRSA infection. 
KEGG pathways were analysed employing DAVID Bioinformatics Resources 6.8. Only 
cellular pathways that were statistically significant after Benjamini correction were 
included (p-value < 0.01).  
 
Twenty proteins were commonly implicated in these five cellular pathways (Fig. 
4.12 and Table 4.2), from which we identified several kinases in our study that 
might be the direct target of Ibrutinib during MRSA infection in HeLa cells, e.g. 
EPHA2, EGFR or ERBB2. 




Figure 4.12. Effects of Ibrutinib on the phosphoproteome of S. aureus-infected HeLa cells. The genes for which we detected a modification in 
their phosphorylation levels are displayed in capitals and surrounded by a red line. The level of inhibition of protein phosphorylation under Ibrutinib 
treatment is represented by the intensity of the red-colour within the circle as shown by the legend. Different pathways that are downstream affected 
by the inhibition of these genes are illustrated in grey-squares. 
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Gene Description Modification Log2Fold p-value 
ABL2 
Tyrosine-protein kinase ABL2 
protein. 
ABL2(T938) -1.187 0.0039 
ARHGAP3
5 








DAXX(S495) -1.304 0.0138 
EGFR 
Epidermal growth factor 
receptor protein. 
EGFR(S695) -1.422 0.0076 
ERBB2 
Receptor tyrosine-protein 
kinase erbB-2 protein. 
ERBB2(T694) -1.364 2.27E-04 
EPHA2 





EPHA2(S901) -2.000 5.57E-04 
FLNA Filamin A protein. 
FLNA(T1739) -3.122 1.23E-05 
FLNA(S966) -2.293 1.88E-04 
FLNB Filamin B protein 
FLNB(S2487) -1.499 0.0013 
FLNB(S2113) -1.168 3.42E-04 
JUN 
Transcription factor AP-1 
protein 
JUN(S243) -3.337 3.83E-05 
JUN(T62) -3.103 6.84E-08 
JUN(S63) -2.037 4.56E-05 
MAP2K2 
Mitogen-activated protein 








MAPK3(Y204) -1.390 1.77E-06 
NCK1 Cytoplasmic protein NCK1 NCK1(Y105) -2.159 5.82E-04 
PAK2 
Serine/Threonine protein 
kinase PAK 2 
PAK2(T21) -1.378 0.0074 
PPP1R12A 
Protein phosphatase 1 
regulatory subunit 12A 
PPP1R12A(T305) -1.531 1.72E-04 
PPP1R12A(S304) -1.443 6.26E-05 
PPP1R12A(S299) -1.294 0.0028 
PPP1R12A(S507) -2.171 5.94E-04 
PTK2 
Focal adhesion kinase 1 
protein 
PTK2(S910) -1.148 7.21E-04 
RPS6KA1 
Ribosomal protein S6 kinase 
alpha-1 
RPS6KA1(S732) -1.189 1.02E-06 
SHC1 SHC-transforming protein 1 
SHC1(S426) -2.853 9.71E-06 
SHC1(Y427) -2.853 9.71E-06 
TGFBR2 
TGF-beta receptor type-2 
protein 
TGFBR2(S352) -1.453 2.48E-04 
TLN1 Talin 1 protein 
TLN1(S1225) -1.595 4.09E-05 




WASL(Y256) -1.112 3.16E-05 
Table 4.4. List of genes involved in KEGG pathways affected by Ibrutinib treatment 
during S. aureus infection.  
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Lastly, a kinase substrate enrichment analysis (KSEA, Casado et al. 2013) was 
performed. KSEA is a powerful tool to estimate kinase activity based on the 
collective phosphorylation status of its substrates. Using this analysis, we identified 
several kinases that belong to MEK/ERK pathway (MEK2, ERK1/2/7, RSK2 and  
p90RSK) and three c-Jun N-Terminal kinases (JNK1/2/3; Fig. 4.13), which is 
showing the importance of the MEK/ERK/c-JUN signalling for intracellular S. 
aureus survival and proliferation. Conversely, none of our analysis flagged up BTK 
as a target in our model, further pointing towards a BTK-independent mechanism 
of action for Ibrutinib during infection of epithelial-like cells by S. aureus. 
 
Figure 4.13. KSEA analysis of the phosphoproteomics results. Size and color intensity 
of each dot is proportional to the ratio of Ibrutinib-treated samples compared to untreated 
samples. The larger and darker the dot is, bigger was the observed effect in Ibrutinib-treated 
samples. Kinases that were activated or inhibited in the presence of Ibrutinib are 
highlighted in blue and red, respectively. KSEA plot was provided by Dr. Pedro Cutillas 
from Barts Cancer Institute facilities. 
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4.2.6. Downstream analysis reveals the importance of EPHA2 for 
staphylococcal invasion 
To further characterize the host cell response to intracellular S. aureus, I 
investigated expression and phosphorylation levels of selected targets by Western 
blot analysis. 
Interestingly, N-WASP was identified as a potential target of the Ibrutinib effect on 
MRSA-infected cells. S. aureus triggers actin comet-tails through N-WASP 
phosphorylation (Schröder et al., 2006). In addition, the intracellular pathogen 
Shigella flexneri promotes Btk expression and N-WASP phosphorylation for its 
intracellular dissemination (Dragoi, Talman and Agaisse, 2013). 
 
 




Figure 4.14. Phosphorylation of N-WASP protein was not significantly affected by 
Ibrutinib treatment. HeLa cells were infected with S. aureus USA300 (MOI 100; 6 hours) 
in the presence or absence of Ibrutinib. (A) Protein lysates were analysed by Western-blot 
against N-WASP and phospho-N-WASP. GAPDH antibody was employed as loading 
control. (B) Quantification of N-WASP and phospho-N-WASP levels observed by 
Western-blot. Data were normalized to GAPDH levels for each condition and are expressed 
as means ± SE of two different experiments. Student´s t-tests were performed to validate 
statistical significance across conditions. (n.s) no statistical significance. Western-Blot was 
performed by Helen Stölting during her placement in our laboratory.  
 
Accordingly, the total protein levels of N-WASP were markedly increased after S. 
aureus infection, and these levels were lowered in infected cells treated with 
Ibrutinib (Fig 4.14A). However, the phospho-N-WASP / N-WASP ratio was not 
significantly affected by Ibrutinib in MRSA-infected cells (Fig. 4.14B), suggesting 
that the effect of Ibrutinib on N-WASP phosphorylation levels is indirect, and ruling 
out again an implication of BTK. 
In concordance with our phosphoproteomics data, we observed that the 
phosphorylation levels of c-JUN were downregulated in infected cells treated with 
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Ibrutinib (Fig. 4.15). Furthermore, basal levels of c-JUN remained stable among the 
three conditions, which indicates that Ibrutinib is either directly controlling the 
phosphorylation of this protein or is inhibiting another kinase involved in the 
activation of c-JUN phosphorylation (Fig. 4.15). 
 
Figure 4.15. Phosphorylation of EPHA2, c-JUN and ERK1/2 proteins in S. aureus-
infected cells treated with Ibrutinib. HeLa cells were infected with S. aureus USA300 
(MOI 100; 6 hours) in the presence or absence of Ibrutinib. Protein lysates were analysed 
by Western-blot against EPHA2, p-EPHA2, c-JUN, p-c-JUN, ERK1/2 and p-ERK1/2. 
GAPDH antibody was employed as loading control. Protein A from S. aureus was also 
detected and included as an internal control of the S. aureus infection. 
 
The basal levels of EPHA2 protein were markedly increased in S. aureus-infected 
cells compared to the uninfected control and were downregulated by Ibrutinib 
treatment (Fig. 4.15). Interestingly, EPHA2 has been shown to be important for 
other models of intracellular infections (Du Toit 2018). As inhibitors of Ephrin 
receptors such as ALW-II-41-27 exhibit cross reactivity with a number of EPHA 
and EPHB receptors (e.g. EPHA2/5/8 and EPHB1/2/3) (Choi et al., 2009), we 
decided to confirm the role of EPHA2 during intracellular S. aureus infection in an 
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EphA2 knockout cell lines derived from HEK293T (Chen et al., 2018). We 
quantified the host cell viability and intracellular bacterial survival and – in 
agreement with our previous results – we found that host cell viability was 
significantly higher in EphA2 knockout cell lines after six hours of S. aureus 
infection when compared to the wild type. Moreover, intracellular bacterial survival 
was significantly reduced after two and six hours of infection in EphA2 knockout 
cell lines (Fig. 4.16), suggesting that the EPHA2 receptor is important for the 
successful internalization of S. aureus inside host cells.  
 
Figure 4.16. The host-membrane receptor EPHA2 plays an important role during 
intracellular S. aureus infection. HEK-293T wild type and EphA2 knockout cells were 
infected with S. aureus USA300 (MOI 100) for 6 hours. (A) Host cell viability was 
quantified by flow cytometry, using a double annexin V-FITC and PI staining. Cell 
viability was normalized by the percentage of uninfected cells. (B) Intracellular MRSA 
survival was quantified by CFU counting after 2 and 6 hours of infection. Data are 
expressed as means ± SE of at least three different experiments performed in duplicates 
and Student´s t-tests were performed to validate statistical significance across conditions. 
p-value ≤0.001 (***). 
 
 




4.3.1. Tyrosine kinase inhibitors as promising host-directed 
therapeutics for intracellular MRSA infection 
In this study, we identified three potential candidates that may contribute to the 
clearance of intracellular MRSA infection (Ibrutinib, Dasatinib and Crizotinib) 
from a pool of 140 host-directed drugs. All three are host tyrosine kinase inhibitors, 
usually employed to treat cancer (D’cruz and Uckun, 2013). For in-depth 
characterisation, we focused on Ibrutinib, which caused a significant reduction of 
intracellular bacterial load at early time points of infection. This suggested that the 
host-pathway inhibited by Ibrutinib could play an important role at early steps of 
infection, such as bacterial invasion or internalization.  
Among all the different host-directed strategies against bacterial and viral 
pathogens, tyrosine kinase inhibitors have shown potential for clearing intracellular 
infections and two drugs are already under preclinical trials: Imatinib and Dasatinib 
(Zumla et al., 2016). Imatinib – an inhibitor of BCR-ABL tyrosine kinase and 
commercially distributed as Gleevec®  – restricts M. tuberculosis replication within 
macrophages and also reduces bacterial load and pathology in mice lungs infected 
with the same pathogen (Bruns et al., 2012). This drug has also been shown to 
decrease Vaccinia virus titre as well as to prevent virus dissemination in vivo 
models (Schwegmann and Brombacher, 2008). Moreover, a recent study showed 
that low doses of Imatinib reduce bacterial load of Franciscella spp. by inducing 
myelopoiesis and thus, the stimulation of host-immune responses by Imatinib may 
promote clearance of several microbial pathogens (Napier et al., 2015). Imatinib 
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also exhibited promising results in our study but did not meet our stringent cut-off 
criteria (Table 4.2). 
Dasatinib was one of the most promising candidates from our drug screening. After 
S. aureus infection, host cell viability was highly increased whereas intracellular 
bacterial load was drastically reduced in the presence of this drug. Dasatinib is a 
tyrosine kinase inhibitor that targets a wide variety of kinases and receptors, 
including ABL, the SRC family kinases, the receptor tyrosine kinases c-KIT, 
platelet-derived growth factor receptor (PDGFR), discoidin domain receptor 1 
(DDR1), c-FMS, and ephrin receptors (Montero et al., 2011). One of these 
pathways may be hijacked by MRSA during intracellular infection and therefore, 
providing a potential mechanism for the significant reduction of intracellular 
bacterial load during Dasatinib treatment. 
Similar to Dasatinib, the host-kinase inhibitors Saracatinib (AZD05030) inhibits 
Dengue virus replication within Huh7 cells via inhibition of Fyn kinase (de 
Wispelaere et al. 2013). In our study, we did not test the effect of Saracatinib 
(AZD05030) on S. aureus infection.  
 
4.3.2. The mode of action of Ibrutinib in MRSA-infected epithelial-
like cells is BTK-independent 
It has previously been shown that some intracellular pathogens are able to 
manipulate host actin to drive movement through the cytosol and to promote cell to 
cell spread (Welch and Way, 2014; Lamason and Welch, 2017). Actin maintains 
tissue integrity by providing structural integrity at cell-to-cell junctions and 
promotes the formation of membrane extensions during cell migration as well as 
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intracellular trafficking (Welch and Way, 2014; Lamason and Welch, 2017). 
Pathogens can trigger host actin-cytoskeleton modifications in different ways: (i) 
using secreted toxins that directly target actin or its regulators (Aktories et al., 
2011), (ii) exploiting actin assembly to promote their invasion (Carabeo, 2011) or 
(iii) hijacking the host-actin polymerization to induce intracellular or surface-
associated motility. 
For the pathogen Shigella flexneri, it has been suggested that it requires BTK 
through N-WASP phosphorylation to facilitate actin-based motility and 
dissemination (Dragoi, Talman and Agaisse, 2013; Valencia-Gallardo, Carayol and 
Tran Van Nhieu, 2015). Based on these observations and since Ibrutinib is a BTK 
inhibitor, we initially speculated that this pathway was also important during S. 
aureus infection. However, the levels of both N-WASP and phospho-N-WASP 
were decreased in MRSA-infected cells after Ibrutinib treatment with the ratio not 
significantly altered across the different conditions. The reduction in the 
phosphorylation of N-WASP detected by LC-MS/MS is due to a reduction of basal 
levels of the protein, probably caused by a reduction of intracellular bacterial load.  
As mRNA expression of BTK is usually limited to hematopoietic cells, specifically 
to B-cells and myeloid cell lines (Genevier et al. 1994), and some off-targets effect 
of Ibrutinib have already been reported, including non-kinase targets – such as 
(Lanning et al., 2014) and other kinases targets (Berglöf et al., 2015), we 
hypothesized that the effect of Ibrutinib is occurring on a BTK-independent 
manner. To confirm, we tested the effect of two other BTK inhibitors – 
Acalabrutinib and ONO-4059 – and found no significant effect on either host cell 
viability or S. aureus intracellular survival.  
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Interestingly, Berglöf et al. reported novel targets of Ibrutinib that are well 
expressed in epithelial cells, such as Epithelial Growth Factor Receptor family: 
EGFR, ERBB2 and ERBB4 (Berglöf et al., 2015). Moreover, EGFR and ERBB2 
were also desribed to be inhibited by Ibrutinib in B-cells (Honigberg at al. 2010). 
Hence, these receptors might represent the potential targets of Ibrutinib in 
epithelial-like cells during MRSA infection. 
 
4.3.3. Ibrutinib alters the phosphoproteome of S. aureus-infected 
cells  
Our analysis revealed that the phosphoproteome of S. aureus-infected cells was 
clearly affected by Ibrutinib treatment. Although we found numerous 
phosphopeptides changes between treatment and control, functional analyses 
allowed us to identify specific affected pathways. Many of the genes that were 
inhibited by Ibrutinib are related to cytoskeleton rearrangement of epithelial cells. 
For example, filamins (FLNA and FLMNB) are actin-binding proteins that stabilize 
actin filament networks and are important for cell locomotion (Zhou, Hartwig and 
Akyürek, 2010). In addition, Abl-family kinases are essential regulators of host 
cytoskeleton. They translate extracellular signals into cytoskeleton rearrangements 
affecting mainly host cell motility. They are also able to control other signalling 
molecules, such as Rho and Rac GTPases, to stimulate assembly of protein 
complexes that activate the formation of actin filaments by the Arp2/3 complex 
(Bradley and Koleske, 2009). All of these proteins were inhibited under Ibrutinib 
treatment after S. aureus cell infection (Fig. 4.12). Similarly, a treatment with the 
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inhibitor of actin polymerization cytochalasin D blocks internalization of S. aureus 
in mammalian cells (Murai et al., 1993).  
In addition, it has previously been shown that many of the proteins that were 
inhibited by Ibrutinib in our study play also a role in other bacterial and viral 
infections. Host Rho-GTPases are involved in actin cytoskeleton remodelling and 
are manipulated by the HIV-1 envelope protein to facilitate its entry to the host cell 
(del Real et al., 2004). The MAPK signalling pathway is one of the most prominent 
host-pathway hijacked by intracellular pathogens (Krachler, Woolery and Orth, 
2011). Specifically, M. tuberculosis activates host p38-MAPK pathway in order to 
inhibit CD1 expression and thus, subvert part of the host-immune response 
(Gagliardi et al., 2009). Additionally, internalization of S. aureus has been related 
to the activation of focal adhesion kinase (FAK) and Src-mediated cortactin 
phosphorylation (Agerer et al., 2005) and this pathway was also inhibited in the 
presence of Ibrutinib during MRSA infection. Moreover, a kinase substrate 
enrichment analyses (KSEA; Fig 4.13) (Casado et al. 2013; Wiredja et al. 2017), 
identified several ERK and c-JUN protein kinases (JNK) as part of the pathways 
inhibited by Ibrutinib during MRSA infection. We have previously observed an 
activation of the host ERK pathway in HeLa cells after S. aureus infection (Bravo-
Santano N, 2018). In addition, other studies have also shown that internalization of 
S. aureus is impaired when using ERK or JNK inhibitors in fibroblasts and 
RAW264.7 cells, respectively (Fang et al., 2014; Zhao et al., 2017).  
Finally, we have identified several host membrane receptors that could play 
important roles on S. aureus cell infection, e.g. Ephrin type-A receptor 2 (EPHA2), 
Epidermal growth factor receptors (EGFR or ERBB1 and ERBB2) and 
transforming growth factor beta receptor (TGFBR). Interestingly, the inhibitor of 
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the host EGFR, CI-1033, has shown therapeutic efficacy against Vaccinia virus 
infection (Yang et al., 2005). Moreover, as mentioned above, EGFR and ERBB2 
have been previously described as off-targets suspects of the drug Ibrutinib (Berglöf 
et al., 2015). Links between EGFR and the ephrin-receptor EPHA2 have already 
been reported (Larsen, Stockhausen and Poulsen, 2010). In addition, ADAM10 
controls EGFR signalling, which in turn regulates EPHA1/2 signalling complexes 
in epithelial cells (Kaplan et al., 2018). Coincidentally, ADAM10 protein 
expression is required for the activity of S. aureus α-hemolysin (Hla) on 
mammalian cells (Wilke and Wardenburg, 2010). Thus, the EPHA2 basal levels 
may be indirectly controlled by Hla during S. aureus infection of epithelial-like 
cells.  
 
4.3.4. EPHA2 plays an important role on S. aureus cell infection 
Internalization into the host cell is a crucial step to successfully establish infection 
for intracellular pathogens. Recently, the Ephrin type-A receptor 2 (EPHA2) has 
been highlighted as a potential common host receptor for the intracellular 
internalization of many different pathogens (Du Toit, 2018). The implication of this 
tyrosine kinase receptor in infection has already been demonstrated in different 
intracellular bacteria such as M. tuberculosis (Khounlotham et al., 2009), 
Chlamydia trachomatis (Subbarayal et al., 2015) and enteropathogenic E. coli 
(Scholz et al., 2015). It is also involved in the entry of Epstein-Barr (Chen et al., 
2018) and Hepatitis C (Lupberger et al., 2011) viruses into the host cell. Therefore, 
we speculated that the facultative intracellular pathogen S. aureus might also 
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exploit this host membrane receptor to facilitate its internalization into epithelial 
cells. 
In accordance with our hypothesis, exposure of EphA2 knockout cell lines to S. 
aureus resulted in a reduction of intracellular bacteria, specially at early time points 
of infection. These results suggest that EPHA2 is important for the successful 
invasion or internalization of S. aureus. Additionally, the EPHA2 receptor is linked 
to many other downstream proteins that may also be involved in the intracellular 
survival or proliferation of S. aureus. For instance, EPHA2 receptor activates focal 
adhesion kinases (FAK) (Miao et al., 2000), which has been previously related to 
the internalization of S. aureus (Agerer et al., 2005). EphA2 is further associated 
with SHC, ERK and JUN proteins that were also inhibited under Ibrutinib treatment 
and play different roles in intracellular infections as afore mentioned. Therefore, 
the host-membrane receptor EPHA2 represents a very promising drug-target for 
intracellular MRSA anti-infectives. 
 
 
4.4. CONCLUSION  
We screened a total of 140 host-directed drugs against intracellular MRSA infection 
and we identified three host-kinase inhibitors – Ibrutinib, Dasatinib and Crizotinib 
– that showed a potential effect against intracellular MRSA. Among these three 
inhibitors, we characterized the role of Ibrutinib during intracellular S. aureus 
infection. In the presence of Ibrutinib, host cell viability was partially restored after 
MRSA infection whereas intracellular bacterial survival as well as S. aureus 
phagosomal escape was hampered. We also carried a phosphoproteomics analysis 
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in MRSA-infected cells in the presence or absence of Ibrutinib and we found twenty 
proteins whose phosphorylation was inhibited under Ibrutinib treatment. In 
particular, we identified EPHA2 as a potential target of Ibrutinib. Accordingly, 
intracellular MRSA survival was significantly reduced in EPHA2 knockout cells 
compared to the wild type. 
Undoubtedly, a novel drug discovery approach to combat intracellular bacterial 
infections is emerging and is focused on identifying and targeting the host 
molecular and/or metabolic factors hijacked by intracellular pathogens (Zumla et 
al., 2016; Bravo-Santano et al., 2018). Ibrutinib has already been described as an 
effective host-directed therapy for S. flexneri and L. donovani (Dragoi, Talman and 
Agaisse, 2013; Varikuti et al., 2018) and this study suggests that this inhibitor could 
also be repurposed to halt intracellular S. aureus when used in combination with 
conventional antibiotics such as gentamicin. This could be a very promising 
strategy to achieve patient decolonization of S. aureus. 
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5.  Identification of novel targets for 
host-directed therapeutics against 





In the previous two chapters, I identified novel host-directed therapeutics against 
intracellular Staphylococcus aureus by means of metabolomics and high-
throughput drugs screening. Furthermore, I found new host-targets by elucidating 
the mechanism of action of a drug candidate by phosphoproteomics. In this chapter, 
we explored the host factors co-opted by S. aureus during cell infection with a 
functional genomics approach.  
There are different strategies available to determine host factors hijacked by 
intracellular pathogens, combining genomics, computational biology, proteomics 
and transcriptomics  (Schwegmann and Brombacher, 2008). These strategies could 
lead to the identification or development of new host-targeted treatments to combat 
intracellular infections.  
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In particular, loss-of-function phenotypic analysis, such as RNA interference 
(RNAi), has been employed to identify host genes or proteins that are necessary for 
the pathogen internalization, growth or replication within mammalian cells 
(Agaisse et al., 2005; Philips, Rubin and Perrimon, 2005; Ng et al., 2007; Brass et 
al., 2008). For example, a genome-wide RNAi analysis was carried out in 
Drosophila cells infected with the cytosolic bacterium Listeria monocytogenes. In 
this study, they identified 358 host genes that were potentially involved in Listeria 
infection, covering a wide range of host cellular functions. Among the identified 
genes, many of them were involved in either vesicle trafficking, signal transduction 
or cytoskeleton rearrangement (Agaisse et al., 2005). Another study identified the 
host-kinase AKT1 as an important host molecular factor during M. tuberculosis and 
S. Typhimurium infections by using an RNAi approach coupled to automated 
microscopy (Kuijl et al., 2007). In addition, the involvement of the host Abl kinase 
in the internalization of Pseudomonas aeruginosa into Drosophila cells was also 
achieved by a RNAi screening (Pielage et al., 2008). 
The assessment of gene function using RNAi approaches relies on degradation of 
specific messenger RNAs (mRNAs) to silence gene expression. In mammalian 
cells, RNAi is usually mediated by microRNAs (miRNA) that are non-protein 
coding transcripts. shRNAs are miRNAs that are processed into shorter RNAs and 
contain a short-hairpin structure. These shRNAs are then further processed into 
short double-stranded pieces of RNA called short-interfering RNAs (siRNAs). The 
molecular mechanism of gene silencing comprises the binding of one strand of the 
siRNA duplex to a protein-coding mRNA transcript within the multi-protein RNA-
Induced Silencing Complex (RISC). Consequently, this interaction triggers 
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cleavage of the protein-coding mRNA by a nuclease in the RISC complex, thereby 
destroying the mRNA and silencing the expression of the gene (Sims et al., 2011).  
In this study, a shRNA screening approach was employed to identify novel host-
genes that could be involved in S. aureus cell infection. One of the main advantages 
of shRNA screenings, compared to siRNA approaches, is their ability to stably 
integrate into the genome of mammalian cells, allowing the generation of 
established knockdown cell lines and therefore, longer experimental time-courses 
(Coussens et al., 2011; Sims et al., 2011). Furthermore, the availability of 
commercial shRNA libraries constitutes a powerful technology that makes it 
possible to perform large-scale loss-of-function genetic screenings in mammalian 
cells (Root et al., 2006; Sims et al., 2011). 
The aim of this chapter was to identify host-factors exploited by S. aureus for host 
cell invasion and intracellular proliferation by employing an unbiased shRNA-





5.2.1. Identification of novel host-genes involved in S. aureus cell 
infection  
The effect of silencing 16,000 human genes during S. aureus cell infection was 
tested by using the Mission® LentiPlex® Human Pooled shRNA Library (Sigma-
Aldrich). The shRNA library comprises over 75,000 shRNA constructs that were 
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divided in 10 different sub-pools. Over 13,500 genes were targeted by at least 5 
different shRNA constructs to ensure reproducibility (Fig. 5.1).  
 
Figure 5.1. Distribution of shRNA constructs included in the Mission® LentiPlex® 
Human Pooled shRNA Library. Most of the genes that are included in the shRNA library 
are targeted by 5 different shRNA constructs. 
 
I transduced HeLa cells with the shRNA library (Material and Methods 2.2.2) and 
performed puromycin selection to obtain cells stably expressing the shRNA library 
(shRNA-HeLa cells; Fig. 5.2.). Subsequently, we infected shRNA-HeLa cells with 
the clinically relevant S. aureus NCTC 13626 strain in the presence of vancomycin 
(Fig. 2.1) to investigate the effect of silencing specific genes on intracellular MRSA 
infection; uninfected shRNA-HeLa cells were used as negative control. After six 
hours of infection, we extracted total genomic DNA to determine by Illumina 
sequencing the total occurrence of each shRNA integrated on the shRNA-HeLa 
cells after infection (Fig. 5.2).  




Figure 5.2. Layout of shRNA screening approach. (A) HeLa cells were first transduced 
with shRNA library until stable cells were produced (shRNA-HeLa). (B) shRNA-HeLa 
cells were infected with MRSA and genomic DNA was extracted to determine by Illumina 
sequencing the occurrence of each shRNA after infection.  
 
By calculating the ratio between the occurrence of all shRNA constructs targeting 
the same gene found in S. aureus-infected cells (sample) versus the uninfected 
condition (control), we identified 5,674 shRNAs that were under-represented after 
S. aureus infection, whereas 9,997 shRNAs were over-represented when compared 
to uninfected cells (Fig. 5.3). Over-represented shRNA vectors may increase the 
host cell viability (and therefore their copy number) by depleting proteins used by 
the pathogen to enter or proliferate inside the host cells. Therefore, our downstream 
analysis was focused on genes targeted by over-represented shRNAs after S. aureus 
cell infection.  




Figure 5.3. shRNA screening in HeLa cells after S. aureus infection. The relative 
quantity of each shRNA found in MRSA-infected cells was divided by the relative quantity 
found in uninfected cells and values were Log-transformed (Log+1). Mean and SE were 
calculated for those shRNAs that were targeting the same gene and plotted into the above 
graph. Means and SE are represented as black dots and grey lines, respectively. Black dots 
become as a continuous black line due to the high number of genes. This figure was 
provided by Pablo Capilla-Lasheras. 
 
Results were firstly visualized in a volcano plot to identify hits based on their 
significance and magnitude of change, where 38 genes were highlighted after 
applying a very strict cut-off (log2 fold change ≥3, -log10 p-value ≥1.3) (Fig. 5.4).  




Figure 5.4. Volcano plots of the shRNA screen results. Screening results of 16,000 genes 
are ranked by fold‐change and significance.  Orange dots comprise genes with Log2 fold 
change of the mean ratio above 3 and -Log10 p-value higher than 1.3.   
 
However, the silencing effect of empirically-designed shRNA vectors could be 
limited by their variable efficiency and specificity (Khandelwal et al., 2015). 
Therefore, we further interrogated our screening results by considering the 
percentage of shRNAs that were under- or over-represented for each gene to 
estimate the consistency of the silencing effect. This is important because a 
consistent silencing effect produced by multiple shRNA constructs targeting the 
same gene is less likely to be due to an off-target effect (Root et al., 2006; Sims et 
al., 2011). We first established several cut-offs to identify the most interesting gene 
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candidates in our model of infection, which included a mean ratio greater than 1 
(LogRatio >1) compared to uninfected cells, a standard error below 2 (SE ˂2) and 
a consistency over 60% (i.e. 60% of gene-specific shRNAs caused an effect in the 
same direction). By applying these criteria, we filtered 2,888 potential genes (Fig. 
5.5). 
 
Figure 5.5. shRNA screening data after applying a strict cut-off. shRNA screening data 
were filtered by establishing three criteria: mean ratio higher than 1 (LogRatio >1) 
compared to the uninfected control, standard error lower than 2 (SE ˂2) and a consistency 
higher than 60%. This figure was provided by Pablo Capilla-Lasheras.  
 
The identified genes were then functionally classified by using DAVID 
Bioinformatics Resources 6.8 (Huang, Sherman and Lempicki, 2009) and the genes 
were categorized in 63 potential cellular pathways (Fig. 5.6). The pathways with 
the highest number of genes were cytokine-cytokine receptor interaction and PI3K-
Akt signalling pathways; both are implicated in a wide range of cellular functions, 
including cell growth, survival, differentiation and death. We also identified cellular 
pathways that may be important during S. aureus cell infection, e.g. regulation of 
autophagy, regulation of actin cytoskeleton, MAPK signalling and Toll-like 
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receptor signalling pathways. To investigate the possible function of those genes 
that are likely to be more biologically relevant for S. aureus cell infection, we used 
the GeneCards database (Stelzer et al., 2011).  




Figure 5.6. Functional classification of genes identified during the shRNA screen. 
KEGG pathways were analysed employing DAVID Bioinformatics Resources 6.8.  
Following all the afore mentioned principles (i.e. magnitude and significance of 
change, consistent silencing effect and biological relevance), we selected a total of 
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29 genes for further validation (Fig. 5.7), of which seven – CDKAL1, MYL2, 
NSUN7, ORC1L, POLA2, TRAM2 and ZNF618 – were also identified in our 
previous Volcano plot analysis (Fig. 5.4).  
 
Figure 5.7. Twenty-nine genes were selected for further validation. High effect in the 
shRNA screening after MRSA infection and/or a biological relevance for intracellular 
pathogenesis comprise the two criteria to choose the most interesting hits. Selected genes 
are highlighted in red. This figure was provided by Pablo Capilla-Lasheras. 
 
The twenty-nine selected-genes along with a summary of the information obtained 
from the shRNA screening are listed in table 5.1. 




Table 5.1. Twenty-nine genes were selected from the shRNA screening for further 
validation. Each gene is identified with its name along with the NCBI identification 
number. Positive hits, refers to the shRNAs constructs whose ratio was a positive number 
and thus, the representation of that shRNA construct was higher in the MRSA-infected 
sample than the uninfected control. By contrast, negative hits include shRNAs whose 
quantification in the MRSA-infected sample was lower than the uninfected sample. 
Consistency is the percentage of shRNAs that produce a similar silencing effect. Means 


















83734 ATG10 5 4 1 80 1.002 1.748 
57099 AVEN 5 3 0 60 1.083 0.649 
10295 BCKDK 9 8 1 89 1.365 0.405 
79780 CCDC82 5 4 0 80 3.030 1.248 
922 CD5L 5 4 1 80 2.379 1.126 
9308 CD83 5 4 1 80 1.250 1.404 
54901 CDKAL1 5 5 0 100 3.438 1.149 
1212 CLTB 5 3 1 60 1.581 0.823 
1438 CSF2RA 5 4 0 80 2.259 0.921 
54629 FAM63B 5 5 0 100 2.596 1.212 
439996 IFIT1B 5 4 1 80 2.441 1.207 
3775 KCNK1 5 5 0 100 2.869 0.930 
1955 MEGF9 5 4 0 80 2.638 0.806 
4633 MYL2 5 5 0 100 3.624 1.045 
10398 MYL9 5 5 0 100 2.938 0.733 
4753 NELL2 5 4 0 80 2.095 0.804 
79730 NSUN7 5 5 0 100 3.111 0.883 
4998 ORC1L 5 5 0 100 3.571 0.646 
23649 POLA2 5 5 0 100 3.838 1.002 
84440 RAB11FIP4 5 4 1 80 1.161 0.419 
25782 RAB3GAP2 5 3 2 60 1.028 0.632 
347517 RAB41 5 5 0 100 2.692 1.102 
285641 SLC36A3 5 5 0 100 2.915 0.780 
8501 SLC43A1 5 5 0 100 3.123 0.878 
7097 TLR2 5 5 0 100 2.179 1.141 
8794 TNFRSF10C 5 5 0 100 2.104 0.503 
9697 TRAM2 5 5 0 100 3.292 0.601 
127733 UBXN10 5 4 1 80 1.813 0.517 
114991 ZNF618 5 5 0 100 3.970 0.732 
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By choosing these genes, we covered a diverse range of cellular pathways that may 
be exploited by MRSA during intracellular infection as well as some other novel 
genes whose functions have not been thoroughly described.  
Among the shortlisted genes candidates, the Autophagy Related 10 (ATG10) gene 
is directly involved in cell autophagy (Jung et al., 2010; Bernard et al., 2015). Other 
genes are associated with programmed cell death or apoptosis, such as Apoptosis 
and Caspase Activation Inhibitor (AVEN) and CD5 molecule-like (CD5L) genes. 
RAB genes are linked to membrane trafficking (Hutagalung and Novick, 2011) and, 
indeed, several intracellular pathogens hijack host-RAB proteins during infection 
(Spanò and Galán, 2017). The components of the cell cytoskeleton also play an 
important role during intracellular infection, and we identified at least three 
proteins, CLTB and MYL2/9, which may be involved in cytoskeleton 
rearrangement (Fletcher and Mullins, 2010).  We also observed proteins linked to 
the host cell metabolism, such as the branched-chain amino acids regulator 
(BCKDK) and the amino acids transporters SLC43A1 and SLC63A3, which could 
be important for intracellular MRSA survival (Bravo-Santano et al., 2018). 
Additionally, we also included the CD83-molecule (CD83) and Toll-Like Receptor 
2 (TLR2) genes in our downstream analysis, which are involved in a wide range of 
host immune responses to fight against bacterial and viral infections (Christiaansen, 
Varga and Spencer, 2015; Mukherjee, Karmakar and Babu, 2016). 
To validate our results, we used individual shRNA constructs with the strongest 
silencing effect for each gene to produce individual knockdowns (Table 2.7). in 
HeLa cells for further investigation. An established cell line expressing an shRNA 
that does not silence any human gene (Non-target HeLa cells) was used as a 
negative control in all downstream experiments.   
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When silencing a gene that is essential for the successful intracellular infection of 
S. aureus, an increase in host cell viability and a reduction in intracellular bacterial 
load is expected. Hence, we first assessed host cell viability of the selected 29 
knockdowns after MRSA infection. We performed infection assays with two 
different strains of MRSA – S. aureus NCTC 13626 (Healthcare-Acquired MRSA) 
and S. aureus USA300 (Community-Acquired MRSA; Fig. 5.8) – in the presence 
of vancomycin and gentamycin, respectively (Fig. 2.1) 




Figure 5.8. Validation of the screening results. Host cell viability after intracellular 
infection with S. aureus NCTC 13626 strain (A) and S. aureus USA300 LAC strain (B). 
After 6 hours of MRSA infection, cell viability was quantified by flow cytometry using a 
double staining of Annexin V-FITC and propidium iodide. Cell viability was normalized 
in relation to the non-target HeLa cells used as negative control. Data are expressed by 
means ± SE of two biological replicates performed in duplicates. Statistical differences 
were tested using Student´s t-test against non-target control. p-value ≤0.05 (*); ≤0.01 (**); 
≤0.001 (***). 
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Overall, the effect on host cell viability of the different knockdowns was more 
noticeable after infection with S. aureus USA300 strain (Fig. 5.8B), where we 
found larger and more consistent differences among knockdowns compared to the 
non-target control. However, the effect of the gene silencing was generally very 
similar in both MRSA strains, with few exemptions. For example, CD5L and TLR2 
knockdowns showed opposite effects depending on the strain employed (Fig. 5.8). 
In addition, cell viability after silencing ORC1L was not affected after S. aureus 
NCTC 13626 infection, while it was significantly increased during S. aureus 
USA300 infection (Fig. 5.8).  
These differences in host cell viability were probably strain-dependent and in order 
to recognize the most interesting hits, we selected knockdowns whose cell viability 
was at least 1.2-fold higher than non-target cells after S. aureus infection. 
Accordingly, silencing ATG10, CD83, CCDC82, FAM63B, MYL2 or TRAM2 genes 
resulted in a significant increase on host cell viability after S. aureus NCTC 13626 
infection (Fig. 5.8A). In the case of S. aureus USA300 infection, the most 
significant effects were also observed with ATG10, CD83, CCDC82, FAM63B, 
MYL2 and TRAM2 knockdowns and we further identified some strains-specific hits 
including CD5L, MYL9, ORC1L and TLR2 knockdowns (Fig. 5.8B).  
In summary, we selected CD83, FAM63B, MYL2 and TRAM2 knockdowns for 
further analysis since the silencing of these four host genes resulted in increased 
host cell viability regardless of the strain that was employed, and these genes were 
not targeted before to halt S. aureus cell infection. In addition, ATG10 could be 
considered a good internal control, because it is well-known that autophagy is 
essential for S. aureus intracellular survival (Bravo-Santano et al., 2018). 
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5.2.2. Silencing of host-genes CD83, FAM63B, MYL2 and TRAM2 
halts intracellular S. aureus replication 
We speculated that the increase in host cell viability after silencing a gene of interest 
may be caused by a reduction in the intracellular MRSA load within the host-cell. 
To test this hypothesis, we assessed the intracellular growth kinetics of S. aureus in 
CD83, FAM63B, MYL2 and TRAM2 knockdown cell lines (Fig. 5.9). Intracellular 
bacteria were quantified by colony forming units (CFU) counting after two and six 
hours post infection. The intracellular growth coefficient (IGC) was calculated by 
normalizing the number of bacteria recovered after six hours of infection by the 
initial time point (two hours).  
 
Figure 5.9. Bacterial and host cell viability after S. aureus infection in CD83, 
FAM63B, MYL2, and TRAM2 knockdowns. (A) Intracellular bacteria were quantified 
by CFU counting after 2 and 6 hours of infection. Number of bacteria recovered after 6 
hours of infection was normalized by the initial time point (2 hours) to calculate the 
intracellular growth coefficient (IGC). (B) Cell viability was quantified in parallel after 6 
hours of infection by flow cytometry, using a double staining of Annexin V-FITC and 
propidium iodide. Non-target HeLa cells were employed as negative control and cell 
viability was normalized in relation to the control’s viability. Data are expressed by means 
± SE of three experiments performed in duplicates. Statistical differences were tested using 
Student´s t-test against non-target control. p-value ≤0.05 (*); ≤0.01 (**); ≤0.001 (***). 
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A clear inhibitory effect on the intracellular growth was observed in every 
knockdown tested in comparison to the non-targeted control; with the most 
pronounced effects after silencing FAM63B, MYL2 or TRAM2 (Fig. 5.9A). Host 
cell viability was measured in parallel by flow cytometry (Fig. 5.9B), confirming 
that the number of viable cells in every knockdown was at least 50 % higher than 
the non-targeted control.  
Taking into consideration both host cell viability and intracellular kinetics assays, 
two genes were consistently identified in all analyses: MYL2 and TRAM2. However, 
since the host cell viability was restored more significantly when TRAM2 was 
silenced compared to MYL2, this gene was chosen for further downstream 
experiments. 
 
5.2.3. Characterization of the host gene TRAM2 on S. aureus cell 
infection 
I first confirmed the silencing of TRAM2 gene in the knockdown measuring 
TRAM2 protein levels by Western-blot. Accordingly, levels of TRAM2 were 
reduced by 50% in the knockdown when compared to the non-targeted control (Fig. 
5.10A/B).  
I then evaluated the effect of S. aureus infection on the protein levels of TRAM2 in 
wild type HeLa cells at different time points (two and six hours post-infection) and 
multiplicities of infection (MOI 10 and 100) (Fig. 5.10C/D). As a control of 
bacterial load, we detected S. aureus Protein A by Western-blot, whose levels 
directly correlated with increasing times of infection and MOI (Fig. 5.10C).  
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Protein levels of TRAM2 changed in MRSA-infected HeLa cells at both time 
points, although some time-specific differences were observed (Fig. 5.10C). Protein 
levels of TRAM2 were increased after two hours of S. aureus infection to become 
up to 40% higher in infected HeLa cells (Fig. 5.10D). However, at six hours post-
infection, I noticed a changed in the migration pattern of TRAM2 upon denaturing 
protein electrophoresis, indicating that it may have been subjected to post-
translational modification such as proteolysis (Fig. 5.10C). This change in the 
migration pattern was proportional to the MOI employed for the infection, 
suggesting that S. aureus may be interfering with the post-translational modification 
of TRAM2 to promote its own survival or replication. This strategy is commonly 
employed by many bacterial pathogens to control host proteins during intracellular 
infection (Ribet and Cossart, 2010).  




Figure 5.10. Validation of TRAM2 Knockdown in HeLa cells and TRAM2 protein 
levels in HeLa cells during S. aureus cell infection. (A) Cell extracts were analysed by 
Western-blot against TRAM2, and GAPDH was used as loading control. (B) Quantification 
of TRAM2 protein levels observed by Western-blot. (C and D) HeLa cells were infected 
with MRSA USA300 (MOI 10 and 100) and cell lysates were collected after 2 and 6 hours 
post-infection. (C) Cell extracts were analysed by Western-blot against TRAM2 and 
GAPDH antibody was employed as loading control. (D) Quantification TRAM2 protein 
levels observed by Western-blot at time point 2. Data are normalized to GAPDH levels and 
are expressed as means ± SE of three biological replicates. Student´s t-tests were performed 
to validate statistical significance across conditions. p-value ≤0.01 (**). Uninfected cells 
(Mock) were used as negative control. 
 
Given that TRAM2 is a membrane protein, we hypothesized that it may be involved 
in the maturation of the vacuole containing S. aureus. Accordingly, TRAM2 
silencing did not have an effect during early time points of infection (i.e. two hours 
post-infection), pointing towards a role on intracellular proliferation rather than cell 
entry (Fig. 5.11).  




Figure 5.11. Intracellular MRSA infection is significantly hampered after 6 hours of 
infection. Non-target and TRAM2 KD HeLa cells were infected with MRSA (MOI 100) 
and CFU were counted after 2 and 6 hours of infection. Data are expressed as means ± SE 
of three biological replicates performed in duplicates. Student´s t-tests were performed to 
validate statistical significance across conditions; p-value ≤0.01 (**); (n.s) no statistical 
significance. 
 
Therefore, I studied the subcellular location of S. aureus and TRAM2 during cell 
infection. HeLa cells stably expressing TRAM2-mCherry were infected with S. 
aureus USA300-GFP (Reichmann et al., 2014). Co-localization assays were 
performed at 6 hours post-infection and MOI 100 by confocal microscopy, and the 
co-localization events between TRAM2-mCherry and intracellular S. aureus 
USA300-GFP were quantified (Fig. 5.12). In most of the cases, we observed large 
sacs of S. aureus cells surrounded by a scattered pattern of TRAM2-mCherry (Fig. 
5.12A). In addition, some individual bacterial cells were enclosed by a membrane 
containing TRAM2-mCherry (Fig. 5.12B).  




Figure 5.12. Co-localization of MRSA-GFP and TRAM2-mCherry by confocal 
microscopy. TRAM2-mCherry HeLa cells were infected with S. aureus USA300-GFP 
(MOI 100) and samples were collected after 6 hours of infection for confocal microscopy. 
DAPI staining was employed for nuclear staining. (A) Confocal picture showing a 
representative pattern of TRAM2-mCherry localization in S. aureus infected cells. (B) 
White arrows depict where co-localization between MRSA and TRAM2 was observed. (C) 
Percentage of infected cells showing co-localization of USA300-GFP and TRAM2-
mCherry. 
 
Nevertheless, these clear co-localization patterns of S. aureus-TRAM2 were 
restricted to approximately 9% of infected cells (Fig. 5.12C). Taken together the 
low number of localization events, we hypothesised that TRAM2 may have other 
roles during cell infection rather than the maturation of the vacuole containing 
intracellular S. aureus. 
  
5.2.4. Thapsigargin impairs intracellular S. aureus infection 
TRAM2 is part of the translocon, a complex of proteins involved in the transport of 
polypeptides across the endoplasmic reticulum (ER) membrane (Stefanovic et al., 
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2004). The C-terminal end of TRAM2 interacts with the Ca2+ pump of the 
endoplasmic reticulum SERCA2b, which is necessary for the correct protein 
folding of proteins such as type I collagen (Stefanovic et al., 2004). Based on this 
evidence, we hypothesized that by silencing TRAM2 in HeLa cells we may in turn 
block Ca2+ pumps of the ER (e.g. SERCA2b), and consequently alter the maturation 
of proteins that are essential for S. aureus during cell infection. To test this 
hypothesis, I performed S. aureus infection assays in the presence of Thapsigargin, 
a selective SERCA inhibitor (Lytton, Westlin and Hanley, 1991), and we measured 
the host cell viability and intracellular MRSA survival. 
 
Figure 5.13. Thapsigargin treatment during S. aureus infection increases host cell 
viability whereas the intracellular bacterial load is reduced. HeLa cells expressing 
mCherry were infected with S. aureus USA300-GFP (MOI 100) for 2 and 6 hours in the 
presence of DMSO (Mock) or 0.1 µM of Thapsigargin. (A) Host cell viability was 
quantified after 6 hours of infection by flow cytometry. Cell viability was normalized by 
the percentage of uninfected and untreated cells. (B) Intracellular MRSA survival was 
quantified by measuring the percentage of host cells with intracellular S. aureus USA300-
GFP after 2 and 6 hours of infection. Data are expressed as means ± SE of two different 
experiments performed in duplicates and Student´s t-tests were performed to validate 
statistical significance across conditions. p-value ≤0.05 (*); ≤0.001 (***). 
 
We employed a low concentration of this inhibitor (0.1 µM), because higher doses 
have been reported to be cytotoxic (Stetler et al., 2011; Sehgal et al., 2017). In the 
presence of Thapsigargin, host cell viability was enhanced at 6 hours post-infection 
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(Fig. 5.13A). Moreover, intracellular MRSA survival was reduced by two-fold at 
early time points of infection (Fig. 5.13B). Conversely, we did not observe any 
significant differences in S. aureus growth curves in vitro in the presence of 
Thapsigargin (Fig. 5.14). Therefore, our findings suggest that a block of Ca2+ 
pumps of the ER mediated by Thapsigargin halts intracellular S. aureus survival in 
HeLa cells. 
 
Figure 5.14. Thapsigargin does not directly affect S. aureus growth. S. aureus USA300 
was grown in the presence of DMSO (Mock), Thapsigargin (0.1 µM) or gentamicin. 
Absorbance (OD600nm) was measured at 2, 4, 6 and 24 hours to produce bacterial growth 






5.3.1. A functional genomics approach identifies novel host-genes 
essential for S. aureus during cell infection 
The coupling of RNA interference (RNAi) with ultra-fast sequencing provides an 
exceptional opportunity to simultaneously screen the implication of thousands of 
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host-genes in different areas of research. In particular, RNAi approaches have been 
employed before to screen novel host-genes implicated in intracellular bacterial 
(Jayaswal et al., 2010), parasitical (Moser, Pollard and Knoll, 2013) and viral 
(Hirsch, 2010) infections.   
The main limitation of this high-throughput approach is the possibility of 
encountering phenotypes caused by off-target effects. To minimize this, 
transductions should be performed with a low multiplicity of infection (Sims et al., 
2011), and different shRNA constructs targeting the same gene should be included 
in the pooled libraries (Root et al., 2006). Accordingly, we performed lentiviral 
transductions using an MOI of 1, and the majority of genes included in the 
commercial shRNA library were targeted by at least five shRNA constructs (Fig 
5.1).  
By employing ultra-fast sequencing, we were able to rapidly estimate the 
occurrence of shRNAs in S. aureus-infected cells in relation to the uninfected 
control. Over-represented shRNA constructs may be silencing human genes that are 
important for the intracellular bacterial survival and thus, any of these genes could 
have an essential role on S. aureus cell infection. We found approximately 10,000 
human genes that were targeted by shRNAs over-represented in HeLa cells at six 
hours post-infection. 
Further validation of our preliminary screening results was necessary and thus, the 
number of potential candidates was filtered. A combination of high consistency of 
the silencing effect, magnitude of the change and biological relevance was 
employed to select genes for further downstream analysis. As a result, 29 human 
genes were selected for further validation by producing individual knockdowns in 
HeLa cells and testing host cell viability after intracellular MRSA infection. Among 
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these genes, we included a varied range of cellular processes, such as autophagy, 
apoptosis, membrane trafficking and cytoskeleton rearrangement, amino-acids 
metabolism and host-immune responses. Many of these host cell pathways have 
previously been described to play a role in intracellular infection and therefore, we 
evaluated how host cell viability was affected during S. aureus infection after 
individually silencing these host-genes.  
Of particular significance is ATG10, which is a vital component of the autophagy 
machinery. ATG10 is essential for the formation of autophagosomes by mediating 
ATG12-ATG5 conjugation and the conversion of soluble LC3 into its membrane-
bound form (Nemoto et al., 2003). ATG10 silencing significantly restored cell 
viability after infection with two different MRSA strains (Fig. 5.4). Accordingly, 
intracellular S. aureus infection in non-phagocytic cells is halted with autophagy 
inhibitors such as dorsomorphin (Bravo-Santano et al., 2018), and 3-Methyladenine 
treatment protects mice from MRSA pneumonia  (Zhu et al., 2018).  
To further identify other host-targeted therapeutics against intracellular MRSA, we 
interrogated our shRNA screening results to identify four genes, i.e. CD83, 
FAM63B, MYL2 and TRAM2, whose silencing in HeLa cells resulted in a significant 
reduction of intracellular S. aureus survival while host cell viability was enhanced 
after cell infection.  
The protein encoded by CD83 gene is a host membrane protein that is part of the 
immunoglobulin family and it is mainly expressed in mature dendritic cells (DCs). 
The main function of these antigen-presenting cells is the activation of host immune 
responses against invading pathogens (Schmidt, Nino-Castro and Schultze, 2012). 
Eukaryotic cells have evolved complex immune mechanisms to combat invading 
pathogens. Consequently, and in order to successfully establish infections, 
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intracellular microorganisms have also developed sophisticated mechanisms to 
subvert and overcome host immune responses (Reddick and Alto, 2014). 
Specifically, it has been shown that interleukin 10 (IL-10) – a cytokine produced 
by macrophages, T-cells, B-cells, mast cells and keratinocytes, among others – can 
be an effective immunosuppressive factor and therefore, the exploitation of this 
cytokine is a common mechanism to evade host immune responses by several 
pathogens. Some viruses induce the production of host IL-10, while others produce 
their own IL-10-homologs. Bacterial intracellular pathogens, such as 
Mycobacterium tuberculosis and Listeria monocytogenes, are able to replicate 
within macrophages by inducing IL-10 (Redpath, Ghazal and Gascoigne, 2001). 
However, further investigation is needed to explain the molecular mechanism 
behind CD83-S. aureus interaction in cells that are not part of the immune system.  
Although its function is unknown, FAM63B has been recently identified as an 
interaction partner of kinesin light chain-1 (KLC1), which is involved in the 
intracellular trafficking of vaccinia virus (Dodding et al., 2011). Kinesins, dyneins 
and myosins comprise three classes of molecular motors that are part of the host 
cell cytoskeleton and are involved in many biological processes related to cell 
movement. Intracellular bacterial pathogens and viruses commonly use this host 
machinery to reach their intracellular niche, as well as to control the membrane 
remodelling of their containing vacuoles (Henry, Gorvel and Méresse, 2006). In 
particular, Kinesin-1 has been implicated in the intracellular dissemination of 
adenovirus and Herpes virus (Greber and Way, 2006; Dodding et al., 2011; Zhou 
et al., 2018). Moreover, Salmonella effector protein SifA targets the host protein 
SKIP, which down-regulates the recruitment of Kinesin-1 to the Salmonella-
containing vacuole and thus, controls its dynamics (Boucrot et al., 2005). 
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Therefore, FAM63B may play a role in the intracellular trafficking of S. aureus by 
targeting kinesin proteins. 
Myosins comprise a superfamily of motor proteins found in actin filaments and 
have an essential role in the organization of actin cytoskeleton. Polymerization and 
depolymerization of actin filaments promote changes in cells shape and, along with 
myosin proteins, control the intracellular organization (Fletcher and Mullins, 2010). 
The host cell cytoskeleton is commonly hijacked by intracellular pathogens to 
support their own intracellular invasion, survival and replication and actin has been 
specifically described as a common target of many bacterial pathogens (Choe and 
Welch, 2016). As above mentioned, bacterial pathogens exploit host-actin for 
different purposes such as intracellular invasion, actin-based motility through cell 
cytoplasm and pathogen dissemination (Haglund and Welch, 2011). Likewise, the 
use of microtubules, motor proteins and intermediate filaments in intracellular 
invasion and dissemination has been highlighted (Haglund and Welch, 2011). For 
instance, the actin-base motor protein myosin 2 has been associated with the 
integrity and location of Salmonella-containing vacuoles (Wasylnka et al., 2008). 
In addition, myosin 2 has been associated with the promotion of vesicle fission from 
the Golgi complex (Miserey-Lenkei et al., 2010). Furthermore, there is a proportion 
of cytosolic Shigella that become covered with septin filaments in a myosin 2-
dependent manner (Mostowy et al., 2010). Moreover, the release of Chlamydia-
intrusions into the extracellular space is mediated by actin, N-WASP, myosin 2 and 
GTPase Rho proteins (Hybiske and Stephens, 2007). Collectively, these studies 
suggest that the intracellular fate of many intracellular pathogens is determined by 
an organized collaboration between actin, microtubules, intermediate filaments and 
motor proteins. Therefore, the gene coding for the myosin light chains 2 (MYL2) 
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could be involved in the intracellular dissemination of S. aureus by controlling host 
actin cytoskeleton.  
 
5.3.1.1. TRAM2 plays an important role during intracellular 
MRSA infection 
Our findings showed that the human gene TRAM2 is important for intracellular S. 
aureus infection. TRAM2 (Translocating chain-associated membrane protein 2) 
was initially identified as being responsible for the translocation of proteins across 
the endoplasmic reticulum membrane (Walter, 1992). Furthermore, TRAM2 
interacts with the endoplasmic reticulum Ca2+ ATPase transporter SERCA2b, being 
involved in collagen type I protein folding (Stefanovic et al., 2004). In addition, 
SERCA transporters pump cytosolic Ca2+ to the endoplasmic reticulum to maintain 
a constant Ca2+ gradient, which controls other key cellular functions such as cell 
growth, proliferation, differentiation and death (Berridge, Bootman and Roderick, 
2003; Vandecaetsbeek et al., 2009). 
Different intracellular pathogens rely on the endoplasmic reticulum and its 
components to ensure intracellular survival and proliferation (Celli and Tsolis, 
2015). For instance, L. pneumophila, an intravacuolar pathogen, hijacks host 
membrane components to contribute to the formation of Legionella-containing 
vacuoles that are mainly derived from endoplasmic reticulum material (Tilney et 
al., 2001; Isberg, O’Connor and Heidtman, 2009). Similarly, B. abortus (Pizarro-
cerda et al., 1998; Celli et al., 2003) and C. trachomatis (Derré, Swiss and Agaisse, 
2011; Dumoux et al., 2012) also exploit host-endoplasmic reticulum to promote 
their intracellular survival and replication within mammalian cells. In addition, 
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SERCA2b has been closely associated with Chlamydial infections in HeLa cells 
(Majeed et al., 1999). In concordance with these observations, co-localization 
assays showed that several chlamydial antigens, such as major outer membrane 
protein (MOMP), inclusion membrane protein and lipopolysaccharides (LPS), were 
specifically associated with the ER and ER-markers (Giles and Wyrick, 2008). 
Because of the interaction of TRAM2 and SERCA transporters, we investigated the 
intracellular S. aureus survival under treatment with Thapsigargin – a promising 
anticancer drug that is a specific host-SERCA inhibitor (Lytton, Westlin and 
Hanley, 1991; Mahalingam et al., 2016).  High doses of Thapsigargin lead to host 
cell death due to the ER stress caused by this inhibitor (Sehgal et al., 2017). 
However, treatment of HeLa cells with low doses of Thapsigargin resulted in a 
notable reduction of intracellular S. aureus, similarly to the effect that we 
previously observed in TRAM2 knockdown cell lines. Furthermore, intracellular 
bacterial load was significantly attenuated at both time points of infection tested 
with Thapsigargin (at two and six hours post infection), whereas this reduction was 
only observed after six hours of infection in TRAM2 knockdown cells. Therefore, 
Thapsigargin may have multiple effects on S. aureus intracellular survival apart 
from the inhibition of Ca2+ pumps in the endoplasmic reticulum. Nevertheless, our 
findings suggest that the anti-cancer drug Thapsigargin may be repurposed to block 
S. aureus cell infection when combined with conventional antibiotics. 
 
 




By using a functional genomics approach, we screened the role of 16,000 host-
genes on intracellular S. aureus infection, to identify potential host targets that 
could be hijacked by S. aureus during intracellular infection. Here, we studied the 
human gene TRAM2, which plays an important role during S. aureus infection. 
TRAM2 is a transmembrane protein which is associated in the endoplasmic 
reticulum with SERCA Ca2+ pumps. Accordingly, a treatment of infected cells with 
Thapsigargin – a potent SERCA inhibitor – resulted in a significant reduction of 
intracellular S. aureus. Therefore, this study provides new insights into host-S. 
aureus interactions and a novel host-directed anti-infective strategy to halt S. aureus 
cell infection. Furthermore, data presented in this study serve as proof-of-principle 
of the functional genomics approach to unravel host molecular mechanisms 










6.1. CONCLUDING REMARKS 
A better understanding of host-S. aureus interactions during intracellular infection 
may lead to novel therapeutic strategies by targeting those host cellular pathways 
exploited by this versatile pathogen. In pursuing of this aim, this thesis unravelled 
some of the host metabolic pathways and molecular factors hijacked by S. aureus 
during intracellular infection as well as host-directed drugs that may be used to 
hamper intracellular S. aureus survival or proliferation.  
The replication of an intracellular pathogen – including S. aureus – inside the host 
cell leads to numerous metabolic changes in the host cell as an adaptation of the 
pathogen to its new environment. In order to identify the specific host-metabolic 
pathways exploited by intracellular S. aureus to survive within mammalian cells, I 
characterized the host metabolic changes upon intracellular infection. Among all 
the metabolic changes observed in MRSA-infected cells, the low levels of glucose 
and amino acids along with an activated glutaminolysis pointed towards a 
starvation-state, which has previously been linked to autophagy. Autophagy was 
also activated in MRSA-infected cells as well as the host AMPK pathway, which is 




aureus was probably due to its metabolic requirements within its intracellular 
environment and this hypothesis was tested by using Dorsomorphin, an inhibitor of 
the host-AMPK pathway. Treatment with dorsomorphin in HeLa cells reduced 
autophagy levels and intracellular MRSA load. Such effect of dorsomorphin against 
intracellular MRSA was further confirmed in a primary human cell line, HUVEC. 
The identification of dorsomorphin – a host-directed drug, which achieved a 
reduction of intracellular MRSA in mammalian cells – encouraged us to look for 
other drugs that could have a similar effect against this pathogen. We therefore 
tested the effect of host-directed drugs, that were commercially available and 
already approved for other clinical purposes, on intracellular S. aureus infection. In 
order to screen dozens of drugs at the same time, we developed a high-throughput 
screening approach, which allowed us to easily quantify both viable host cells and 
intracellular bacteria. In this study, we screened a total of 140 host-directed drugs 
and found three host kinase inhibitors – Ibrutinib, Dasatinib and Crizotinib – whose 
treatment in HeLa cells significantly reduced intracellular MRSA. We further 
characterized the role of Ibrutinib on MRSA infection and carried out a 
phosphoproteomics analysis to reveal its mechanism of action. Although the 
phosphorylation of several proteins was inhibited by Ibrutinib treatment in HeLa 
cells, we particularly identified the host receptor EPHA2 as one of the potential 
targets of Ibrutinib in epithelial cells during MRSA infection. In line with this 
hypothesis, intracellular MRSA survival at early time points of infection was 
significantly hampered in EPHA2 knockout cells, suggesting that this host receptor 
may be involved in the invasion or internalization of S. aureus. 
Moreover, we performed and validated another high throughput based on functional 




intracellular survival and/or replication. Using this approach, we found four 
potential candidates: CD83, FAM63B, MYL2 and TRAM2 and we specifically 
investigated the role of the host gene TRAM2 on intracellular MRSA infection. The 
reduction of intracellular MRSA after six hours of infection suggested that TRAM2 
protein is likely required for intracellular proliferation rather than for early steps of 
infection, such as invasion or internalization. In addition, TRAM2 has been 
associated with the endoplasmic reticulum SERCA Ca2+ pumps for the synthesis of 
collagen and hence, we investigated whether the SERCA inhibitor Thapsigargin 
had a similar effect on intracellular MRSA infection. Accordingly, intracellular 
MRSA proliferation was halted by the treatment with Thapsigargin in HeLa cells. 
Overall, this study provides novel insights into host and S. aureus interactions 
during intracellular infection as well as new host-directed drugs that halt 
intracellular S. aureus growth. Furthermore, we have standardized and validated 
two high-throughput methods that could be applied to other intracellular pathogens 
(not only S. aureus) to identify novel host targets as well as host-directed drugs to 
improve the treatment of infections caused by intracellular bacteria. 
Although we did not achieve complete clearance of intracellular MRSA, the 
combination of conventional therapies and host-directed drugs may improve the 
outcome of the infection. Therefore, targeting the host cellular pathways exploited 
by the facultative intracellular pathogen S. aureus could represent a promising 
therapeutic strategy. Table 6.1 highlights the host factors and pathways that have 
been described to be important for intracellular S. aureus infection so far, including 




Host-factor Putative function Reference Host-directed drug Type 
Adherence and Internalization 
α5β1-integrins  Internalization into non-phagocytic cells Sinha et al. 1999 Volociximab * Antibody 
FAK Internalization into non-phagocytic cells 
Agerer 2005; Richter et al. 
2016 
PF-562271 Inhibitor 
Src-mediated cortactin Internalization into non-phagocytic cells 
Agerer 2005; Richter et al. 
2016 
PP2 Inhibitor 
β1-integrins  Internalization into mast cells Goldmann et al. 2015 R1295 * Antagonist 
Annexin 2 Internalization into epithelial cells Ashraf et al. 2017   
(PI3K)-Akt  Internalization into endothelial cells Oviedo-Boyso et al. 2011 Nelfinavir * Inhibitor 
αVβ3-integrin  Internalization into endothelial cells McDonnell et al. 2016 Cilengitide * Inhibitor 
 ERK  Internalization into osteoblast and Hep-2 cells Ellington et al. 2001 SCH772984 * Inhibitor 
ERK1/2/MEK Penetration into airway epithelial cells Soong et al. 2011 UO126 Inhibitor 
ERK Invasion to fibroblasts Zhao et al. 2017 PD98059 Inhibitor 
Hsp60 Internalization into epithelial cells Dziewanowska et al. 2000   
Hsc70 Internalization into 293T cells Hirschhausen et al. 2010   
Desmoglein 1  Adherence to keratinocytes Askarian et al. 2016   
Scavenger protein gp340  Internalization into A549 cells  Yang et al. 2014   
EGFR Penetration into airway epithelial cells Soong et al. 2011 BPDQ Inhibitor 
ROCK Penetration into airway epithelial cells Soong et al. 2011 Y-27632 Inhibitor 
JNK Penetration into airway epithelial cells Soong et al. 2011 SP600125 Inhibitor 
p38/MAPK Penetration into airway epithelial cells Soong et al. 2011 SB202190 Inhibitor 
EPHA2 Invasion/Internalization into epithelial cells This study Ibrutinib Inhibitor 
CDK Adhesion to human bronchial epithelial cells Richter et al. 2016 Roscovitine  
PKA Internalization into Thp1 macrophages 
Miller et al. 2011; Richter 
et al. 2016 
H-89 Inhibitor 
PKC Internalization into Thp1 macrophages 
Miller et al. 2011; Richter 
et al. 2016 
Bisindolylmaleimide-I Inhibitor 




Host-factor Putative function Reference Host-directed drug Type 
Intracellular survival and proliferation 
ADAM10 Cleavage of adherens junction protein E-cadherin Inoshima et al. 2011 GI 254023X  Inhibitor 
AMPK Induction of autophagy This study Dorsomorphin Inhibitor 
ERK Induction of autophagy This study SCH772984 * Inhibitor 
TRAM2 Ca2+ pump to promote collagen synthesis This study Thapsigargin Inhibitor 
p38/MAPK Subversion of autophagy Neumann et al. 2016 Skepinone-L * Inhibitor 
PAK Cytoeskeleton rearrangements Richter et al. 2016  FRAX597 * Inhibitor 
MYL2 Cytoeskeleton rearrangements This study Blebbistatin * Inhibitor 
FAM63B Intracellular trafficking This study   
Actin Promote bacterial movements within the host cell 
Sinha et al. 1999; Schröder 
et al. 2006 
Cytochalasin D  Inhibitor 
Rab5 Promote bacterial movements within the host cell Schröder et al. 2006   
NWASP 
Production of actin-comet tails to facilitate 
movement 
Schröder et al. 2006 Wiskostatin Inhibitor 
TMEM59 Activation of selective-autophagy Boada-Romero et al. 2013   
RAPGEF3 Induction of autophagy Mestre & Colombo 2012 Salirasib * Inhibitor 
RAP2B Induction of autophagy Mestre & Colombo 2012   
S. aureus-induced host cell death 
Caspase 2 S. aureus-induced apoptosis Imre et al. 2012  Z-VDVAD-FMK Inhibitor 
Caspase 9 S. aureus-induced apoptosis Rudel et al. 2010 Z-LEHD-FMK Inhibitor 
NLRP3 S. aureus-induced pyronecrosis Muñoz-Planillo et al. 2009 MCC950 * Inhibitor 
Table 6.1. Host molecular factors hijacked by S. aureus during intracellular infection and potential host-directed drugs against intracellular 





6.2. LIMITATIONS AND FUTURE WORK 
We have validated some of the host cellular pathways and factors – AMPK, EPHA2 
and TRAM2 – that I identified as relevant for the intracellular survival of S. aureus. 
Nonetheless, there are many other unsolved questions that could be interesting to 
address in the future.  
The experimental approaches we employed in this study – metabolomics, drug-
screening, phosphoproteomics and shRNA screening – provided us with a long list 
of potential candidates that may be worthwhile to further investigate: 
(i) Besides the starvation-status and upregulation of the host-AMPK pathway, 
another metabolic hallmark of MRSA-infected cells was the large increase of lower 
glycolysis metabolites (PEP and 3-PG). I hypothesize that such accumulation could 
be due to a downstream block caused by the inhibition of different enzymes such 
as pyruvate kinase or pyruvate dehydrogenase. Testing the effect of inhibitors of 
these two enzymes during MRSA infection could explain the increase of these two 
metabolites in MRSA-infected cells compared to the uninfected control.  
(ii) From the host-directed drug screening, I characterized the role of Ibrutinib since 
it showed the highest effect, however, we also identified other tyrosine kinase 
inhibitors that could have a potential against intracellular S. aureus. One example 
is Imatinib, a BCR-ABL tyrosine kinase inhibitor, which is currently under clinical 
trials to be included as a treatment for M. tuberculosis infection. Similarly, 
Dasatinib, a BCR-ABL, SRC and EPHA2 tyrosine kinase inhibitor, may also 
represent a promising candidate to halt intracellular S. aureus replication. 
Moreover, the fact that ABL was also identified by our phosphoproteomics analyses 




(iii) The phosphoproteomics analysis also revealed several proteins as well as host 
pathways that seem important for intracellular S. aureus infection. For instance, 
several targets – ABL, EGFR, ERBB2, Filamin, RhoGAP35 and Talin – are related 
to the host actin cytoskeleton rearrangements, which can be particularly interesting 
because of the importance of host actin in the internalization of S. aureus. We could 
improve our knowledge in S. aureus internalization by investigating the role of 
these proteins more in detail.  
(iv) Likewise, it would be interesting to study the role of the other three potential 
host candidates – CD83, FAM63B and MYL2 – identified from our shRNA 
screening. In particular, FAM63B has been related to kinesins and these proteins 
along with myosins (such as MYL2) play an important role in host cytoskeleton 
rearrangement and cell movement. As mentioned above, host actin and 
cytoskeleton rearrangement has already been demonstrated to be relevant in 
intracellular trafficking of several pathogens. Therefore, these two proteins may 
also be hijacked by S. aureus once it has been internalized to promote its 
intracellular trafficking or to promote the infection to neighbour cells. 
Another parameter that should be considered is the cell line employed. I firstly 
chose HeLa cells in our model because (i) it is a well-stablished model in research 
and (ii) they could be considered epithelial-like cells, which make them a good 
candidate to investigate intracellular MRSA infection since S. aureus causes mainly 
skin infections and it can replicate within epithelial cells. However, we are aware 
that our findings may vary when using a different cell line. Nevertheless, the 
reduction of intracellular S. aureus achieved under Dorsomorphin treatment was 
also confirmed in the primary human cell line HUVEC.  Hence and following the 
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